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ABSTRACT 
SCHOOL OF LIFE SCIENCES 
Master of Philosophy 
ENGINEERING FUNCTIONAL RECOMBINANT 
PROTEINS BASED ON ANTIBODY DOMAINS AND 
FRAGMENTS OF C. botulinum NEUROTOXIN 
By Jolanta Eliza Tolkacz 
Genetic engineering alows the construction of many diverse antibody-related molecules. The 
focus of this study is single chain Fv (Fragment variable) and single domain antibodies. 
Recombinant botulinum neurotoxin fragments derived from serotype A, B, C and D are 
selected as backbones for an investigation into the feasibility and properties of novel 
recombinant targeted multidomain proteins.  
Single chain Fv’s consist of a VH region of heavy chain linked by a stretch of synthetic peptide 
to a VL region of the light chain. Fv is the region for binding to antigens as determined by 
immunoglobulin Ig hypervariable domains caled complementary-determining regions (CDR’S). 
The selected scFv binds to CD117 that is a membrane tyrosine kinase receptor present on the 
surface of various tumour cels. The variable part of chains shows great variability in amino 
acid sequence among the chains. The unique sequence of amino acid residues for variable 
fragments leads to the large diversity of structure, which counts for antibody specificity. 
For the creation of single domain antibodies (sdAbs), where the antibody domain is 
engineered to comprise only the variable heavy or variable light chain (and therefore consist of 
three CDR’s), six of the anti-EGFR sdAbs have been chosen in order to obtain variety of data. 
Al botulinum neurotoxin backbones include an activation site, which is cleaved by a protease 
such as EK (Enterokinase) or FXa (Factor Xa) at specific residues within the sequence.  The 
contrast in molecule activation wil distinguish the best candidates. 
It was decided that targeting the tyrosine kinase receptor family was most suited to this 
research because (i) there is significant knowledge in the literature regarding receptor biology; 
(i) ligands such as epidermal growth factor (EGF) which bind to EGFR were of importance to 
Syntaxin Ltd, (ii) growth factors (including EGF) are involved in tumour maintenance and 
growth, therefore many tumour cels express high levels of EGFR; and (iv) antibodies to EGFR 
are promising leads in cancer biology. There are now 26 successfuly cloned clostridial 
endopeptidase-antibody fragment/ antibody domain constructs and six ful-length high quality 
proteins available for further investigation.  
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"A fact is a simple statement that everyone believes. 
It is innocent, unless found guilty. 
A hypothesis is a novel suggestion that no one wants to believe. 
It is guilty, until found efective. " 
Edward Teler 
To my parents, a special mention for al of their great encouragement during my study. 
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Abbreviations 
 
aa   Amino acid 
Ab   Antibody 
AX   Absorbance at wavelength X nm 
BBB  blood-brain barrier 
BCA  Bicinchoninic acid 
Bis-scFv  Bispecific Single-chain variable fragment 
BLE  blepharospasm 
BoNT  Botulinum neurotoxin 
BoNT/A  Botulinum neurotoxin serotype A 
BoNT/B  Botulinum neurotoxin serotype B   
BSA  Bovine serum albumin 
BTX-A  Botulinum toxin type A 
C   Protein concentration 
CAPS   3-(Cyclohexylamino)-1-propanesulfonic acid 
CDR  complementary-determining region 
CDR-H3  Variable antibody hypervariable loop of heavy chain 
CDR-L3   Variable antibody hypervariable loop of light chain 
CH   Constant domain of immunoglobulin heavy chain 
C-kit  Cytokine receptor (CD117) 
CL   Constant domain of immunoglobulin light chain 
dH2O  Distiled water 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E. coli  Escherichia coli 
ECL  Erythrina cristagali lectin 
EDTA  Ethylenediamineteraacetic acid 
EGF  Epidermal growth factor 
EGFR  Epidermal Growth factor receptor 
EGFR  epidermal growth factor receptor 
EGTA  Ethylene Glycol-bis(β-aminoethyl ether) 
EK   Enterokinase 
Fab  Antigen binding fragment 
FBS  Fetal Bovine Serum 
Fc   Crystaline fragment 
FDA  Food and Drug administration 
Fv   Fragment variable 
Fwd  Forward 
FXa  Factor Xa 
GST  glutathione S-transferase 
H2L fragment of BoNT comprising the light chain and N-terminal 
domain of the heavy chain 
Hc   Heavy chain 
hcAbs  heavy chain antibodies 
hcAbs  Heavy chain antibodies 
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HCC  Heavy chain C-terminal ganglioside binding domain 
HCN   Heavy chain N-terminal translocation domain 
HIC  Hydrophobic interaction chromatography 
His tags  Histidine tag 
HRP  Horseradish Peroxidase 
Ig   Immunoglobulin 
IgA   Immunoglobulin A 
IgD   Immunoglobulin D 
IgE   Immunoglobulin E 
IgG   Immunoglobulin G 
IgM  Immunoglobulin M 
IM   Inner membrane 
IMAC  Immobilized metal afinity chromatograph 
IPTG  Isopropyl-B-galactosidase 
K. lactis  Kluyveromyces Lactis 
Kan  Kanamycin 
KDS   dissociation constants 
L   Path length 
LB   Luria Bertani 
LC   Light Chain 
LDS  Lithium Dodecyl Sulphate 
LHA  Modified recombinant Botulinum neurotoxin serotype A 
LHB  Modified recombinant Botulinum neurotoxin serotype B 
LHD  Modified recombinant Botulinum neurotoxin serotype D 
LHn  Modified recombinant Botulinum neurotoxin 
mAb  monoclonal antibodies 
MAPK/ ERK Mitogen activated protein kinase 
MBP  maltose-binding protein 
MEK  Mitogen-activated protein kinase 
mTB  modified Terrific Broth 
MW  Molecular weight 
NAD  Nicotinamide adenine dinucleotide 
NEB  New England Bioscience 
NMJ  Neuromuscular junction 
ODX  Optical density at wavelength X nm 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate bufered Saline 
PVDF  Polyvinylidene fluoride 
Qa   syntaxins 
Qb   SNAP N-terminal 
QC   Quality Control 
Qc   SNAP C-terminal 
rAb  recombinant antibody 
RAF  Proto-oncogene serine/threonine-protein kinase 
RAS  Abbreviation of Rat Sarcoma (protein subfamily of GTPases 
Rev  Reverse 
RME  Receptor-mediated endocytosis 
RNA  Ribonucleic acid 
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RTK  tyrosine kinase receptors 
S. cerevisiae Saccharomyces cerevisiae 
ScFv  Single-chain variable fragment 
SdAbs  Single domain antibodies 
SDS  Sodium dodecyl sulphate 
SNAP  synaptosomal – associated protein 
SNAP-ON  set of restriction enzymes at Syntaxin Ltd. 
SNARE  soluble N-ethylmaleimide – sensitive factor attachment protein 
SV   synaptic vesicle 
TAE  Tris-Acetate-EDTA 
Tris  Tris (hydroxymethyl) aminomethane 
TSI   Targeted secretion inhibitor 
t-SNAREs  SNARE located in the plasma membrane target compartment 
Tween  Polyoxyethylenesorbitan monolaurate 
UV   Ultra violet 
VAMP  vesicle-associated membrane protein 
VH   Variable domain of immunoglobulin heavy chain 
VHH  Heavy chain antibody (Nanobody) 
VL   Variable domain of immunoglobulin light chain 
v-SNAREs  SNARE located in the vesicle 
α -chain  Alpha heavy chain of immunoglobulin 
γ -chain  Gamma heavy chain of immunoglobulin 
δ -chain   Delta heavy chain of immunoglobulin 
ε –chain  Epsilon heavy chain of immunoglobulin 
ε   Molar extinction coeficient 
κ -chain  Kappa light chain of immunoglobulin 
λ -chain  Lambda light chain of immunoglobulin 
μ –chain  Mu heavy chain of immunoglobulin 
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Chapter 1. Introduction 
 
The main aspect of this research is to engineer novel recombinant proteins that wil 
deliver fragments of botulinum neurotoxin to cels of therapeutic interest. The 
application of this research wil be to increase the eficacy of biotherapeutics, for 
example novel agents for the treatment of solid cancers. 
The focus of this research is to create antibody-botulinum toxin molecules using 
publicly available DNA sequences for the targeting antibodies. These novel antibody-
botulinum toxin molecules are expressed in an E. coli expression system and purified 
using afinity chromatography. The antibody-botulinum toxin molecules were applied 
to cels to determine the functionality of the component domains, for example 
receptor activation and internalization of the warhead. 
 
1.1 Syntaxin Ltd. Strategy for recombinant chimera construction 
 
 
 
 
Figure 1 Protein domain structure of recombinant botulinum neurotoxin 
 
The replacement of heavy chain (HC) domain with alternative binding ligands is a 
possibility for targeting the botulinum neurotoxin endopeptidases to new target cels. 
This approach forms the basis of Syntaxin Ltd’s strategy for development of novel 
recombinant therapeutics (Foster, 2004) (Fig. 1). 
Recognition 
Transport 
Enzyme 
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In furtherance to this idea, there are many potential avenues to engineer new 
molecules for therapeutic use; such as vaccine components, modification of 
intracelular process by delivery of enzymes into cels, manipulation of cel interactions 
with the extracelular environment and inhibition of secretion for extended periods 
within specific cels (Chaddock and Marks, 2006).  
The use of a targeting monoclonal antibody fused to the tetanus toxin light chain to 
block transmiter release from targeted neurones provides a useful approach for 
inducible and reversible control of synaptic transmission in specific neuronal types in 
the brain. (Kobayashi et. al., 2008). However, there is no evidence for the similar 
production of recombinant BoNT re-targeted with smal antibody fragments. The 
antibody-botulinum toxin conjugates could potentialy bind to relevant antigens that 
would result in eficient internalisation into the cels and suppression of transmitter 
release from the target neurons via the proteolytic cleavage of protein from the SNARE 
complex. Used within the area of biotherapeutics this could increase the eficacy of 
biopharmaceuticals for example in the treatment of solid cancers. The novel molecules 
could improve accessibility with efective transport across the cel barrier, block 
specific signal transduction receptors to prevent cancer cels from growing or dividing 
and promote a local immune response known as an antibody-dependent cel-mediated 
cytotoxicity against the tumour. 
The re-targeting of recombinant botulinum neurotoxin with antibodies and antibody 
fragments is the focus of this study. Therefore the characteristics of both antibody and 
botulinum neurotoxin features wil be discussed in detail.  
1.2 Botulinum neurotoxin 
Botulinum neurotoxin (BoNT) is the most potent neurotoxic protein known to man and 
is produced by strains of neurotoxigenic clostridia, including Clostridium botulinum, 
and more rarely by strains of Clostridium baratti, Clostridium butyricum and 
Clostridium argentinense. The toxin produced by a number of species of Clostridia has 
been classified into seven serologicaly diferent Botulinum neurotoxins (BoNTs) 
named A, B, C, D, E, F and G. Al of these BoNTs difer from one to another in the 
specific intracelular target proteins that they target, their characteristics of activation 
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and their potencies. However, they cannot be distinguished from each other based 
upon the toxins inhibition of acetycholine release from nerve terminals and their 
primary structure (Dressler et. al., 2005). 
1.2.1 Discovery of Botulinum neurotoxin action and its application 
Botulinum neurotoxin causes botulism, which is characterised by flaccid paralysis 
leading to sufocation and death in severe cases when no adequate treatment is 
administered (Johnson, 2005). 
Human botulism occurs in three forms; food borne, wound and intestinal. Based upon 
a number of historical sources food borne botulism was the most prevalent disease 
before the 19th Century.  
Medical oficer Justinus Kerner published the first wel-documented descriptions of 
food borne botulism symptoms caused by botulinum toxin (caled, sausage poisoning’) 
which occurred between 1817 and 1822 in Southern Germany. He is the pioneer of the 
idea to use botulinum neurotoxin as a therapeutic agent in neurologic diseases 
because it paralyzed skeletal muscle (Erbguth and Naumann, 1999). 
In 1895, Emile Pierre van Ermengem discovered the pathogen of Botulinum toxin 
during an investigation of a botulism outbreak after a funeral dinner with smoked ham. 
He proposed the name Bacilus botulinus after the Latin botulus (sausage). Just over 30 
years later in 1928, P. Tessmer Snipe and Hermann Sommer purified the toxin for the 
first time. This was folowed, in 1949, by the discovery by Burgen's group that 
botulinum toxin blocked neuromuscular transmission.  
The engineering of BoNT as a therapeutic, using the toxin’s ability to relax tense 
muscles, originates in the work of two researchers. In the late 1960s, Alan Scott and 
Edward Schantz were the first to work on a standardized botulinum toxin preparation 
for therapeutic purposes (Crouch, 2006). 
Alan Scott was an ophthalmologist who, in 1973,  pioneered the preclinical use of 
botulinum toxin type A (BTX-A) in experiments on monkeys and in 1980 the 
subsequent clinical use in patients with strabismus (crossed eye) and blepharospasm 
(uncontrolable blinking) using the crystalized botulinum neurotoxin type A produced 
by Edward Schantz, a protein chemist (Jankovic, 2004). Scott proposed that botulinum 
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toxin could be used as a denervating agent in humans for the treatment of many 
conditions involving neuromuscular activity. Treatment of strabismus was the first 
therapeutic application of botulinum toxin developed by Alan Scot. He successfuly 
demonstrated that the loss of vision associated with strabismus did not occur in any 
cases during 22 years of treatment (Crouch, 2006). 
In the same period, Drachman’s studies at John Hopkins University using material 
provided by Schantz provided the supportive data that botulinum toxin A induced 
selective denervation, muscle weakening and muscle atrophy in developing chicken 
embryos. The experiments indicated that botulinum toxin did not have a generalized 
toxin efect on cardiac muscles or a cytotoxic efect. In 1971, Drachman proposed 
botulinum toxin as a model of an “ideal (nerve) blocking agent.” He emphasised the 
folowing criteria for the blocking agent: 
(i) mode of action in selectively blocking cholinergic transmission, 
(i) specificity in blocking only cholinergic transmission, 
(ii) reversibility in not permanently impairing function or structure of nerve or muscle, 
(iv) generality of action in blocking exocytosis from al motor neuron terminals of 
striated skeletal muscle,  
(v) convenience of use in requiring simple injection of soluble toxin preparation into 
desired muscle regions,  
(vi) safety, if used with appropriate precautions and proper doses, and  
(vi) absence of systematic or CNS efects (Johnson, 2005). 
The possibility of using botulinum toxin as a therapeutic agent was further investigated 
in the early 1980’s by groups of university-based ophthalmologists scattered 
throughout the U.S.A. and Canada. By 1985, a scientific protocol of injection sites and 
dosage had been determined for treatment of blepharospasm (BLE) and strabismus. 
Side efects had been estimated as a mild and treatable. The beneficial efects of the 
injection lasted only 4-6 months, so that BLE patients had to return to the clinics for re-
injection two or three times a year. 
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In December 1989, the U.S. Food and Drug Administration (FDA) approved BTX-A 
(BOTOX®) a crystaline botulinum toxin type A produced in 1979 by Schantz, for the 
treatment of strabismus (crossed eyes), blepharospasm (uncontrolable blinking), and 
hemifacial spasm (twitching) in patients over 12 years old (Johnson, 2005). It was 
subsequently approved for the treatment of cervical dystonia and later for the 
treatment of glabelar wrinkles (frown wrinkles) and hyperhidrosis (abnormal 
sweating) (Barnes, 2007). 
The cosmetic efect of BTX-A on wrinkles was originaly documented by a plastic 
surgeon from Sacramento, Dr. Richard Clark, and published in Plastic and 
Reconstructive Surgery in 1989. On April 15, 2002, the FDA announced the approval of 
botulinum toxin type A (BOTOX Cosmetic®) for the reduction of frown lines between 
the eyebrows. BTX-A was later approved for the treatment of excessive underarm 
sweating.  
The acceptance of BTX-A for the treatment of spasticity and muscle pain disorders is 
pending in many European countries. In addition, there are many studies currently 
involving the use of BTX-A for the treatment of headaches (including migraine), 
prostatic symptoms, asthma, obesity and many other possible indications. There are a 
number of producers of botulinum neurotoxin for therapeutic and cosmetic use which 
include; Alergan, Inc. the manufacturers of BOTOX® which is used for both therapeutic 
and cosmetic use; Ipsen who manufacture Dysport® which is a therapeutic formulation 
of the type A toxin developed and manufactured in Ireland and which is licensed for 
the treatment of focal dystonias and certain cosmetic worldwide and Medy-Tox Inc. of 
South Korea who introduced another BTX-A product, Neuronox® onto the market. 
Finaly,  botulinum Toxin Type B (BTX-B) received FDA approval for the treatment of 
cervical dystonia and is marketed under the trade names of Myobloc® in the United 
States, and Neurobloc® in the European Union. 
1.2.2 Biochemical structure of BoNT 
Botulinum neurotoxins are composed of a heavy and a light chain linked together by a 
single disulphide bond. The BoNTs are synthesised as an inactive single chain 
polypeptide with a molecular mass of approximately 150kDa. This polypeptide chain 
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become active, when proteolyticaly cleaved into a di-chain molecule consisting of a 
100kDa heavy chain and a 50kDa light chain (Dressler, 2005) (Fig 2). 
 
 
Figure 2. Tertiary structure of botulinum neurotoxin type A (3BTA) (adapted from 
Turton, Chaddock and Acharya, 2002) 
 
The light chain (LC) is a globular structure of α-helix and β-strands, which acts as a zinc 
–dependent endopeptidase (Turton, Chaddock and Acharya, 2002). This catalytic 
subunit has a His-Glu-Xaa-Xaa-His (HEXXH) motif (Matthews, 1988) responsible for 
cleavage of the substrate SNARE protein and inhibition of neurotransmitter release 
(Foster, 2004). 
The heavy chain consists of two functional domains, each of 50kDa. The N- terminal 
part of the heavy chain (Hn) forms low pH-induced ion channels in lipid bilayers in the 
intracelular endosome membrane and therefore acts as a translocation domain 
(Shone et. al., 1985). This cylindrical shaped heavy chain domain delivers the light 
chain (LC) into the cytosol to access the SNARE substrate. It also contains a belt region, 
an unstructured polypeptide, which wraps around the LC to protect the active site cleft 
preventing access to the zinc atom (Chaddock and Marks, 2006). The C-terminal part of 
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the heavy chain (HC) is a ganglioside binding domain which is responsible for the high 
afinity neuronal binding (Halpern and Loftus 1993, Shone et. al., 1985) to the target 
cel membrane and consequent internalisation of the toxin molecules into cholinergic 
neurons. The HC domain contains two subdomains, HCN and HCC. They enclose highly 
important residues responsible for the ganglioside binding of the neurotoxins (Schiavo 
et. al., 2000). The N-terminal subdomain (HCN) is a structure of two seven-stranded 
antiparalel  β sheets sandwiched together in  a jely-rol motif. The C-terminal 
subdomain (HCC) has a β trefoil fold (Umland et. al., 1997). 
The crystal structure of BoNT/A (Lacy et. al., 1998) and BoNT/B (Swaminathan and 
Eswaramoorthy, 2000) have been determined and published. The crystal structures 
shows the three distinctive structural domains, which correspond to the three steps 
process of intoxication: binding to the target cels, translocations, and catalytic activity, 
which leads to inhibition of neurotransmitter, release (Hanson, Stevens, 2002, 
Swaminathan and Eswaramoorthy, 2002). The three structuraly individual domains 
are organized sequentialy; therefore, there is no interaction between the binding and 
catalytic domains (Foster, 2004) (Fig. 3). 
 
Figure 3. Clostridial Endopeptidase: Building Blocks for Engineering (adapted from 
Foster, 2004) 
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1.2.3 Process of Intoxication 
 
The neurointoxication process is a series of biochemical events, in which five distinct 
steps can be identified: 
1. Transcytosis of the neurotoxin from the gut to the blood stream 
2. Binding of the neurotoxin to the pre-synaptic membrane of the neuromuscular 
junction (NMJ) 
3. Uptake of the toxin into the motor neurons by endocytosis 
4. Translocation of the LC into the cytosol 
5. Cleavage of the target substrate, a key component of the vesicular fusion 
machinery 
The last step of this process leads to inactivation of the neuronal vesicular release 
mechanism (Chaddock and Meling, 2001) and inhibition of acetylcholine release from 
motor neurons or sensory nerves (Foster, 2004).  The blockade of neurotransmitter 
release from peripheral cholinergic nerve terminals (Rossetto et. al., 2001) is regulated 
by proteolytic cleavage of the soluble N-ethylmaleimide – sensitive factor attachment 
protein (SNARE) proteins (Foster, 2004). This route prevents the stimulation of the 
muscle fibre at the neuromuscular junction, which subsequently leads to the flaccid 
paralysis known as botulism (Chaddock and Meling, 2001). 
The introduction of BoNT (botulinum neurotoxin) into a target tissue acts as a signal to 
initiate a cascade of reactions. This cascade involves a concentration step via complex 
polysialo-gangliosides at the plasma membrane and the uptake into recycling synaptic 
vesicles initiated by binding to a specific protein receptor (Binz and Rummel, 2009). 
The HC-fragment of the heavy chain of the botulinum neurotoxin binds to a 
glycoprotein structure found on cholinergic nerve terminals at the neuromuscular 
junction (Dressler, Saberi and Barbosa, 2005). This binding requires the presence of 
polysialo-gangliosides complex such as GD1a, GD1b, GT1b, as wel as 
glycosphingolipids that are found particularly in the outer leaflet of neuronal cel 
membranes (van Heyningen and Miler, 1961; Simpson and Rapport, 1971). 
Ganglioside distribution and afinity binding studies contributed to an understanding 
of the binding process that leads to the dual-receptor-model (Montecucco, 1986). This 
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model involves two sequential binding steps: the toxin binds initialy to the abundant 
polysialo gangliosides, which act as low afinity receptors that accumulate CNTs and 
then the neurotoxins linger in that position until they get access to protein receptors. 
Simultaneous interaction with ganglioside and protein receptor may be considered as 
high afinity binding and be mandatory for the specific Endocytosis step (Binz and 
Rummel, 2009) (Fig. 4).  
 
Figure 4 Model for the entry of BoNTs into nerve cels (adapted from Binz and 
Rummel, 2009). 
 
(a) BoNTs bind initialy to a ganglioside molecule on the cel surface.  
(b) The intra-vesicular parts of synaptic vesicle proteins become exposed on the plasma 
membrane upon SNARE mediated neurotransmiter release.  
(c) BoNTs access their protein receptor (exemplified here for Syt) possibly by means of lateral 
difusion while bound to the ganglioside receptor.  
(d) Having bound the protein receptor, the neurotoxins become endocytosed via retrieval of 
synaptic vesicles.  
(e) The lumen of the recycling vesicle becomes acidified via the action of the vesicular proton 
pump.  
(f) Acidification provokes a structural rearrangement in the neurotoxins, whereby the HN-
domain forms a channel through the vesicular membrane. 
(g) The LCs pass the channel subsequent to partial unfolding and are released to the cytosol 
folowing reduction of the disulfide bond. 
(h) Ultimately, the LCs cleave their target SNARE(s), Synaptobrevin (Syb, light blue), Syntaxin 
(Syx, orange), or SNAP-25 (light green), and thus block the synaptic vesicle cycle which they 
had exploited for cel entry. ee, early endosome; le, late endosome; sv, synaptic vesicle.  
 
 In this theory, it was proposed that the binding of BoNT to a protein receptor is 
required before internalization commences. In a number of cases, the details of these 
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protein receptors are unknown, however there is some evidence based on 
crystalographic data that provide structural insights into receptor recognition by 
BoNT/B. BoNT/B co-crystalized with synaptotagmin (Syt I) shows binding in crevice at 
the tip of the HC-fragment (aa 44-60) in the neighbourhood of ganglioside binding 
pocket (Chai et. al., 2006). This study provides a molecular basis for studying other 
potential neurotoxin-receptor interactions and support dual-receptor concept. BoNT/B 
uses two homologues of synaptotagmin (Syt-I and Syt-I) (Dong et. al., 2003), as wel as 
BoNT/G also binds Syt-I and Syt-I as their protein receptors (Rummel et. al., 2004b). 
BoNT/A use al three isoforms of synaptic vesicle 2 (SV2A, SV2B and SV2C) (Dong et. 
al., 2006; Mahrhold et. al., 2006); BoNT/E relies on SV2A and SV2B, but not on SV2C 
(Dong et. al., 2008). SV2 and Syt-I/Syt-I are synaptic vesicle membrane proteins. Their 
toxin-recognition domains are located in the vesicle lumen and are exposed to the 
extracelular milieu transiently after synaptic vesicles fuse with the plasma membrane 
(Chai et. al., 2006). 
Folowing the binding of the heavy chain to the surface of the neuron, the clostridium 
neurotoxin internalizes into acidic compartments through an endocytic process 
(Turton, Chaddock and Acharya, 2002).  Research indicates that the structural 
arrangement of botulinum neurotoxin inside an acidic compartment is a pH-dependent 
(Montecucco et. al., 1994) and most probably, a pH reduction activates the structural 
change in BoNT (Turton, Chaddock and Acharya, 2002). The toxin light chain probably 
unfolds at low pH and refolds after interchain disulphide reduction in the cytosol 
folowing its transport through a pore that is formed in the membrane through a 
structural change in the heavy chain (Rosseto et. al., 2001). 
After translocation to the cytosol, the light chain of botulinum neurotoxin binds with 
high specificity to the SNARE protein complex, (Rizo and Sudhof, 1998). SNAREs 
comprise of three proteins: synaptosomal – associated proteins of 25kDa (SNAP – 25), 
syntaxin, and vesicle-associated membrane protein (VAMP /synaptobrevin/) 
(Montecucco, Schiavo and Pantano, 2005). SNARE complexes mediate fusion of 
synaptic vesicles with the plasma membrane (Bajalieh, 1999), which regulate 
secretion of neurotransmitter in cholinergic neurons (Montecucco, Schiavo and 
Pantano, 2005). 
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SNARE complex formation continues even if BoNT cleaves the individual SNARE 
protein. Nevertheless, these complexes are non-functional, as the coupling between 
Ca2+ influx and fusion is broken (Humeau et. al., 2000). It has been observed that Ca2+ 
has a particular role in the inhibition of neurotransmiter release, because increasing 
Ca2+ concentration in the synaptic terminal reverses the efect of BoNT/A (Meunier et. 
al., 2002). The proteolytic cleavage of the SNARE protein complex prevents the docking 
of the acetylcholine vesicle on the inner surface of the celular membrane. This results 
in the blockade of vesicle fusion. This process of acetylcholine secretion inhibition by 
clostridial neurotoxins is terminated by restoration of a functional SNARE protein 
complex (Dressler, 2005). 
 
 
 
Figure 5 Stages of botulinum neurotoxin action: Inhibiting cel secretion (adapted 
from Turton et. al., 2002). 
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1.2.4 SNARE complex 
 
SNAREs are distinguished by structural and functional classifications. The functional 
organization describes them as v-SNAREs and t-SNAREs. The SNAREs incorporated into 
the membranes of transport vesicles, where they are required as a component of the 
vesicle, are v-SNAREs. The SNAREs located in the membranes of target compartments 
are t-SNAREs (Solner et. al., 1993). Individual sets of SNAREs build the core for 
diferent intracelular membrane fusion processes. V-SNAREs have homology with 
neuronal synaptobrevin; t-SNAREs have homology with neuronal syntaxin and SNAP-
25. These proteins have a helical structure and the interaction between v-SNAREs and 
t-SNAREs leads to the formation of a trans-SNARE complex. This complex consists of 
four SNARE motifs in paralel, in which the four-helical bundles catalyse the docking 
and fusion of the vesicle with the target compartment (Weber and Zemelman, 1998 
Fukuda et. al., 2000). The zippering of such SNAREs into paralel four-helix coiled-coil 
Legend to figure 5 
Mechanism of action of botulinum neurotoxin (BoNT). Each of the structural elements of 
botulinum neurotoxin, the light chain (LC) endopeptidase (yelow), the HN translocation domain 
(green) and the HC cel-binding domain (blue) have a role in the mechanism of action of 
neurotoxin. 
The first stage in the intoxication process (interaction with gangliosides and an, as yet 
unidentified, 
protein receptor) (1) is folowed by stage two, internalization of the toxin-receptor complex into 
an 
intracelular vesicle (2). The third stage (translocation) is characterized by release of the light 
chain 
endopeptidase from an acidic intracelular compartment into the cytosol (3). Once liberated 
from the 
vesicle, the light chain performs the final stage of intoxication; highly specific proteolytic 
cleavage of 
one of the proteins of the SNARE complex (4). BoNTs B, D, F and G cleave proteins of the VAMP 
family 
(purple) and BoNTs A, C and E cleave SNAP-25 (light blue). BoNT/C also has the capacity to 
cleave 
syntaxin (orange). Cleaved SNARE proteins are competent for facilitating docking of the 
secretory 
vesicle with the synaptic membrane, but fusion of the vesicle is compromised. Thus 
neurotransmitter 
release is inhibited. Abbreviations: HN, heavy chain N-terminal subdomain; HC, heavy chain 
C-terminal subdomain; SNARE, soluble NSF-atachment protein receptors; VAMP, vesicle-
associated 
membrane protein; SNAP-25, synaptosomal-associated protein of 25 kDa; ACh, acetylcholine; 
AChR, acetylcholine receptor. 
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bundles provide the driving force for membrane to merge (Suton et. al., 1998; Jahn 
and Scheler 2006), ʹsqueezing  outʹ  water  until the lipid  bilayers  are  within  1.5nm  of 
each other. This alows lipid to achieve hemifusion and then ful fusion. 
When the three cognate partners meet, SNARE motifs form four intertwined paralel 
helices that have extraordinary stability (these are two helices from SNAP-25, 1 helix 
from the Syntaxin t-SNARE and 1 from the v-SNARE). These larger hydrophobic 
interactions give rise to the newer nomenclature relating to the single hydrophilic 
residue lying in the middle of each helix (at the so caled 0 layer) where there are 3 Gln 
(Q) and an Arg (R) (Fasshauer and Sutton, 1998). The Q group can be further divided 
into three sub-groups according to their overal homology within the SNARE domain: 
Qa (or syntaxins), Qb (or SNAP N-terminal) and Qc (or SNAP C-terminal) R refers to 
synaptobrevin-like SNAREs (Bock, 2001). 
VAMP/ synaptobrevin 1 and 2 are 13kDa, large dense-core granular membrane 
proteins of SV (synaptic vesicle). Syntaxins 1 and 2 are bound to presynaptic 
membrane of neurons by a TM segment linked to a short C-terminal domain exposed 
to the cel surface and a large cytosolic portion. Synaptosomal - associated membrane 
protein of 25kDa (SNAP-25) is localized on the cytosolic face of nerve membranes 
(Montecucco, 2005). 
The diferent serotypes of BoNT difer in their functional characteristics, particularly 
regarding to specific cleavage of target SNARE, potency and duration of action. For 
instance, BoNT/A and BoNT/C have the longest inhibitory efect in comparison to the 
other BoNT’s; where BoNT/E causes the shortest on-set time for paralysis (Eleopra et. 
al,. 1997, Eleopra et. al., 1998, Foran et. al., 2003). BoNT/A and BoNT/B are the most 
widely used serotypes of botulinum neurotoxin. The various BoNTs and their specific 
substrates are given in Table 1.  
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Table 1 Serotypes and SNARE cleavage 
 
Endopeptidase 
Serotype 
SNARE Substrate 
Duration 
(in vivo / rat) 
Duration 
(clinic / man) 
A SNAP25 30 days 3-4 mo 
B VAMP 18 days 2-3 mo 
C SYNTAXIN - ∼3 mo 
D VAMP - - 
E SNAP25 4.5 days <30 days 
F VAMP 7.5 days 30 days 
G VAMP - - 
 
(-) lack of data 
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1.3 The Immunoglobulin 
Immunoglobulins are glycoproteins produced by B cels and plasma cels in the 
immune system in the blood or tissues in response to a specific antigen, such as a 
bacterium or a toxin. They can neutralize or destroy bacteria by binding to critical 
portion of the toxin or blocking proteins necessary for attachment to cels. 
These proteins, known also as an antibodies or gamma globulins (abbreviated Ig) are 
products of the white blood cels caled B-lymphocytes, where they function as a 
receptor for antigen. They comprise the principle component of the adaptive humoral 
immune response (Lucas, 2001). The term "antibody" dates to 1901. Prior to that time, 
an "antibody" referred to any of a host of diferent substances that served as "bodies" 
(foot soldiers) in the fight against infection and its il efects. 
Antibodies have been found in the immune system of al vertebrates. They represent a 
strong evolutionary solution to recognize and eliminate microbial pathogens to which 
they can bind with high specificity and afinity (Du Pasquier and Flajnik, 1999). These 
characteristics have enabled the use of antibodies as molecular tools for the purpose 
of diagnostic and therapeutic applications (Auf der Maur, 2002). 
1.3.1 Antibody structure 
The structure of the monomeric immunoglobulin molecule consists of four polypeptide 
chains: two identical heavy (H) chains and two identical light (L) chains covalently 
bonded by several intra- and inter- chain disulfide bridges between cysteine residues 
(Fig 6) (Edelman et al., 1969). 
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Figure 6 Ilustrating the disulphide bonds (red) that link the light (green) and heavy 
(blue) protein subunits of Immunoglobulin G (IgG) molecules. 
This diagram also ilustrates the relative positions of the variable (V) and constant (C) 
domains of an IgG molecule. The heavy and light chain variable regions come together 
to form antigen binding sites at the end of the two symmetrical arms of the antibody. 
VL-variable light chain domain; VH-variable heavy chain domain; CH1, CH2 and CH3-
constant domains of heavy chain; CL-constant domain of light chain (adapted from 
Edelman et al., 1969). 
 
In addition, the chains are arranged in the way that the H and L chains form pairs 
(Lucas, 2001). The approximate molecular weight of antibody is estimated to be 150 
kDa. However there are exceptions from this rule, and for example pentameric IgM 
antibodies have a high molecular weight, which can be 900 kDa. Each Ig H chain is 
about 440 amino acid long and each L chain is about 220 amino acid long. Stabilized by 
disulphide bonds the H and L chains form 110 amino acid domains, which are a 
common feature of many soluble molecules and membrane bound receptors.  
Al antibodies have one of two types of light chain (L): kappa (κ) or lambda (λ) and one 
of five types of heavy chains (H): alpha (α), gamma (γ), delta (δ), epsilon (ε) and mu (μ) 
(Gottlieb et. al., 1968). The H and L chains are divided into two regions: the variable V 
region, which is located at the N –terminal end of polypeptide chains and the constant 
C region at the C terminus. The amino acid sequence of N-terminal of each chain varies 
considerably between diferent antibodies, and is known as the variable region. The 
amino acid sequence of the carboxyl half of the light chain (~110 residues) and 3/4 of 
the heavy chain (~330 residues) has limited variation and therefore is caled the 
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“constant region". The VH (heavy chain) and VL (light chain) domains distinguish the 
variable regions. Each light chain has one VL domain and each heavy chain has one VH 
domain. The variable regions of L+H chains consist of hypervariable regions with high 
sequence variability and framework regions with insignificant sequence variability. 
Each antibody molecule has two identical binding sites (Wu and Kabat, 1970) because 
the hypervariable regions during folding produces the antigen binding pockets, which 
are composed of one VH and one VL domain. 
The vast antigen binding capacity of the antibody structure is achievable by the 
association of polymorphic VH and VL regions (Lucas, 2001). These hypervariable 
regions, which represent the closest contact between antibody and antigen, are the 
complementary determining regions (CDRs) (Gauci and Alderton, 2001). There are six 
CDR’s that produce the binding pocket (Weisser and Hal, 2009 Kort et. al., 2001), 
three in the hypervariable regions of the variable light chain and three in the variable 
heavy chain (Fig. 7). The antigen-binding site accommodates approximately four to 
seven amino acids or sugar residues. An antibody binds its specific antigens using a 
combination of hydrogen bonds, ionic bonds, hydrophobic interactions, and Van der 
Waals interactions. This binding is reversible, as there are no covalent bonds formed 
between antigen and antibody (Montero, 2003). 
 
Figure 7 The position of six CDRs in the light and heavy chain of an antibody. 
Heavy chain CDR’s are depicted in yelow and light chain CDR’s are in purple. Regions 
in grey provide the framework upon which the CDR's are supported. The space-filing 
model ilustrates the way in which CDR’s from both heavy and light combine in three 
dimensions to create a binding pocket (adapted from Vaccinex, 2007). 
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The constant region of the antibody has one CL domain for each light chain and three 
(α, γ and δ chains) or four (ε and μ chains) CH domains for each heavy chain (Montero, 
2003). The function of CH domains is to mediate biological efector function (Lucas, 
2001) such as complement activation, FC receptor binding, avidity and serum half-life 
(Ravetch and Kinet, 1991). 
The only region, which does not fold into a domain, is a hinge region between H chain 
CH1 and CH2, which is, connected via intrachain disulphide bridges (Gauci and 
Alderton, 2001). The hinge region alows independent movements of two antigen-
binding regions to bind antigen (Montero, 2003). It is also responsible for the 
separation of antigen-binding sites from the Fc (crystaline fragment) segment, where 
proteolytic enzymes preferentialy target this region (Gauci and Alderton, 2001). 
An epitope is a portion of antigen recognized and bound by antibody domain. Each 
epitope has its own antibody(s) directed against it. The strength of the interaction 
between a single antigen-binding site on the antibody and its specific epitope is caled 
the binding afinity of the antibody. The afinity measures the association between 
antigen and antibody, the strength of which depends on afinity levels. A high afinity 
guarantees the presence of antigen in the binding side (Ofek et. al., 2010). 
The beta-sheet and loop topology of the immunoglobulin fold has a core of four beta – 
strands covered in a curled beta-sheet sandwich. On the edge of this structure are 
additional beta-strands, which exhibit high structural flexibility. The infinite potential 
for protein – protein interactions between antibodies and antigens occur as the loops 
between beta-strands ensure sequence specific topology (Hoogenboom, 2005). 
1.3.2 Immunoglobulins and their fragments 
Antibody molecules belong to groups or classes according to their heavy chains. In 
humans, there are five classes of immunoglobulin: IgM, IgD, IgG, IgA and IgE (Fig. 8). 
The biological properties vary between the classes (Lucas, 2001). Immunoglobulin G 
(IgG) has been identified as the most suitable antibody molecule for use studying 
research and therapeutic purposes, as it has higher afinity for antigen in comparison 
to other immunoglobulin classes (Guci and Malcolm, 2001). After 35 years of study on 
the use of monoclonal antibodies (mAb) as a potential therapeutic this is able to 
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recognize a specific molecular target (Köhler and Milstein, 1975). The USA Food and 
Drug Administration (FDA) have approved 30 therapeutic monoclonal antibodies or 
antibody-derivatives (Fab fragments, radioimmunoconjugates, immuneconjugates and 
FC fusion proteins) until 2008 (Beck et. al., 2008). They are directed against cancer, 
treatment of transplant rejection and to combat autoimmune diseases (Reichert, 
2001). In addition they are being used to treat rheumatoid arthritis (Centocor’s 
Remicade and Abbot Laboratories Humira), non-Hodgkin’s lymphoma (Genentech’s 
Rituxan and IDEC’s Zevalin) and respiratory syncytial virus infection (Medimmune’s 
Synagis) (Holt et. al., 2003). FDA approved five mAbs until 2010 and the additional two 
mAbs in 2011. Although this success is significant, there is a need to produce smaler 
antibody fragments that wil avoid the formulation and manufacturing issues that are 
present in the production of conventional antibodies. These include limited expression 
systems (Holt et. al., 2003), inability to trigger human efector functions and the 
danger of repeated administrations due to a reaction by the immune system against 
murine Ab domains (Sanz, Blanco and Alvarez-Valina, 2004). These drawbacks partly 
have been resolved by chimerization (fusion of mouse variable regions to human 
constant regions) and humanization (grafting complementary determining regions 
onto human acceptor Ab frameworks) (Hudson and Souriau, 2003), however the use of 
high volume bacterial or yeast cel culture (Holt et. al., 2003) of smal antibody 
fragments has higher potential for new class of drugs. 
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Figure 8 Main classes of immunoglobulin IgG, IgA, IgM, IgD and IgE. 
The heavy chains are depicted as blue, and the light chains are depicted in green. 
Orange circles denote areas of glycosylation. The polymeric IgM and IgA molecules 
contain a polypeptide known as the joining (J) chain, which is disulfide-linked to the tail 
pieces and stabilizes the multimeric structure. The dimeric IgA molecule shown 
includes the secretory component in red. The parts labeled V represent the variable 
regions, and the parts labeled C represent the constant regions (adapted from 
Goldsby et. al., 2003).   
 
 
Early studies of antibody structure showed that antibody molecules could be digested 
with enzymes to generate diferent functional fragments that demonstrated the whole 
molecule is not required to maintain specificity (Porter, 1973). The discovery of 
antibodies by Parventjev (Parventjev, 1936), and subsequent studies on horse antibody 
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performed by Petermann and Pappenheimer (Petermann and Pappenheimer, 1941) 
and folow-up experiments with papain by Petermann (Petermann, 1946) to generate 
functional fragments has opened up new opportunities for the development of new 
therapeutic antibodies. The specific cleavage sites of pepsin and papain are shown in 
figure 9. These studies, combined with investigations of antigenic specificity of protein 
antigens (Landsteiner, 1942) suggested that antigenic sites and antibody combining 
sites did not include the complete antibody molecule (Porter, 1973). Although various 
experiments in diferent conditions and enzymes were performed (Porter, 1950), only 
papain gave active products (Porter, 1973). 
The digestion of immunoglobulin IgG with papain generates three fragments: two Fab 
fragments (antigen binding) and an Fc fragment (crystalizable) (Fig. 9). Fab fragments 
are composed of entire L chain and the VH and CH1 domains of heavy chain. The Fc 
fragment poses efector functions, such as complement fixation and binding to the 
surface of phagocytic cels (Lucas, 2001). The isolated antibody heavy (Utsumi and 
Karush, 1964) and light chains (Yoo et. al., 1967) are able to retain antigen specificity, 
but their afinity and solubility is normaly reduced (Ward et. al., 1989). 
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Figure 9 Schematic of Ig domains (A); Use of pepsin and papain to generate F(abʹ)2 
and Fab fragment (B) respectively. 
A) The antigen binding sites formed by the heavy and light chain variable regions are 
labeled, so too are the hinge region and disulfide bonds (adapted from Janeway and 
Travers, 1996). B) The sites where two wel used proteases, pepsin and papain, cleave 
IgG and the resulting fragments Fab and F(ab’)2 (adapted from Molecular Probes, 
2005). 
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The paired N terminal variable domains of heavy and light chains are suficient for 
antigen binding (Sundberg and Mariuzza, 2002). This type of antibody structure can be 
produced as a monovalent (Fab) fragment or a single chain antibody fragment (scFv) 
where just the VH and VL domains are fused by a peptide linker (Harmsen and Haard, 
2007). The recombinant Fabs (~57 kDa) and single chain Fv fragments (scFv ~27 kDa) 
have two important advantages over the whole immunoglobulin: expression is 
possible in a bacterial host and isolation can occur without the need for animal 
immunisation (Jung, 2009, Solner et. al., 1993). Another breakthrough was the 
discovery of single domain antibodies (sdAbs), especialy those produced by camels, 
with fragments ranging from 11 kDa to 15 kDa. They are highly stable and soluble and 
can be formulated into larger molecules to create drugs with prolonged serum half-life 
(Holt et. al., 2003) (Fig 10). After taking into consideration the smaler size of scFvs and 
sdAbs, in comparison to Fabs fragments; the higher yields in bacterial culture and the 
increased ease of combining them with another protein of biopharmaceutical potential 
they were chosen for the purpose of this MPhil study. The sdAbs and scFv fragments 
were used for experimental work; therefore, the more detailed description of 
properties is given in the appropriate chapters. 
 
 
Figure 10 Various Antibodies and derived fragments from them (adapted from Holt, 
2003). 
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1.4 Therapeutic use of clostridia neurotoxin fragments 
Research of the biochemical neurotoxin action and structure lead to the realisation 
that it could be possible to design novel molecules with the ability to inhibit secretion 
(Foster, 2004). BoNTs have an efect on the cholinergic neurones at the neuromuscular 
junctions and on acetylcholine – releasing neurons in the autonomic nervous system 
(Bhidayasiri and Truong, 2005). Lately identification of the efects on non-cholinergic 
pathways of BoNTs has extended the spectrum of diseases against which the 
botulinum neurotoxin can be used (Foster, 2004). Each domain of botulinum 
neurotoxin is independently functional and therefore there is an opportunity to utilize 
them individualy. The HC, HN and LC are responsible for diferent stages of celular 
intoxication (Foster and Chaddock, 2007). It has been reported that a molecule named 
LHN/A is a representative of the LC and HN domains of type A neurotoxin coupled by 
single disulphide bond (Shone, Hambleton and Meling, 1985). The LHN/A fragment is 
nontoxic because it lacks the HC domain responsible for binding to receptors on the 
neuronal surface. The substitution of HC domain with novel ligands gives an 
opportunity to retarget the LHN/A fragment into diferent neuronal and non-neuronal 
cels. This subsequently leads to inhibition of those cels by cleavage of specific SNARE 
proteins, in this case SNAP 25 (Chaddock, Purkiss and Fris, 2000, Chaddock, Purkiss 
and Duggan, 2000). The first crystal structure of LHN/A fragment without the (HC) 
binding domain of botulinum neurotoxin has been determined. This structure does not 
show any apparent structural diferences between the ful-length of BoNT/A and the 
recombinant fragment lacking HC domain. It therefore opens up an opportunity for the 
development of optimized proteins for the medical industry (Masuyer et. al., 2009). 
1.5 Chimeric protein conjugates with toxin  
Within the last 30 years, many attempts have been made to create targeted cytotoxic 
agents that have the potential to specificaly kil target cels, for example in the 
treatment of cancer. Some of these agents have used existing proteins as the targeting 
component, for example, the therapeutic agent, which contains human interleukin-2 
and FDA approves truncated diphtheria toxin for use in cutaneous T-cel lymphoma 
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(Kreitman, 2006). Additionaly, smal proteins such as geneticaly fused growth factors 
and cytokines to protein toxin were useful for this type of study (Cawley et. al., 1980). 
A second class of retargeted agent are Immunotoxins. Immunotoxins are proteins that 
contain a toxin with an antibody that binds specificaly to target cels. The successful 
action of immunotoxin takes place when it binds to and is internalized into the target 
cels to release the warhead (Kreitman, 2006). Originaly, immunotoxins were created 
by chemical conjunction of an antibody to a whole protein toxin or by using a protein 
toxin devoid of its natural binding domain to achieve selective activity (Moolten and 
Cooperband, 1970, Krolick et. al., 1980). The most common use of immunotoxins has 
been applied for investigating new approaches to cancer treatment (Fig 11). 
There are the folowing advantages of using immunotoxin: 
• Increases the eficacy of chemotherapeutic agents in the treatment of solid 
cancers;  
• Improves accessibility through efective transport across cel barriers; 
• Targets a specific cel type; 
• Recognizes tumour specific-antigens; 
• Binds to the cel and internalizes; 
• Assists toxin to kil the target cel; 
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Figure 11 Antibodies as Cancer Therapeutics. 
 
 
There are the folowing disadvantages of using immunotoxin: 
• May show lack of  translocation within cels; 
• VLS (vascular leak syndrome); 
• Immune response to foreign toxin; 
• Short Half-life in the circulation; 
• Hepatotoxicity implies chemical driven liver damage; 
• Lack of the target efects; 
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1.6 Functionality of novel molecules 
The construction of recombinant neurotoxin chimera with antibody molecules, such as 
scFv (single chain antibodies) or sdAbs (single chain antibodies) gives an opportunity to 
develop new class of biopharmaceuticals.  
However, in order to generate novel drugs is important to know principles of signaling 
mechanism in which this drug is involved. The choice of the antibody molecule against 
the particular receptor directs which cel pathway would be activated and controled; 
for example, EGF activates the tyrosine kinase pathway initiated from EGFR. The 
strength of the signal depends on the molecule characteristics, such as size, 
penetration time, and level of recognition of the target cel. The measure of activation 
and internalization of novel antibody-LHN chimeras was not a part of this study, 
however the primary research towards this concept have been initiated. Al single 
chain and single domain antibody fragments designed for this research are directed 
against EGF (Epidermal Growth Factor) receptor. The EGF belongs to Tyrosine Kinase 
family. The binding of EGFR on cels leads to phosphorylation and activation of kinases 
family, which are commonly known as a MAP (Mitogen Activated Protein) kinases. EGF 
is a growth factor that plays an important role in cel growth, proliferation, 
diferentiation by binding to its receptor EGFR. Growth factors (including EGF) are 
involved in tumour maintenance and growth and many tumour cels therefore express 
high levels of EGF-R. Therefore, recombinant antibodies to such receptors are 
promising leads in cancer biology. A more detailed description about EGF, its activation 
and internalization can be found in the Chapter 6 and 7.  
Stem Cel Factor (SCF) is a glycoprotein that signals through the cels and membrane 
tyrosine kinase receptor defined as a proto-oncogene C-KIT (CD117). Altered forms of 
this receptor may be associated with some types of cancer. The design of humanized 
C-KIT antibodies, play an important role in treatment of C-KIT, associated inflammatory 
and cancerous diseases. GIST (gastrointestinal stromal tumour) is a tumour that grows 
in the connective tissue between muscle layers in the digestive tract. Al GISTs can 
become cancerous. The tumour usualy starts when a gene caled kit develops a 
mutation (defect) and forms a protein caled Kit. The abnormal Kit protein sends out a 
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signal that causes the cel to multiply out of control, forming a tumour. The production 
of recombinant neurotoxin chimera with antibody molecules to CD117 has the 
potential to be therapeuticaly beneficial where secretion from the particular cel plays 
a causative role in a disease or medical condition.  
 
1.7 Aims of the thesis 
 
The initial aims of the project: 
• Design of antibodies used for the construction of recombinant molecules. The 
antibody can be tumour specific that wil eficiently target the tumour and 
transport the drug conjugates into and even across the tumour endothelium 
for direct delivery to the underlying tumour cels (Chapter 3). 
• Construction of botulinum based antibody-related molecules. The delivery of 
antibody molecule into cels to target cancer can has greater potential with 
botulinum endopeptidase translocation domain than on its own. The antibody- 
botulinum toxin molecule binds to the relevant antigens and eficiently 
internalize into the cels, where can suppress transmiter release from target 
neurones via proteolytic cleavage of specific SNARE protein (Chapter 4). 
• Expression of recombinant chimeras; standard expression E. coli system was 
explored for suitability for expression of the recombinants (Chapter 5). 
• Purification of recombinant chimeras. The purification system based on nickel 
metal afinity chromatography matrices for protein tagged with ten 
consecutive Histidine residues is the most suitable one for recombinant 
proteins produce within Syntaxin Ltd. Company (Chapter 6). 
 
 
Once these aims had been met, further aims were established that made use of the 
tools developed in the initial stages of the project. 
• The standard expression protocol in E. coli system was changed to reach higher 
purity of purified molecules (Chapter 5). 
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• Other purification systems were introduced to the project to achieve beter 
results than this provided by afinity purification. New systems were 
incorporated to aid an unspecific cleavage within LHN single chain antibody 
fragment molecules (Chapter 6). 
• The activation assay for family ligands of tyrosine kinase such as EGF (Epidermal 
growth factor) was established that would alow testing novel molecules 
(Chapter 7). 
• Internalization experiments were performed to check if the internalization of 
chimeras is possible and the same time the secretion pathway can be inhibited 
(Chapter 8). 
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Chapter 2. Materials and Methods 
The studies on the novel recombinant antibody LHN chimeras required a selection of 
techniques on the level of DNA, microbiology, and protein production and analysis. 
This chapter describes common techniques use at Syntaxin Ltd. as wel as techniques 
developed for the purpose of this study or personal interest, such as assay for process 
of EGFR activation and internalization. 
2.1. Chemicals 
General chemicals were purchased from Fisher Scientific UK; Loughborough UK; Sigma 
Aldrich, Poole, UK; Melford Laboratories, Ipswich, UK; Anachem, Luton, UK; Bio-Rad 
Laboratories, Hemel Hempstead, UK; Invitrogen by Life Technologies, Paisley, UK; 
Merck, NJ, USA; Milipore, Bilerica, MA, USA; Prebio/Pierce, Rockford, IL, USA; 
Sartorius, Gottingen, Germany; VWR, East Grinstead, UK; Corning, NY, USA;  
Specialized chemicals, kits and services were described under each chapter that 
required their use. 
 
2.2 Design of recombinant antibody based constructs 
2.2.1 Antibody selection 
2.2.1.1 Single chain antibody fragments 
 
Single chain antibody fragments scFvs sequences were obtained from the patent 
(WO/2007/127317) Humanized C-KIT antibody, as seen in the table 2. Inventors of this 
patent are NG, Gordon; (US); SHEN, Wenyan; (US). This invention relates to 
compositions and methods for treating c-Kit associated disorders such as fibrosis, and 
more particularly, to compositions containing humanized c-Kit antibodies. 
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Table 2 WO/2007/127317 Patent data for CD117I and CD117I 
PATENT DATA humanized light 
chain 
humanized SR-I 
IgG2 heavy chain 
humanized SR-I 
MULC IgG2 heavy 
chain 
SEQ ID NO 2 4 6 
Length (amino 
acids) 
20 - 248 19 - 467 19 - 463 
CDR1 43 - 58 50 - 54 26 - 35 
CDR2 74 - 80 69 - 85 50 - 66 
CDR3 113 - 121 118 - 125 99 - 106 
CD117I YES YES NO 
CD117I YES NO YES 
 
 
2.2.1.2 Single domain antibodies 
Sequences for single domain antibodies were obtained from the patent (WO 
2008/141449 A1) Single domain antibodies and heavy chain antibody against EGFR and 
uses thereof. Figure 12 represents amino acids sequences that were used for design of 
the single domain antibodies. Inventors of this patent are ZHANG, Jianbing; (CA). 
MACKENZIE, Colin Roger; (CA). BELL, Andrea; (CA). The present invention relates to the 
field of antibodies directed towards epidermal growth factor receptor (EGFR). More 
particularly, the present invention relates to anti-EGFR polypeptides (e.g. single-
domain antibodies: sdAb) and nucleic acid sequences encoding same, directed towards 
and clones thereof, which target EGFR. The invention also concerns an sdAb, which is 
fused with a crystalizable fragment (Fc) of an immunoglobulin protein in order to 
generate a chimeric protein. These anti-EGFR proteins can thus be used in the 
targeting of tumors presenting EGFR on their surface, as wel as for diagnosing and 
treating several types of cancer associated with cels over-expressing EGFR on their 
surface. 
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Figure 12 Sequences of single domain antibodies. 
 
2.2.2 Antibody design and optimisation 
2.2.2.1 Back-translation of amino acids to DNA 
Using Entelechon back-translation tool at 
http://www.entelechon.com/2008/10/backtranslation-tool/ the folowing steps in the 
number of title tabs were completed: 
Protein: Paste in aa sequence 
Genetic code: Should be set to Standard 
Codon usage: Under ͵Download codon usageʹ set to Escherichia coli and download cut 
Edit cut: Leave seting as they are 
Optimize: Under ͵Generalʹ discard codons below 10% of theoretical ratio and Select: 
distribute to other codons, and then Apply 
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Motifs: on right hand panel find al SNAP-ON restriction sites and add them to bad 
motifs 
Output: Under ͵Sequenceʹ select Start  
The raw DNA sequence is codon optimised for expression in E. coli. The insertion of 
SNAP-ON restriction sites were blocked and should not appear during synthesis.  
 
2.2.2.2 Optimisation of DNA 
The raw DNA sequence from back-translation tool was past into the Word Document. 
The changes to DNA were applied by the Graphical Codon Usage Analyser at 
[htp:/www.gcua.schoedl.de/] 
It contains two programmes: 
1. Each triplet position vs. usage table – this shows each amino acid in the 
sequence and gives visual representation of the frequency of the codon usage 
of each codon. This was utilised to reduce the usage of rare codons or runs of 
less frequently used codons to prevent pausing or staling of translation. 
2. Each codon usage vs. table – this shows the codons that can be used for each 
amino acid and compares how often it should be used in a sequence (%) 
against how often it is used in optimised sequence. This was utilised to choose 
which codons to use for replacement in the sequence. Figure 13 represents 
codon usage in E. coli system.  
 
The  originating  organism for  each  of these  programs  was set to ͵Syntheticʹ  with 
Escherichia coli codon usage. Each novel designed molecule has a number of iterations 
in order to get the optimal sequence. The changes of DNA nucleobases were made in 
the way that the common codons are not overloaded; therefore, the spread generaly 
matches the usage table. The rare codons were avoided as wel as less common 
codons. The optimised sequences were dropped into SeqBuilder (DNASTAR Lasergene 
8) program to check if any of SNAP-ON restriction sites have not been introduced 
during redesign.  
The redesign sequences were submitted in the chapter 3. The copies of the each triplet 
position vs. usage table and each codon vs. usage table can be seen in the appendix. 
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Figure 13 Codon Usage in E. coli genes. 
 
2.2.3 Gene synthesis 
Entelechon GmbH (synthetic genes company) based in Regensburg, Germany, 
synthesized single domain antibodies as wel as single chain antibody fragments: 
[htp:/www.entelechon.com]. The genes were received in the tubes containing 5-10 µg 
of lyophilised DNA. The exact concentrations of genes are stated on the gene synthesis 
report.  
The DNA was dissolved in 50 µl distiled water by carefuly shaking for 10 minutes. The 
final DNA concentration was approximately 100-200 ng/µl.  
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2.2.4 Archive of newly synthesised DNA 
The newly synthesized DNA has a summary of design process and sequence selection 
recorded in the lab book belongs to Syntaxin Ltd. When DNA was delivered, it was 
archived using DNA and microbank archive protocol. The lab book references and an 
annotated sequence of that DNA were recorded in the microbank databases on the BIX 
home page at http://192.168.0.6/BIX_Home.html. Each newly synthesized DNA has a 
unique clone number SXN10xxxx. Each newly created an annotate sequence saved as a 
SeqBuilder file is named with the clone number A00xxxx. Clones were then archived 
using the folowing Protocol for microbank and DNA stock.  
 
2.2.5 DNA stock and microbanks  
2.2.5.1 Microbank clone stocks 
 
The delivered synthesised DNA or sequence confirmed new chimera DNA was 
transformed with TOP10 cels. 5 µl plasmid DNA with 25 µl TOP10 cels were treated as 
described in the TOP10 cel method in the section 2.2.5.3 
For each clone green, yelow and red microbank tubes was labeled with the clone 
number (A00xxxx) and the construct name. 
A streak from the transformation plate was then taken and added to each of the 
microbank tubes. The tubes were shaken to coat the beads with cels, left for 10-15 
minutes and the liquid was removed. 
The completed microbank tubes were placed into the appropriate boxes in the -80°C 
freezers. 
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2.2.5.2 DNA clone stocks 
40 µl of the plasmid DNA (at a concentration of approximately 100 ng/µl, i.e. the 
standard concentration from a plasmid miniprep) from the delivered synthesised DNA 
or the sequence confirmed new chimera DNA was placed in a tube labeled with the 
clone number and construct name. 
The tube was placed in the designated box and stored at -20°C.  
The DNA stock and the yelow and red microbanks are archive stock and should not be 
used as working stocks.  
 
The green microbank is the working stock and was used for preparation of any plasmid 
DNA required. 
2.2.5.3 Transformation to TOP10 cels 
One Shot® TOP10 Chemicaly Competent E.coli (Cat. No. C4040-06) were purchased 
from Invitrogen, Inchinnan Business Park, Paisley, UK. 
TOP10 E.coli is provided at a transformation eficiency of 1 x 10e9 cfu/µg supercoiled 
DNA and are ideal for high-eficiency cloning and plasmid propagation. It alows stable 
replication of high-copy number plasmids. The genotype of TOP10 cels is similar to the 
DH10B™strain. Each new batch of TOP 10 cels is check by transformation of pUC19 
control plasmid DNA supplied with the kit to verify the eficiency of competent cels. 
The test transformation was prepared according to the protocol provided in the kit.  
Calculating Transformation Eficiency 
Use the folowing formula to calculate the transformation eficiency as transformants 
(in cfu) per μg of plasmid DNA. The total volume of the transformation mixture is 300 
μl.  
Transformation eficiency (# transformants/μg DNA) =  
 
 
DNApgpCU
ofcolonies
1910
#
×
g
pg
µ
610
×
lplatedX
meltotalvolu
µ
µ

300
×dilution factor 
For example, if transformation of 10 pg of pUC19 DNA yields 100 colonies when 30 μl 
of a 1:10 dilution is plated, then the transformation eficiency is:  
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pgDNA
colonies
10
100
×
g
pg
µ
610
×
lplated
meltotalvolu
µ
µ
30
300
×10 = 1×109 
Transformation of synthesized DNA or new chimera DNA  
 
Thaw on the ice one-shot competent TOP 10 cels for each transformation 
Add 5 µl of ligation mixture to 50 µl Top 10 cels and mix by flicking the tube 
Incubate vials on ice for 20 minutes 
Heat shock the mixture by immersing in 42̊C water bath for 45 seconds. 
Return the mixture to the ice for 10 minutes (be careful not to agitate the mixture as 
this could shear the DNA being taken up by the cels) 
Add 150 µl of LB to the mixture and incubate at 37˚C for 45-60 minutes at 225 rpm in a 
shaking incubator 
Plate the mixture onto an agar plate with kanamycin to dry for 30 minutes 
Place the plate into the 37˚C incubator and leave overnight.  (Alternatively leave the 
plate on the bench over the weekend.)  
 
2.3 Cloning of antibody-LHN chimeras 
2.3.1 Restriction digest 
The inserts and backbones were digested by restriction enzymes XbaI and Hind II at 
37̊C for 3 hours.  
 
Table 3 Reaction mixture for double digestion (50 µl) 
 
Reagent Volume (µl) 
DNA 22 
BSA (10×) 5 
NEB buffer 5 
Xba I 3 
Pst I 3 
dH20 12 
Total volume 50 
 
The successfuly cleaved a DNA substrate with two restriction endonucleases (double 
digestion) depends on selecting the best NEB bufer to provide reaction conditions that 
optimize enzyme activity as wel as avoid star activity associated with some enzymes. 
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NEB provides four standard colour-coded NEB bufers (1, 2, 3 or 4) for optimal activity. 
The NEB bufer 2 (blue, cat. no. B7002S) was use for purpose of this cloning.  
The composition of NEB bufer 2 (1×) 
10 mM Tris-HCl, 10 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol, (pH 7.9 @25̊C) 
 
The best enzyme combination and choice of appropriate bufer can be found in the 
Double Digest Finder at www.neb.com 
 
To obtain 100 % activity the bovine serum albumin (BSA×100, cat. no: B9001S, NEB, 
UK) was added to reaction to a final concentration of 100 µg/ml.  
2.3.2 Agarose gel electrophoresis 
The digested DNA samples were run on 0.8 % agarose gel.  
 
2.3.2.1 Agarose gel preparation 
The gel tank Bio-Rad with appropriate size comb was assembled. 
1.2 g Agarose (Agarose MB 1200, cat no: 9012-36-6, Melford Laboratories) and 150 ml 
with 1x TAE bufer (Tris-Acetate-EDTA 50× bufer, cat no: BP1332-20, Fisher Scientific) 
was mixed in a conical flask. It made up 0.8% Agarose gel. The mixture was heated in 
the microwave for 4-5 minutes until Agarose completely dissolved and cool in water 
down for about 20-30 seconds. 
Subsequently, 15 µl of SYBR® (Safe DNA gel stain, cat no: S33102, Invitrogen) was 
added to 0.8% agarose gel poured into the sledge. The gel was ready to use after 30-45 
minutes. 
 
2.3.2.2 Sample preparation 
20 µl Orange G (x5) (cat no: O3756, Sigma Aldrich) added to each digest. Orange G is a 
tracking dye in nucleic acid gel electrophoresis, running approximately at the size of a 
50 base pair (bp) DNA molecule. 
Added 10 µl of Orange G to each digested sample, therefore samples in the volume of 
60 µl were loaded onto the agarose gel. 
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2.3.2.3 1kb DNA Ladder preparation 
1 kb DNA ladder (cat no: N3232L, NEB) yields 10 bands suitable for use as molecular 
weight standards for agarose gel electrophoresis. The digested DNA includes 
fragments ranging from 0.5-10.0 kilobases (kb). The 3.0 kb fragment has increased 
intensity to serve as a reference band. The 1 kb DNA ladder is not design for precise 
quantification of DNA mass, but it can be use for approximating the mass of DNA in 
comparably intense samples of similar size. 
Add 2 µl of 1Kb DNA ladder to 4 µl Orange G and 14 µl dH2O. 
1 kb DNA ladder in the volume of 20 µl was loaded onto the Agarose gel. 
 
 
Figure 14 1 kb DNA Ladder visualized by ethidium bromide staining on a 0.8% 
agarose gel. Mass values are for 0.5 µg/lane. 
 
2.3.2.4 Agarose gel run 
The wels were set at the negative end of the tank and the agarose gel run for 1 hour 
at 120 V. 
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2.3.2.5 The extraction and purification of DNA from the agarose gel in TAE 
bufer. 
The bands on the gel were visualized under U.V. light in the Gene Flash from the 
Syngene Bio Imaging. The desire bands were cut from the gel out on the Safe Imager 
from the Invitrogen and the taken picture of agarose gel confirmed correct sizes of 
bands.The extraction and purification of DNA was prepared according to the QIAquick 
Gel Extraction protocol provided with kit (www.QIAGEN.com, cat. no. 28706) 
The 30 µl of eluted DNA was used for the ligation. 
2.3.3 Ligation 
The reaction mix shown in table 4 was incubated  at  16̊C  overnight  or  at  21̊C for  3 
hours and then entire ligation product was transformed to TOP 10 cels (refer to 
section 2.2.5.3). The T4 DNA ligase together with bufer (10×, with 10 mM ATP) was 
purchased from (cat. no. B0202S) NEB, UK,  
Table 4 Reaction mixture for ligation (20 µl) 
 
Reagent Volume (µl) 
Insert (Abs domain or fragment) 14 
Backbone (LHN) 2 
T4 DNA Ligase bufer 2 
T4 DNA Ligase (400,000 U/ml) 2 
Total volume 20 
 
The concentration of insert and backbone is approximately 100 ng/µl. U stands for 
Unit. 
2.3.4 Grow overnight and DNA purification of newly designed molecules 
Preparation of agar plates 
 
The 200 ml of solid agar (cat. no. 44391, BioMerieux, Basingstoke, UK) was dissolved in 
the microwave for 10 minutes. Subsequently, it was cooled down to the appropriate 
temperature, therefore 200 µl of 30 µl/mg kanamycin (Kanamycin sulphate from 
Streptomyces kanamyceticus, cat. no. K4000-5G, Sigma-Aldrich, UK) was added and 
mixed with agar. The ready agar was poured into Petri dishes. 
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E. coli Growth overnight 
The transformed to TOP 10 cels ligation mixtures were plated on the agar plate with 
kanamycin that were left at 37̊C incubator, overnight. Two colonies for each molecule 
were picked from the plates up and inoculated in 10 ml LB (Luria Bertani, cat. no. 
44393, BioMerieux, Basingstoke, UK) with 10 µl of 30 µl/mg kanamycin. The inoculated 
cultures were grown at 37̊C, overnight on the shaking platform. 
 
Minipreps DNA purification 
The DNA was purified from 10ml overnight cultures using Wizard® Plus SV Minipreps 
DNA Purification System provided with kit from the Promega, UK (cat. no. A1460).  
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Figure 15 Flow diagram of plasmid DNA isolation and purification using the Wizard® 
Plus SV Miniprep DNA Purification System. 
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2.3.5 The screening test for purified DNA 
The newly cloned molecules were tested by digestion with Xba I and Hind II restriction 
enzymes in order to confirm correct insertion of new genes.  
Table 5 Reaction mixture for sequential digest 
Digest mixture for sequential digest  
Reagent Volume (µl) 
BSA (10×) Stock conc. 10 mg/ml  1 
NEBufer 2 1 
DNA (100 ng/µl) 4 
Hind II 20,000 U/ml 1 
dH2O 3 
Total volume 10 
 
Table 6 Reaction mixture for double digest 
Digest mixture for double digest 
Reagent Volume (µl) 
BSA (10×) Stock conc. 10 mg/ml 1 
NEBufer 2 1 
DNA (100 ng/µl) 4 
Hind II 20,000 U/ml 1 
Xba I 20,000 U/ml 0.5 
dH20 2.5 
Total volume 10 
 
2.3.6 DNA sequencing 
Tested molecules in the volume of 20 µl were sent to Sources Bioscience (former 
Geneservice) based in the Oxford, UK, htp://www.lifesciences.sourcebioscience.com/. 
Molecules were sequenced using Geneservice universal primers and custom primers 
designed in house. Universal primers that are suitable for sequencing are T7 forward 
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and T7 terminator. The choice of custom primers was based on the type of serotype to 
be screened.  
The DNA sequencing data were obtained in the DNA Star Lasergene 8 format and they 
are stored on the Syntaxin Ltd. database. MegAlign programme was used to align 
Sources Bioscience sequences with predicted ones created on the SeqBuilder 
programme. 
The copy of al alignments can be found in the lab books. Each new clone was then 
archived and microbanked according to the protocol (refer to section 10.2.4 and 
10.2.5).  
 
2. 4 Expression of recombinant antibody based constructs 
2.4.1 Modified Terrific Broth 
The expression were performed using modified Terrific Broth (mTB) purchased from 
Melford, UK. The modified Terrific Broth is supplied in a dry form in the capsules. 
Table 7 mTB composition 
Modified Terrific Broth Media composition 
Components Formula for one capsule (g/l) 
Tryptone 12 
Yeast extract 24 
di-potassium phosphate 9.4 
Mono-potassium phosphate 2.2 
 
Preparation of 1L expression media 
2 capsules, 4 ml of glycerol and 1 litre of warm distiled water. The water was warmed 
up to  37̊C, so  gelatine capsules can  be  easily dissolved. The capsules need to be 
dissolved prior to autoclaving of mTB media. The media was autoclaved in sterile 
conditions at 121̊C for 15 minutes. 
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2.4.2 Expression strain stock 
Chimeras transformed with an expression E. coli strain for protein purification were set 
up from transformation plate into a single blue microbank tube. A unique expression 
stock numbers E00xxxx were obtained from the expression microbank databases on 
the BIX Syntaxin Ltd. home page. Al tubes were labeled with the unique expression 
stock number, the construct name and cel strain. 
BL21 (DE3) Competent cels are T7 expression host strain that were purchased from 
Novagen, UK (cat. no. 69450-4). They are supplied in 0.2 ml aliquots and can be used 
for 10 transformations. 
Bacterial Strain Genotype of BL21 (DE3) is F– ompT hsdSB(rB– mB–) gal dcm (DE3) 
The guaranteed transformation eficiency is 2 × 106 cfu/μg of Test Plasmid. 
 
Transformation to BL21 (DE3) cels 
5 µl DNA was added to 20 µl BL21 (DE3) cels. The transformation procedure was the 
same as described in the section 10.2.5.3. However the eficiency of BL21 (DE3) is 
higher than TOP 10 cels, therefore 50 µl of transformation mixture was plated onto 
the agar plate. The lower volume on the plate should give single colonies and prevent 
the plate from over growing. The streak of colonies was taken on the loop and mixed 
with microbank broth of the blue tube. The tube was shaken to disperse cels and left 
for 10-15 minutes. Eventualy the broth was removed and microbank was stored at -
80̊C freezer labeled  with number  E00xxxx.  The  expression  numbers  are  available at 
BIX Syntaxin Ltd. home page.  
 
2.4.3 Standard expression protocol 
The expressions were prepared on the shaking platform in the incubator from the New 
Brunswick Scientific, US. 
100 ml modified TB + 0.2% glucosamine + 100 µg/ml ampicilin/ or 30 µg/ml 
kanamycin in 250 ml flasks was inoculated using a microbank bead from the LHN-ligand 
expression strains or a single colony from a streaked agar plate. The cultures grew at 
37̊C, 225 rpm for 16 hours. The OD600nm was checked to ensure that readings are 
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between 0.1 and 0.5 OD by dilution with fresh mTB, so a record of the growth 
conditions can be maintained.  
After 16 hours 1-litre cultures of modified TB + 0.2% glucosamine + 100 µg/ml 
ampicilin/ or 30 µg/ml kanamycin in  2-litre flasks were inoculated with 10 ml of 
overnight culture for each DNA. The cultures grew at 37̊C, and 250 rpm until an 
approximate OD600nm of 0.5 was reached at which point the temperature was turned 
down to 16̊C while continuing to shake at 250 rpm.  1 hour later the OD600nm was 
recorded to ensure reading between 0.1 and 0.5 OD by dilution with fresh broth. On 
that  point, the cultures were induced with 1 mM IPTG. The cultures grew for 
approximately 20 hours at 16̊C, 250 rpm. 
The final OD600nm was measured to ensure that readings are between 0.1 and 0.5 OD 
diluted in TB, so a comparison of the final cel density of the cultures could be made. 
The cultures were spun down at 5000 rpm, 4̊C for 20 minutes. The supernatant was 
removed as much as possible and each litre of cel paste was re-suspended in 20 ml 
room temperature lysis bufer (50 mM HEPES pH 7.2, 200 mM NaCl). The lysed cel 
pastes were placed in 50 ml falcon tubes labeled with construct, expression strain, 
weight, date, and cel expression number.  
The cel pastes were weighed by subtracting the pre-weighed 20 ml of bufer and 
falcon tube from the total mass of the cel paste mixed with bufer and frozen at -80̊C.  
 
2.4.4 Changes applied to the standard expression protocol for purpose of study 
To obtain higher enrichment of expressed proteins the harvested cel pastes were re-
suspended in the lysis bufer 50 mM HEPES pH 7.2, 500 mM NaCl and then they were 
spun down at 4̊C, 12500 rpm for 30 min to remove as many contaminates and debris 
as possible. The supernatant was removed and cel pastes were frozen dry at -80̊C 
freezer. 
 
2.5 Purification of recombinant antibody based constructs 
The production of target proteins was prepared using two purification systems 
AktaExpress and AktaPurifier bought from the GE Healthcare, UK & Ireland. The resins 
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and columns were purchased from GE Healthcare, UK and al product codes can be 
find on this website: 
http://www.gelifesciences.com/aptrix/upp01077.nsf/content/protein_purification. 
A ful description of the purification protocol is found below. 
2.5.1 Cleavage enzymes 
New England BioLabs, USA supplies cleavage enzymes: EK (Enterokinase) and FXa 
(Factor Xa) upon request. Each new batch is tested at Syntaxin Ltd. and acceptance to 
general use is made on the outcome of successful activation of molecule. 
The Recombinant Human Coagulation Factor X bought from the R&D System was used 
for purpose of this study. 
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Table 8 Activation enzymes  
Enzyme Source Molecular Mass (kDa) 
 
Factor Xa (FXa) 
Purified from bovine 
plasma and activated by 
treatment with the 
activating enzyme from 
Russel’ viper venom 
43 (consists of two 
disulfide-linked chains of 
approximately 27 and 16) 
On SDS-PAGE the reduced 
chains have apparent MW 
of  30 and 20 
 
Recombinant Human 
Coagulation Factor X 
(rhFX) 
Expressed with a C-
terminal 10× His tag in an 
insect cel lines, Sf21; the 
secreted pro enzyme was 
purified and activated 
Consists of heavy 
chain/catalytic domain and 
two fragments of light 
chain, 
On SDS-PAGE under 
reducing conditions 
migrates at 33-36 and 13-
14 
 
Enterokinase (EK) 
Purified from K.lactis 
containing a clone of the 
light chain of the bovine 
Enterokinase gene 
26.3 
On SDS-PAGE gel is 31 
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2.5.2 Metal Ion afinity chromatography (IMAC) using AktaExpress 
The appropriate cel paste was thawed from -80̊C and re-suspended in the bufer 50 
mM Hepes pH 7.2, 200 mM NaCl. The re-suspended cel paste was homogenized at 
4̊C, 15000 psi on the Constant System homogenizer and it was spun down at 13000 
rpm at 4̊C for at least 1 hour. The lysate was clarified by filtration using 0.2 µm filter 
units on the Watson-Marlow peristaltic pump. The supernatant was loaded at 3 
ml/min onto pre-packed 5 ml His Trap HP column (GE Healthcare) pre-charged with Ni 
Sepharose High Performance and equilibrated with 50 mM Hepes pH 7.2, 200 mM 
NaCl, 20 mM Imidazole. 
 
After loading lysate onto the column, the column was washed with 15 CV (column 
volumes) of equilibration bufer. The fusion protein was eluted with diferent 
concentrations of Imidazole. The 40 mM Imidazole wash was set up to 15 CV, while the 
250 mM Imidazole elution step was set up to 12 CV. The protein eluted at 4 ml/min. 
The bufer 50 mM Hepes pH 7.2, 200 mM NaCl was used during purification process. 
The eluted protein at 250 mM Imidazole was stored in loops on the AktaExpress 
system and passed through desalt column for the bufer exchange to 50 mM Hepes pH 
7.2, 150 mM NaCl. Consequently, the fusion protein was activated on the same day as 
the capture purification step.  
5.2 µl of EK was added per 1 mg of fusion protein and activated at 25̊C for 
approximately 10 hours or 1.5U of FXa was added per 1 mg of fusion protein and 
activated  at  4̊C for  10  hours. A Nanodrop measured the concentration of fusion 
protein at A 280nm. 
The next day the presence of the precipitations in the fraction was visible. It was 
required to spin the sample down in the centrifuge for 15 min, at 4̊C, at 4000 rpm. In 
order to estimate the loss in yield the concentration of protein was checked in the 
sample before and after spin.    
The second His column has the same parameters and bufer conditions as first His 
column. Eluted fusion protein was dialysed at 4̊C, o/n in 5L of 50 mM Hepes, and 150 
mM NaCl bufer.  
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On the third day of the purification process, the dialyzed fusion protein was 
concentrated to approximately 1 mg/ml in the VivaSpin concentrators and frozen at -
20̊C freezer. Each new purified molecule has a batch number made of initials, reverse 
date. Al information regarding to process and outcome of purified molecule are stored 
on the BIX home page at Syntaxin Ltd.  
 
2.5.3 Metal Ion afinity chromatography (IMAC) using AktaPurifier 
The purification process using AktaPurifier was slightly diferent from that using 
AktaExpress. The cel pastes used for this purification process were washed in the 
bufer and frozen dry at -80̊C. The thawed cel pastes were re-suspended in the bufer 
50 mM Hepes pH 7.2, 500 mM NaCl and homogenized  at  4̊C,  15000  Psi  on the 
Constant System homogenizer, then it was spun down at 12500 rpm at 4̊C for at least 
1 hour. Lysate was clarified by filtration using 0.2  µm filter units on the Watson-
Marlow  peristaltic pump.  The XK16 (GE Healthcare) column was packed with 10 ml 
Chelating Sepharose resin and charged with a 0.1 M NiSO 4. The equilibrated column 
with 50 mM Hepes pH 7.2, 500 mM NaCl was ready to use for purification. The clarified 
lysate by filtration using 0.2 µm filter units was loaded onto a column at 4 ml/min. The 
fusion protein was eluted with step-wise gradient of Imidazole (40 mM, 80 mM and 
250 mM) in the bufer 50 mM Hepes pH 7.2, 500 mM NaCl at 4 ml/min.  
The target protein eluted at 250 mM Imidazole concentration. The AktaPurifier system 
can be use only for one column at the time; therefore, bufer exchange in the fusion 
protein  was  prepared  by  dialysis  at  4̊C, for  5  hours.  The composition  of  bufer 
depends on the activation enzyme used and 5L of 50 mM Hepes pH 7.2, 50 mM NaCl 
was applied when activated with EK or 5L of 50 mM Hepes pH 7.2, 150 mM NaCl bufer 
was used while activated with FXa.  
To activate the toxin 3.2 µl of EK per 1 mg of fusion protein was added and incubated 
at  4̊C for  10  hours with an additional 1.6  µl of EK per 1 mg of protein added for 4 
hours prior to purification alternatively, 1.5 U of FXa per 1 mg of fusion protein was 
added and incubated at 4̊C for 10 hours. After 3 to 4 hours, activation of Enterokinase 
is lost. After the activation process, the fusion protein was purified by Hydrophobic 
Interaction Chromatography (HIC), which is described below. 
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2.5.4 Hydrophobic Interaction Chromatography (HIC) using AktaPurifier 
The XK16 (GE Healthcare) column was packed with 30 ml Phenyl Sepharose 6 Fast Flow 
resin and equilibrated with 50 mM Hepes pH 7.2, 1 M ammonium sulphate. 1 M 
ammonium sulphate in the solution was added to activate the fusion protein during 
the polishing step or to a clarified lysate for initial capture step. The fusion protein was 
eluted at 3 ml/min with a linear gradient of increasing bufer B concentration; where 
bufer B was 50 mM Hepes pH 7.2 and bufer A was 50 mM Hepes pH 7.2, 1 M 
ammonium sulphate. 
The samples were analyzed on the SDS-PAGE gel under reducing conditions by addition 
of 0.1 M DTT (dithiothreitol) and non-reducing conditions if the activation process was 
completed. This way the only wel activated samples were chosen for further 
purification. The eluted fusion protein was dialysed against 5 L of 50 mM Hepes pH 7.2, 
150 mM NaCl at 4̊C, overnight. Subsequently, the fusion protein was concentrated in 
the VivaSpin concentrators to approximately 1 mg/ml and stored at -20̊C  or -80̊C 
freezer. The recording process of newly purified protein is the same as described in the 
chapter 10.5.2. 
Throughout the initial capture process, the analyzed fusion protein was discarded, as 
only this stage was important for the purpose of study. 
2.5.5 Anion Exchange Chromatography – Q Sepharose FF 
The anion exchange chromatography was used in the initial capture step as a 
possibility to avoid unspecific cleavage of the single chain antibody fragments - LHN 
chimeras.  Anion-exchange resins are positively charged and bind (and exchange) 
negatively charged ions (anions). The column XK16 (GE Healthcare) was packed with 20 
ml of Q Sepharose Fast Flow resin. The column was equilibrated with two bufers. 
Initialy, in order to charge column it was equilibrated with 50 mM Hepes pH 7.2, 1 M 
NaCl and next with 50 mM Hepes pH 7.2. The clarified lysate was re-suspended in 50 
mM Hepes pH 7.2, 50 mM NaCl bufer, loaded onto a column at 3 ml/min, and eluted 
with decreasing concentration of 1 M NaCl in 50 mM Hepes pH 7.2. The sample was 
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analyzed by the SDS-PAGE. The purification was completed at this stage and fusion 
protein was discarded. 
2.5.6 Protein Analysis 
2.5.6.1 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Separation of protein to determine content and purity was carried out using a 
discontinuous Tris-glycine SDS-PAGE (Sodium Dodecyl Sulphate) system. 10 or 12 well 
4-12 % NuPAGE Bis-Tris commercial gel was placed in the BioRad gel tank and filed up 
with 1× MOPS SDS Running Bufer (20×, cat. no: NP0001-02, Invitrogen) diluted with 
dH2O.  
 
Sample under non-reducing conditions 
50 µl of tested protein sample 
25 µl of NuPAGE LDS sample bufer (4×, cat. no: NP0007, Invitrogen) 
25 µl of dH2O 
Sample under reducing conditions 
50 µl of tested protein sample 
25 µl of NuPAGE LDS sample bufer (4×, cat. no: NP0007, Invitrogen) 
15 µl of dH2O 
10 µl of 1M DTT (100 mM in reduce sample) 
 
10 µl of sample was loaded onto a 4-12% NuPAGE Bis-Tris stacking gel. The gel was run 
at 200 V (volts) for 45 minutes. It was stained with SimplyBlueTM SafeStain bufer (cat. 
no: LC6065, Invitrogen). After electrophoresis, the gel was placed in 100 ml of 
deionized water and microwaved for 2 minutes to remove SDS and bufer salts. This 
step was repeated again and then gel was covered with 20 ml of SimplyBlueTM 
SafeStain bufer and microwaved for the additional 1 minute. The gel was shaking on 
the orbital shaker until bands were visualized. After detection of bands, the SafeStain 
bufer was removed with dH2O and G: BOX from Syngene Bio Imagine took a picture of 
gel.  
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Protein ladders 
5 µl of Benchmark ladder (cat. no: 10747-012, Invitrogen) was used for story gels and 
His tag Western blots. 3 µl of Magic Mark (cat. no: LC5602, Invitrogen) was used for 
any another blots prepared for experiments related to this study. The only exception is 
Biotinylated protein ladder (cat. no: 7727L Cel Signaling) used for internalization 
study in the volume of 5 µl. 
 
 
Figure 16 Protein Standards for electrophoresis. 
 
2.5.6.2 Spectrophotometric determination of protein concentration 
The concentration of total protein in a sample was determined using the Beer Lambert 
law. 
A=ε C l 
Where A – Absorbance 
  ε – Molar extinction coeficient 
  C – Protein concentration 
   L – Path length 
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The A280nm reading was taken by a Nanodrop. The molecular weight of the protein and 
the molar extinction coeficient were calculated on the ExPASy proteomics server 
ProtParam tool: htp://www.expasy.org/tools/protparam.htlm. 
 
2.5.6.3 Purity and activation assessment 
The purity and activation assessments were prepared using densitometry and 
recorded in percentage. The final sample at 0.1 mg/ml loaded in 10 µl on the SDS PAGE 
gel was used to determined purity. The sample at 0.1 mg/ml in reducing conditions 
(100 mM DTT) loaded in 10µl on the SDS PAGE gel was used to determined activation. 
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2.5.6.4 Western blot system 
 
Figure 17 Western blot system. 
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2.5.6.4.1 Electroblotting procedure 
The electrobloting procedure was used for transferring proteins to membranes. The 
protein was separated by gel electrophoresis. Next, the gel was soaked in the protein 
transfer bufer. 
Protein transfer bufer 
200 ml Tris – Glycine SDS-Running Bufer (10×, cat. no: LC2675-5, Invitrogen)  
400 ml Methanol 
1400 ml Distiled water 
The total volume for one transfer tank is 2000 ml 
The protein was transferred to pre-cut Nitrocelulose Membrane (cat. no: LC2000, 
Invitrogen). The electroblotting cassette was assembled and placed between 
electrodes in the blocking unit in the way that a protein was migrating through electric 
current from cathode to anode. The wet transfer took 1 hour at 400 mA with variable 
volts.  
2.5.6.4.2 Immunodetection 
Blocking the membrane 
Non-specific binding sites were blocked by immersing the membrane in the blocking 
reagent: 0.5% BSA (Albumin from bovine serum, cat. no: A8022-500G, Sigma) or 3 % 
Marvel (dried skimmed milk, TESCO) in PBS -T (1× PBS – Phosphate Bufered Saline 
(10×), 0.1 % Tween (20%) for at least 1 hour or overnight  at  4̊C  on the shaking 
platform. 
Washing membrane 
Prior to application of antibody the membrane was washed for 30 minutes in the PBS – 
Tween changed three times during this time.  
Primary and secondary antibody 
Purification sample were tested using: 
1/2500 dilution His Tetra Antibody (cat. no: 34670, QIAGEN) – 1/1000 dilution anti-
Mouse 
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1/1000 dilution Light chain antibody produce against specific serotype of LHN molecule 
– 1/1000 dilution anti – Rabbit 
Internalization was tested using: 
1/2000 dilution Streptavidin-HRP (Sigma)  
Activation was tested using: 
1/1000 dilution phospho-MAPK (#9101Cel Signaling Technology)-1:1000 anti-Rabbit  
1/1000 dilution MAPK (#9102 Cel Signaling Technology)-1:1000 anti-Rabbit   
1/1000 dilution phospho-EGFR (#2236 Cel Signaling Technology)-1:1000 anti-Mouse   
1/1000 dilution EGFR (#2232 Cel Signaling Technology)-1:1000 anti-Rabbit   
1/500 dilution β-actin (Abcam ab8227)-1:1000 anti-Rabbit   
 
Secondary antibodies were purchased from Sigma. 
Anti-Rabbit IgG (whole molecule), Peroxidase developed in Goat, cat. no: A6154-1ML 
Anti-Mouse IgG (γ-chain specific), Peroxidase developed in Goat, cat. no: A3673-1ML 
After primary and secondary antibody, the blots were washed three times in PBS-T for 
10 minutes. 
Detection 
1 ml of ECL detection reagent (Super Signal west duration substrate) was applied (0.5 
ml reagent A + 0.5 ml reagents B) on each blot. After 5 minutes, each blot was 
developed inside the GENOME (Syngene Bio Imagine) for 3 to 5 minutes what depends 
on the used antibody. 
 
2.5.6.5 N-terminal protein sequencing 
Alta Bioscience at University of Birmingham prepared the order of amino acids at N-
terminus of sample. The laboratory uses the Edman N-terminal sequencing method. 
The detection of protein sequencing is only possible by transferring the protein to a 
PVDF membrane. PVDF membranes were blotted in 10 mM CAPS (3-
(Cyclohexylamino)-1-propanesulfonic acid) pH 11.0 and stained by Ponceau S solution 
(cat. no: P7170-1L, Sigma) to visualized bands on the membrane. The membranes were 
prepared at Syntaxin Ltd.  
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2.6 Activation studies 
2.6.1 Reagents 
Media – Gibco 31966 (should be left 1 h at the room temperature and half an hour in 
the water bath at 37̊C before actual experiment). 
FBS- 50 ml takes half an hour to be defrosted; it should be filtered using 20 ml syringe 
and 0.2 µm filter, 
A549 (Human cels) - EGF receptor activation,  
EGF-SIGMA E9644-2MG 
2.6.2 Preparation of EGF 
Used human, recombinant EGF, expressed in S. Cerevisiae 50 ng/ml, (6 kDa) purchased 
from Sigma; cat. no. E1264. 
Reconstitute the contest to 1 mg/ml using filtered 10 mM acetic acid. Dilution to lower 
concentrations (not less than 10 pg/ml) wil require addition of 0.1% BSA. 
1mg/ml was reconstituted in 200 µl 10mM acetic acid (166.7 µM = 166667 nM) 
2.6.3 Dilution of EGF in media 
32 ml of media was added to 19.2 µl of EGF stock (1 mg/ml) to get 100 nM stock, 
9 ml of media was added to 1 ml of 100 nM stock to get 10 nM stock, 
27 ml of media was added to 3 ml of 10 nM stock to get 1 nM stock, 
The 10 nM stock solution wil be discarded. 
Al dilutions were prepared under fume cupboard.  
2.6.4 Preparation of plates for activation experiment 
Seven plates were prepared for this experiment: 
Plate nr 1- serum - free control 
Plate’s nr 2, 3  –  1 nM, and 100 nM keep for 5 min. in the 37̊C incubator to detect 
phospho-EGFR 
Plate’s nr 4, 5  –  1 nM and 100 nM keep for 20 min. in the 37̊C incubator to detect 
phospho-ERK ½  
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Plate’s nr 6, 7  –  1 nM and 100 nM keep for 45 min. in the 37̊C incubator to detect 
phospho- ERK 1/2 
Plates were prepared two days before experiment; amount of plates depends on time 
of experiment and dilutions of ligand or fusion protein, the media should be changed 
in the plates each day, 
1. Plates were removed (serum-free media) from the incubator 37̊C and cel grow 
was checked under microscope, positive results suggested about the 
continuation of the experiment, 
2. Media were discarded from the plates under fume cupboard. 
3. Plates were numerate and 10 ml of media + EGF was added to each plate (the 
best start with plate of the lowest to the highest concentration). It is important 
to keep pipete on the side of Petri dish when adding media + EGF to avoid 
damage of cels. 
4. Plates were placed at the 37̊C in the incubator and time was counted from that 
moment.  
5. In the meantime in the fume cupboard the folowing reagents and products 
were placed : bucket with ice to stop phosphorylation, 50 ml of dH2O in the 50 
ml falcon tube, seven eppendorfs (amount depends on the amount of plates), 
10 ml sterile pipettes, sterile scraper, piece of tissue, 200 µl and 500 µl pipetes 
and sterile tips for them, squeezing pipettes, bijou. PBS 1% from the fridge was 
placed on the ice under fume cupboard as wel as 500  µl of lysis bufer (10×, 
cat. no: 9803, Cel Signaling Technology). 
6. Preparation  of  Cel  Lysis  Bufer:  4.5 ml  of  dH2O add  500  µl  of  Lysis  Bufer 
(10×). 
7. After first 5 min, two plates were removed to stop phosphorylation on ice. 
8. Petri-dishes were washed twice with 10 ml of PBS-1% applied on the edge of 
plate avoid damage of the cels. Plates were place in the vertical position on the 
side of bucket and squeezed al PBS-1% out. 
9. 200 µl of Lysis Bufer was applied on the plate for a few minutes. Al cels were 
scraped from the edge of plate and next towards the middle of the plate 
surface. Cels were moved to one point of plate and transferred to eppendorfs 
using sterile pipete. 
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10. Steps from number 7 were repeated for another nine plates.  
11. Control plate was prepared on the end of experiment. 
12. Al lysates were kept in the freezer -20̊C. 
 
2.6.5 BCA assay and Western blots 
2.6.5.1 BCA assay 
The concentration of protein was determined by BCATM  Protein assay according to 
Pierce protocol. The microplate procedure was used with Maxisorp Nunc-
Immunoplate. 
The BCA standards were 0.1 mg/ml; 0.2 mg/ml; 0.4 mg/ml; 0.6 mg/ml; 0.8 mg/ml; 1.0 
mg/lm; 2.0 mg/ml. 
The lysate were thawed from -20̊C and spun in the micro centrifuge at 4̊C for 10 min 
at 14000 xg.  
10  µl of each lysate was diluted 1:5 (can be lower or higher dilution depending on 
estimated concentration). 1:5 dilutions of lysate were prepared by addition 10  µl of 
lysate to 40 µl of dH2O. 
2.6.5.2 Western blots 
Western  Blots  were prepared  against  β-actin, EGFR, phospho-EGFR, MAPK, phospho-
MAPK 
The Western blots were prepared according to the chapter 10.5.6.4 with some 
exceptions described below. 
Samples; lysate + LB + DTT, volume of each wil depend on BCA calculations. 
Wet Transfer 
Phospho-MAPK and MAPK, β-actin -40 V for 45 min folowed by 60 V for 30 min. 
Phospho-EGFR and EGFR- 60 V for 45 min folowed by 100 V for 30 min. 
Chiled transfer bufer: (200 ml of Tris - Glycine, 400 ml of Methanol and up to 2000 ml 
of dH2O). 
Blotting membranes 
Phospho-MAPK, MAPK, phospho-EGFR, EGFR were blotted in 5% BSA in PBST. 
β-actin was blotted in 5% Marvel milk in PBST. 
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2.7 Internalization studies 
Cels were grown in the flasks, when semi-confluent was harvested in warmed HANKS 
based dissociation bufer, peleted and re-suspended in ice-cold DMEM with 1 mg/ml 
BSA. The cels were counted, so that the same numbers of cels were used for each 
experimental point (1-5 x 106). The biotinylated protein (300-600 nM) was added on 
this stage and incubates for 1 h on ice. 
The appropriate tubes were transferred to 37°C and incubated for the desired time (2-
180 min), folowed by rapid chiling on ice and centrifugation for 2 min at 1200 x g.  
Cels were washed in  a cold PBS containing 1 mM MgCl2 and 0.1 mM CaCl2 three 
times. Cels were left on the ice without acid stripping until step 8. 
Some of cels were acid stripped by re-suspending in acid bufer (50 mM Glycine pH 
5.0, 450 mM NaCl) and left on ice for 2 min. After that time, cels were spun down and 
washed once in PBS. Next, cel were re-suspended in Proteinase K (1 µg/ml) and left on 
ice for 5 min. Subsequently, they were washed twice with PBS. On this stage, the lysis 
was checked using a haemocytometer. 
Cels were spun down and re-suspended in 250 µl of lysis bufer (Cel signaling 
technology: 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1mM Na2EDTA, 1 mM EGTA, 1% 
Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerphosphate, 1 mM Na3VO4, 1 
µg/ml leupeptin) with cocktail protease inhibitors (Roche) and left for 15 min on ice. 
The lysate was cleared by 15 min centrifugation at 16,000 x g. The supernatant was 
adsorbed with Streptavidin magnetic particles (Pierce), overnight at 4°C or 2 h at room 
temperature. 
The particles were washed three times in lysis bufer at 4°C, folowed by one wash in 
the water. The biotinylated protein was eluted by boiling in 100 µl of LDS-PAGE sample 
bufer with 100 mM DTT. The beads were separated from sample using the magnet.  
The samples were run on a 4-12% SDS-PAGE gel (50 min at 200 V) and subsequently 
were blotted onto nitrocelulose membrane by the wet transfer method (400 mV, 100 
V  for 1 h at 4°C). Blots were blocked in 5% BSA in PBS-Tween for 1 h. The membranes 
were probed with streptavidin-HRP (Sigma) 1/2000 dilution (1 h at RT or overnight at 
4°C), washed and developed using Super-signal West Dura substrate (Pierce). 
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Chapter 3. Design of recombinant antibody based constructs 
 
3.1 Single chain variable fragments 
 
 A variety of recombinant antibody (rAb) formats has been tailored for specific 
applications. One of most common types of rAb are scFvs (single chain variable 
fragments) which are superior to their Fab and IgG counterparts due to their higher 
afinity to the target antigens, successful modification into a number of diferent 
antibody formats, and uncomplicated expression by several expression systems. For 
these reasons, the scFvs were the choice for this study.  
 
3.1.1 Single chain variable fragment antibody 
Single chain variable fragments, developed independently by Huston et al. (1988) and 
Bird et al. (1988) (Weisser and Hal, 2009), are one of the most widely used antibody 
formats engineered into larger, multivalent and conjugated forms which are used for 
many clinical applications.  
A single chain variable fragment antibody consists of antibody variable light (VL) and 
heavy (VH) fragment linked together by peptide linker (Raag and Whitlow, 1995). Also 
known as single chain variable fragments (scFvs), their size range is from 27,000 to 
30,000 Da. Single chain antibodies are the smalest antibody fragments encoded by a 
single gene to carry the entire antigen-binding region (Bird et. al., 1988). They retain 
the binding properties of their parent antibodies (Glockshuber et. al., 1990) and can be 
expressed in functional form in Escherichia coli expression systems (Hu, O’Dwyer and 
Wal, 2005). Single chain Fv fragments have demonstrated intracelular properties, 
such as binding to a specific target in the cel (Tanaka, Lobato and Rabbits, 2003). 
Since they have been efective against target proteins in vivo (Rondon and Marasco, 
1997, Biocca, Pierandrei-Amaldi and Cattaneo, 1993, Tavladoraki et. al., 1993) they can 
be use in the treatment of human diseases and in functional genomics (Rondon and 
Marasco, 1997, Cataneo and Biocca, 1999) in which the target protein interactions 
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can be found only inside the cel (Tanaka, Lobato and Rabbits, 2003). ScFvs are 
suitable for tumour targeting (Owens and Young, 1994) due to rapid tissue penetration 
and fast blood clearance. In summary the single –chain variable fragment (scFv) are a 
wel characterised format of recombinant antibody (rAb) and they have been 
engineered into larger, multivalent and conjugated forms for many therapeutic 
applications (Weisser and Hal, 2009). Single chain variable fragments were selected as 
potentialy favourable candidates for engineering novel recombinant proteins based 
on the botulinum neurotoxin chimera.  
3.1.2 Single chain variable fragment antibody structure 
The VH and VL domains of the single chain antibody fragments are tethered together 
with a peptide linker (Weisser and Hal, 2009). The common structure of scFv 
monomers is designed with the C –terminal end of VH domain joined by a peptide 
linker to the N-terminal residue of VL; and in the reverse orientation, the C-terminal 
end of the VL domain is linked to the N-terminal residue of VH (Malby et. al., 1993, 
1998). The peptide linker is typicaly 10-25 amino acid residues in length and includes 
hydrophilic amino acids that connect the carboxyl terminus of one variable fragment 
with the amino group of the other variable fragment (Fig 18). 
 
 
Figure 18 A single chain variable fragments (scFv) molecule. 
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The choice of peptide linker is based on factors, such as the suitability of the linker 
conformation and length (Takkinen et. al., 1991) and the intended application of the 
scFv (Raag and Whitlow, 1995). The selection of linkers should not influence major 
obstructions to variable chains structure (Takkinen et. al., 1991). The non-specific 
interactions between long linkers and variable fragments need to be avoided in order 
to achieve the increased antigen binding selectivity (Leong and Chen, 2007). 
Proteolytic stability of the linkers is another critical feature in order to minimise 
protein aggregation, which wil result in function and yield losses (Arndt et. al., 1998, 
Trinh et. al., 2004). Two practical considerations in scFv design are (i) maintaining 
solubility and (i) optimizing linker sequences to minimize the possibilities of protease 
attack and minimize scFv oligomerization. 
3.1.3 Selection of scFv 
Mast/stem cel growth factor receptor (SCFR) also known as proto-oncogene c-kit or 
CD117 is a protein that in humans is encoded by the Kit gene. The overexpression or 
mutation of this protein can lead to cancer. CD117 is of great importance for the 
classification of tumours, therefore the single chain antibody against CD117 was 
generated.  Recombinant scFv CD117 sequence was obtained from the patent WO/ 
2007/ 127317. The patent covered two diferent sequences for the heavy chain of 
whole immunoglobulin (SR-1 IgG) and only one sequence for the light chain of whole 
immunoglobulin (SR-1 IgG) against CD117. In this instance, the variable light chain  
and one of the variable heavy chains were used for design of scFv against CD117. The 
variable part of chains show great variability in amino acid sequence among the chains 
and has areas caled hypervariable regions that form the antigen-binding sites.  The 
unique sequence of amino acid residues for variable fragments leads to the large 
diversity of structure, which counts for antibody specificity. Single chain antibody (scFv 
CD117) targets C-kit receptors belonging to the family of tyrosine kinase receptors 
(RTK), which have a critical role in the development and progression of many types of 
cancer (Nygren et. al., 1994). The tumour usualy starts when a gene caled kit 
develops a mutation. The abnormal Kit protein sends out a signal that causes the cel 
to multiply out of control, which causes the formation of a tumour. This happens in 
gastrointestinal stromal tumours (GIST). It is has already been established that the 
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humanized C-kit antibodies play an important role in the treatment of cancerous 
diseases. Imatinib (Gleevec) is a multi-target tyrosine kinase receptor inhibitor that 
targets C-kit signaling activity. Gleevec is a unique drug developed to fight a cancer by 
turning of the enzyme that causes the cels to become cancerous (LaValie and McCoy, 
1995). This successful product from Novartis increased the anticipation for the 
possibility of generating a new class of drugs based on antibody structure. This 
evidence of the possibility to produce novel drugs with scFvs gives a beter opportunity 
to develop LHN-scFv molecules. The choice of recombinant scFv enabled the targeting 
of EGFR (epidermal growth factor receptor) which would alow experiments to be 
performed on the activation and internalization of the receptor. 
3.1.4 Results 
Recombinant scFvCD117 was designed with the sequences provided in the patent 
WO/2007/127317 (taken from a PATENTSCOPE website 
http://www.wipo.int/patentscope/search/en/WO2007127317). 
A peptide linker (Gly4Ser)3 caled GS15 links the variable heavy chains to the variable 
light chains was introduced. The new scFv was recorded in the central stock under 
name scFvCD117I. 
3.1.4.1 Choice of light and heavy chain variable regions 
3.1.4.1.1 The kappa light chain of SR-1 IgG   
The nucleic acid encoding the humanized kappa light chain SEQ ID NO: 2 from the 
patent, includes amino acids 20 to 248 of SEQ ID NO: 2.  
The folowing amino acids sequence in the SEQ ID NO: 2 represents the CDR’s 
(complementarity determining regions): CDR1 is amino acids 43 to 58, CDR2 is amino 
acids 74 to 80 and CDR3 is amino acids 113 to 121. 
The CDR’s sequences are in blue. The variable part of light chain is in black. The 
constant part of light chain is in grey. 
DIVMTQSPDSLAVSLGERATINCRASESVDIYGNSEMHWYQQKPGQPPKLLIYIASNIESGVPDR
FSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIKR 
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TVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTFNRGEC  
The coding DNA sequence of the light chain is prepared by  back-translation of the 
protein sequence. This wil alow the scFv molecule to be synthesized. 
3.1.4.1.2 The heavy chain of SR-1 IgG 
The nucleic acid encoding the humanized heavy chain SR-1 IgG2 SEQ ID NO: 4 is from 
the patent. The folowing amino acid sequence in the SEQ ID NO: 4 represent the 
CDR’s: CDR1 is amino acids 50 to 54, CDR2 is amino acids 69 to 85 and CDR3 is amino 
acids 118 to 125. The raw SEQ ID NO: 4 pg (atached Heavy chain – raw from patent)  
The CDR’s sequences are in blue. The variable part of heavy chain is in black. The 
constant part of heavy chain is in grey.  
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSY
NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSSAS 
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSWT
VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS
RTPEVTCVWDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYQSTYRWSVLTVLHQDWLNGKE
YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 
The coding DNA sequence of the heavy chain is prepared by  back-translation of the 
protein sequence. This wil alow the scFv molecule to be synthesized. 
3.1.4.2 Design of scFVCD117I  
The gene organization of scFvs represents the variable regions connected in either the 
VH- linker-VL or VL-linker-VH orientation, where linker can be (Gly4Ser)3. However, the 
most common form is where the scFv gene starts with the N terminus of the variable 
heavy chain sequence, which run through to 13-18 amino acids past CDR-H3 (CDR3 of 
the heavy chain). The final typical set of VTVSA/S amino acids is maintained within 
variable heavy chain antibody domain. This variable heavy chain amino acid sequence 
is joined by peptide linker for instance (Gly4Ser)3 to the N terminus of the variable light 
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chain. The scFv gene ends on or one residue after TK motif 8 residues from end of CDR-
L3 CDR3 of the light chain. 
The choice of linker was based on a number of considerations. The length of the linker 
according to the information within the patent indicates that it should be around 10 
residues in length, however according to the data colected in-house a linker that has 
20 residues shows the best results for solubility and folding of the purified molecules. 
On the other hand, most of literature provides information that the scFvs peptide 
linker can vary between 10 to 25 residues. The proposed linker in the patent is 
EEGEFSEAR, but after taking to account the above suggestions it was decided to use a 
GS15 (Gly4Ser)3  linker, which combines the length characteristics. 
3.1.4.2.1 ScFv –CD117I 
QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYNMHWVRQAPGQGLEWMGVIYSGNGDTSY
NQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCARERDTRFGNWGQGTLVTVSSASGGGG
SGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCRASESVDIYGNSEMHWYQQKPGQPPKLLI
YIASNIESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPYTFGGGTKVEIR  
        10         20         30         40         50         60  
QVQLVQSGAE VKKPGASVKV SCKASGYTFT SYNMHWVRQA PGQGLEWMGV IYSGNGDTSY  
 
        70         80         90        100        110        120  
NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARER DTRFGNWGQG TLVTVSSASG  
 
       130        140        150        160        170        180  
GGGSGGGGSG GGGSDIVMTQ SPDSLAVSLG ERATINCRAS ESVDIYGNSE MHWYQQKPGQ  
 
       190        200        210        220        230        240  
PPKLLIYIAS NIESGVPDRF SGSGSGTDFT LTISSLQAED VAVYYCQQNN EDPYTFGGGT  
 
 
KVEIKR  
Number of amino acids: 246 
Molecular weight: 26180.8 
 
 
 
 
87 Engineering botulinum-antibody proteins 
 
 
The conversions of amino acid sequence to the coding DNA sequences for CD117ScFv 
was prepared using Entelechon’s backtranslation tool. This tool is available at the 
website htp://www.entelechon.com/backtranslation-tool. 
The sequence  was entered into the Entelechon programme and the codon usage 
parameters were set to Escherichia coli. The SNAP-ON restriction sites (Table 9) 
belonging to the open reading frame of the LHN backbone, therefore they needed to 
be identified as bad motifs to avoid their presence within the sequence in order to 
clone them into the correct position of molecule. The existence of these restriction 
sites within the sequence can be a reason of unsuccessful cloning of scFvs to 
recombinant botulinum chimeras. The sequence from Entelechon back-translation tool 
is codon-optimised for the expression in E. coli system and it lack insertion of 
restriction sites. This sequence was further optimised across the whole sequence. 
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Table 9 SNAP ON Restriction enzymes in LHN open reading frame 
Restriction enzyme Cleavage site 
Ava I C↓(C/T)CG(G/A)G 
Avr I C↓CTAGG 
BamH I G↓GATCC 
Bgl I A↓GATCT 
EcoR I G↓AATTC 
Hind II A↓AGCTT 
Nde I C↓ATATG 
Nhe I G↓CTAGC 
Pst I CTGCA↓G 
Sal I G↓TCGAC 
Spe I A↓CTAGT 
Xba I T↓CTAGA 
Xma I C↓CCGGG 
 
 
 NdeI AvaI PstI SpeI SalI BamHI XbaI HindII 
A -  linker LC Tag HN spacer ligand 
 
Figure 19 The most common SNAP-ON restriction enzymes within LHN backbone. 
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3.1.4.3 Optimisation of DNA  
The optimised sequence was then copied from the results of the back-translation tool 
and pasted into the word document, so the changes in the DNA sequence could be 
identified. 
The optimisation of DNA was checked by a second software package caled the 
graphical codon usage analyser. The programme is available at 
http://www.gcua.schoedl.de/ website. This tool analyses two parameters and the 
results are displayed in appendix each triplet position vs. usage table and each codon 
vs. usage table.  
3.1.4.3.1 Each triplet position vs. usage table 
The each triplet position vs. usage table shows each amino acid in the sequence and 
gives a visual representation of the frequency of the codon usage of each codon. This 
was utilized to reduce the usage of rare codons or runs of less frequently used codons 
to preventing pausing or staling of translation.  
3.1.4.3.2 Each codon vs. usage table 
The each codon vs. usage table shows the codons that can be used for each amino acid 
and compares how often it should be used in a sequence (in %) against how often it is 
used in designed sequences. This was utilized to choose which codons to use as 
replacements in the designed sequences.  
The back-translated sequences were optimized according to Escherichia coli codon 
usage table. The iterations were introduced avoiding very rare codons and overloading 
very common codons. 
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3.1.4.4 Back-translated and optimised DNA  
3.1.4.4.1 Back-translated 
The substitutions made within the sequence are highlighted in blue. 
CD117IScFv 
CAAGTCCAGCTGGTACAGAGTGGCGCTGAGGTCAAAAAGCCAGGAGCAAGCGTTAAAGT
TTCCTGTAAGGCGTCGGGTTACACTTTCACAAGTTATAATATGCATTGGGTACGCCAGG
CGCCTGGACAAGGGCTTGAATGGATGGGTGTCATTTATTCGGGTAACGGTGATACCAGC
TATAACCAGAAATTCAAAGGGCGTGTGACGATAACTGCTGATAAAAGTACCTCTACAGC
TTACATGGAGCTTTCTTCGTTGCGTTCAGAAGACACGGCAGTGTACTATTGTGCACGGG
AGCGCGATACGCGTTTTGGGAATTGGGGACAAGGCACTCTGGTGACAGTATCCAGCGCG
TCAGGGGGCGGAGGTTCTGGGGGAGGCGGATCAGGGGGAGGTGGTTCCGATATTGTCAT
GACTCAGTCTCCGGACTCCCTGGCCGTTTCGCTGGGTGAAAGAGCTACGATAAACTGCC
GAGCCAGCGAGAGCGTAGACATCTATGGCAACAGTGAAATGCACTGGTATCAACAGAAA
CCGGGTCAACCCCCTAAGCTCTTAATCTATATAGCATCGAATATCGAGTCTGGAGTTCC
AGATCGCTTTTCCGGCAGTGGGTCAGGCACAGACTTTACCTTGACAATAAGTTCATTAC
AGGCGGAGGACGTGGCAGTTTACTACTGCCAACAAAATAATGAAGATCCCTACACTTTC
GGAGGCGGGACCAAGGTAGAAATTAAGAGA 
The prepared sequence of scFv  was checked using SeqBuilder programme of the 
DNASTAR Lasergene package to confirm that no unwanted changes had been 
introduced during the redesign, such the SNAP-ON restriction sites. 
The final predicted sequence  was inserted into  a new DNA folder in the SeqBuilder 
programme. Then the restriction site XbaI was added to the N-terminal of sequence 
with addition of “A” base after TCTAGA motif to avoid a frame shift. Therefore, after 
digestion it wil leave CTA GAA (LE) at the start of the sequence.  
The restriction site HindII (AAGCTT) was added on the C-terminus of the sequence. 
HindII wil leave one bp “A” at the end of the sequence. The sequence of ScFv has two 
stop codons: TAA and TAG from the C-terminus side of the molecule. 
 
 
 
91 Engineering botulinum-antibody proteins 
The predicted sequence of CD117IScFvs  was prepared. The drop out fragment 
between the restriction sites: XbaI and HindII from ScFv, separately was inserted into 
the backbone construct SXN101327 (pK7-10HT-LB-EK-HB (K191A)-GS20-EGF). The 
insertion of CD117IScFv in place of the EGF ligand was performed using the SeqBuilder 
program to ensure that there were no unintentional changes in the sequence. 
3.1.4.4.2 Optimized DNA 
CD117IScFv 
tctagaaCAAGTCCAGCTGGTACAGAGTGGCGCTGAGGTCAAAAAGCCAGGAGCAAGCGTTAA
AGTTTCCTGTAAGGCGTCGGGTTACACTTTCACAAGTTATAATATGCATTGGGTACGCCAGGC
GCCTGGACAAGGGCTTGAATGGATGGGTGTCATTTATTCGGGTAACGGTGATACCAGCTATA
ACCAGAAATTCAAAGGGCGTGTGACGATAACTGCTGATAAAAGTACCTCTACAGCTTACATGG
AGCTTTCTTCGTTGCGTTCAGAAGACACGGCAGTGTACTATTGTGCACGGGAGCGCGATACGC
GTTTTGGGAATTGGGGACAAGGCACTCTGGTGACAGTATCCAGCGCGTCAGGGGGCGGAGG
TTCTGGGGGAGGCGGATCAGGGGGAGGTGGTTCCGATATTGTCATGACTCAGTCTCCGGACT
CCCTGGCCGTTTCGCTGGGTGAAAGAGCTACGATAAACTGCCGAGCCAGCGAGAGCGTAGAC
ATCTATGGCAACAGTGAAATGCACTGGTATCAACAGAAACCGGGTCAACCCCCTAAGCTCTTA
ATCTATATAGCATCGAATATCGAGTCTGGAGTTCCAGATCGCTTTTCCGGCAGTGGGTCAGGC
ACAGACTTTACCTTGACAATAAGTTCATTACAGGCGGAGGACGTGGCAGTTTACTACTGCCAA
CAAAATAATGAAGATCCCTACACTTTCGGAGGCGGGACCAAGGTAGAAATTAAGAGAtaataga
agctt 
The synthesized scFv gene was subsequently cloned into LHN backbones derived from 
diferent serotypes of botulinum neurotoxin.  
Entelechon prepared the synthesis of 757bp scFv sequence. The Entelechon reports 
are atached in the appendix. 
3.2 Single domain antibodies 
The naturaly occurring single domain antibodies that lack L-chain were discovered in 
the serum of camels. This, the smalest known antigen binding fragments, attracted a 
lot of attention from many research groups al over the world and become a one of the 
most important molecule in the creation of novel drugs. It was advantageous to 
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introduce the repertoire of these antibodies as a part of LHN molecules because of 
their smal size, which may increase expression levels of the ful-length protein.  
3.2.1 Single domain antibodies 
Single domain antibodies (sdAbs), also known as domain antibodies (dAbs) or 
nanobodies are the smalest antibody fragments with a size of 11-15 kDa (Saerens, 
Ghassabeh and Muyldermans, 2008) and Ilamas, other camelids (Genst et. al., 2006) 
and sharks, naturaly produce these heavy chain antibodies (hcAbs) that lack light 
chain altogether. Single domain antibodies have been also isolated from either heavy 
chain or light chain variable regions of human antibodies (Wesolowski et. al., 2009). 
The single domains of camelids are more often used for biotechnological applications 
than those from sharks because the immunization process is more simple (Harmsen 
and Haard, 2007). Some of the properties of single domain antibodies are noteworthy. 
They remain functional with an active antigen-binding specificity after prolonged 
incubation at temperatures from 80 to 92̊C (Vranken et. al., 2002, Tanha et. al., 2002, 
Ewert et. al., 2003, van der Linden et. al., 1999, Dumoulin et. al., 2002), they show an 
increased resistance against denaturation (Perez et. al., 2001, Ewert et. al., 2003), they 
have rapid blood clearance and fast tissue penetration. This makes them exceptional 
useful for targeting VHHs coupled to toxic substances to tumours (Cortez-Retamozo et. 
al., 2004). The short serum half- live of dAbs has been extended by their targeting to 
long-lived proteins, such as albumin (Coppieters et. al., 2006, Roovers et. al., 2007) and 
immunoglobulin (Harmsen et. al., 2005a). They could be used for many therapies 
including the treatment of cancer. It has been recorded that sAbs binds to epidermal 
growth factor receptor (EGFR), so they block EGF binds to this receptor. This approach 
is currently being investigated in treatment of solid cancers (Roovers et. al., 2007). 
Further experiments showed that they could be used in targeting drugs across the 
blood-brain barrier (BBB) into the brain (Muruganandam et. al., 2002) what 
subsequently could be used for treatment of neurological disorders (Gueorguieva et. 
al., 2006). Overal, the biophysical properties of VHH antibodies seem to be good 
candidates for the construction of recombinant antibody – botulinum toxin hybrid 
molecules.  
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3.2.2 Single domain antibody structure 
Camelids and sharks produce functional antibodies composed only of heavy chains 
(Brekke and Sandlie, 2003, Hamers-Casterman et. al., 1993). They are devoid of the 
light chains (Hamers-Casterman et. al., 1993) and in the case of camelids antibodies; 
the CH1 domain is absent (Holiger and Hudson, 2005). The CH1 domain in the 
conventional antibody associates with the light chain and to some degree interacts 
with VH domain (Harmsen and Haard, 2007). Their single domain of hcAbs binds 
antigen without requiring domain pairing and is linked directly via a hinge region to the 
Fc domain (Wesolowski et. al., 2009). The antigen-binding domain is designated VHH 
for camelids hcAbs and VNAR for shark hcAbs (Holiger and Hudson, 2005). Each single 
domain antibody therefore contains three of the six naturaly occurring 
complementarily determining regions (CDRs) from an antibody (Holt et. al., 2003). A 
comparison of the structure of CDR1 and CDR2 with the set of loops found in human 
antibodies exposed significant diferences in their main chain conformation 
(Decanniere et. al., 2000). The CDR3 regions of these antibodies have an extraordinary 
capacity to form long extensions that can extend into cavities present on antigens 
(Wesolowski et. al., 2009). For this reason, they are able to recognize enzyme active 
sites and conserved cryptic epitopes (Lauwereys et. al., 1998). In addition, the CDR3 
regions of VHHs and VNARs are much longer in comparison to the conventional VH 
domains (Wu, Johnson and Kabat, 1993, Harmsen and Haard, 2007) being up to 17 
residues in length compared the 12 residues in human or 9 residues in mouse (Holt et. 
al., 2003). An additional disulphide bond connecting the CDR3 to CDR1 loop or to CDR2 
loop occasionaly stabilizes the extended CDR3 (Wesolowski et. al., 2009) (Fig 20). The 
CDR2 region in the shark single domain antibodies does not contribute to antigen 
binding (Streltsov et. al., 2004). 
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Figure 20 Schematic diagram of the VHH domain of a camelid heavy chain antibody 
and disulphide bond framework regions (adapted from Wesolowski et al., 2009) 
 
a The three complementarity determining regions (CDRs) of the antigen-binding 
paratope are depicted as coloured loops: CDR1 red, CDR2 green, and CDR3 blue. 
b The canonical disulfide bond connecting framework regions 1 and 3 (FR1 and FR3) in 
the two β-sheets of the immunoglobulin domain is indicated in yelow. Many camelid 
antibodies contain an additional disulfide bond (S–S) connecting the CDR3 with the 
end of the CDR1 (camels) or the beginning of the CDR2 (lamas). h Hinge, M 
transmembrane domain of membrane isoform, G glycosylation site, S stop codon of 
secretory isoform. 
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3.2.3 Selection of sdAbs 
For the creation of single domain antibodies (sdAbs), where the antibody domain is 
engineered to comprise only the variable heavy or variable light chain (and therefore 
consist of three CDR’s), the amino acid sequences of 11 anti-EGFR sdAbs have been 
obtained from patent WO 2008/141449 A1 (taken from a PATENTSCOPE website 
http://www.wipo.int/patentscope/search/en/WO2008141449). 
They are named EGX, where X symbolizes a number of each single domain antibody. 
Six of the anti-EGFR sdAbs have been chosen from the patent for purpose of this study. 
The selection of sdAbs was based on the experimental description in the patent WO 
2008/141449 A1. The scope of the patent relates to the field of antibodies directed 
towards epidermal growth factor receptor (EGFR). The anti-EGFR proteins in this case 
single domain antibodies (sdAb) represented in this patent can be used in the targeting 
of tumours presenting EGFR on their surface and for the diagnosis and treatment of 
certain types of cancer associated with cels over-expressing EGFR on their surface.  
Based on the sequence identity of their CDR’s, the sdAbs has been divided into four 
groups: 
Group 1: EG2; EG5; EG28 
Group 2: EG6; EG10 
Group 3: EG7; EG16; EG29; EG30 
Group 4: EG31 
The amino acid sequences of 11 sdAbs specific for EGFR-extra celular domain (ECD) 
with complementarily determining regions CDR1, CDR2, CDR3 have been ilustrated 
(Fig 12 in chapter 2). 
The single domain antibodies were selected according to the description of 
experiments in the patent WO 2008/141449 A1, a brief explanation of which is given 
below. 
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The data recorded on the sensorgrams from the reading by the surface plasmon 
resonance show the binding of 0.5  µM EG2, EG10, EG31; EG43 to EGFR-extracelular 
domain (ECD). The EG2 shows the strongest binding in the longest period. The EG10 
and the EG43 have the same ability of binding; however, the EG10 lasts for the longer 
phase than the EG43. The EG31 has the lowest binding capability in the shortest 
period. 
One of the sdAb gene from each of four groups was chosen and subcloned into an E. 
coli periplasmic expression vector (pSJF2) to generate four clones: pEG2, pEG10, 
pEG31, pEG43. The four sdAb, each tagged with a 6 Histidine (His) at their C-termini 
were produced in E. coli and purified using IMAC (Immobilized Metal Afinity 
Chromatography). The yields of EG2, EG10, EG31, and EG43 were 11, 19.4, 7.8, 43 mg 
per litre of TG1 culture, respectively. 
The same four anti-EGFR sdAbs were analyzed for their binding to EGFR-ECD by surface 
plasmon resonance. The dissociation constants (KDS) of the sdAbs ranged from 55 nM 
to 440 nM and are shown below 
EGF2: 55 nM 
EG10: 126 nM 
EG31: 440 nM 
EG43: 316 nM 
A high value of KDS indicates that the anti-EGFR sdAbs have a low binding to EGFR-ECD. 
Therefore, the best binding abilities of the sdAbs are as folows in the folowing order: 
EG2, EG10, EG43, and EG31. 
The data obtained from the size exclusion chromatography of EG2, V2C-EG2, and EG2-
hFc folowing EG2 and V2C-EG2 expression in E. coli and EG2hFc expression in HEK293 
cels gave another characteristic to consider. 
The elution position of V2C-EG2 and EG2-hFc are almost identical, whereas that of EG2 
is diferent. This suggests that al sdAbs wil behave similar to EG2 during purification, 
as the expression system was the same for EG2 and V2C-EG, but they varied during 
purification.  
 
 
 
97 Engineering botulinum-antibody proteins 
According to the given results in the patent the folowing sdAbs were chosen for the 
cloning of sdAbs-LHN 
Group 1: EG28 
Group 2: EG10, EG6 
Group 3: EG7, EG43 
Group 4: EG31 (It should represents a weak example) 
 
3.2.4. Results 
3.2.4.1 Design of single domain antibodies 
The sequences of six sdAbs were obtained from the table (Fig 12 in the chapter 2) 
provided in the patent WO 2008/141449 A1. The CDR’s: CDR1, CDR2, and CDR3 are 
highlighted in blue. Introduced changes to the DNA sequence after optimisation by the 
graphic codon usage analyser are in grey (Atached documents for graphic codon 
usage analyser). 
As previously described in the section ͵Design  of  CD117Iʹ it is important to check for 
the presence of SNAP-ON restriction enzyme recognition sites within the sequence. 
The back-translated and optimised sdAbs were therefore checked using the SeqBuilder 
programme of the DNASTAR Lasergene package. 
The final predicted sequences of six sdAbs were inserted into a new DNA file in the 
SeqBuilder programme and the restriction enzyme recognition site for XbaI was added 
to the 5’-terminal of the sequences with the addition of an “A” base after TCTAGA 
motif to avoid a frame shift. Therefore, after digestion it wil leave the sequence CTA 
GAA (coding for amino acid residues LE) at the start of the coding sequence.  
The restriction enzyme recognition site for HindII with the sequence AAGCTT was 
added onto the C-terminus of the sequences. The inserted HindII recognition site wil 
leave one bp “A” at end of the sequence. Both sequences of ScFvs have two stop 
codons: TAA and TAG from the C-terminus side of the molecule. The XbaI and HindII 
restriction enzymes are coloured in green, where additional ‘A’ base residue and STOP 
codons are coloured in red. Entelechon synthesized the DNA. 
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Group 1:  
EG28 with identified CDRs                
QVQLVESGGGLVQAGDSLRLSCVDSGRDFSDYVMGWFRQAPGKEREFVAAISRNGITTRYADS
VKGRFTISRDNDKNTVYLQMNSLKPEDTAVYYCATNSAGTYVSPRSRDYDGWGQGTQVTVSS 
 
Back-translated and optimised EG28  
CAAGTTCAGCTGGTCGAATCGGGAGGTGGGTTAGTTCAAGCCGGAGATTCTCTTCGCCTGAG
CTGTGTAGACTCCGGAAGAGACTTTTCAGACTACGTAATGGGGTGGTTTCGCCAAGCGCCTGG
CAAGGAGCGTGAGTTCGTTGCTGCCATCTCACGCAACGGTATTACCACGCGGTATGCGGACA
GTGTCAAAGGCCGTTTCACAATAAGTAGAGATAATGACAAGAACACAGTATACTTGCAGATAA
TAGCCTGAAACCGGAAGATACGGCTGTCTATTACTGCGCAACCAATAGTGCAGGTACTTATGT
GTCGCCACGGAGCCGTGATTATGATGGCTGGGGACAGGGGACACAAGTGACTGTGTCCTCT 
Final EG28 synthesized by Entelechon 
tctagaaCAAGTTCAGCTGGTCGAATCGGGAGGTGGGTTAGTTCAAGCCGGAGATTCTCTTCGC
CTGAGCTGTGTAGACTCCGGAAGAGACTTTTCAGACTACGTAATGGGGTGGTTTCGCCAAGC
GCCTGGCAAGGAGCGTGAGTTCGTTGCTGCCATCTCACGCAACGGTATTACCACGCGGTATGC
GGACAGTGTCAAAGGCCGTTTCACAATAAGTAGAGATAATGACAAGAACACAGTATACTTGC
AGATGAATAGCCTGAAACCGGAAGATACGGCTGTCTATTACTGCGCAACCAATAGTGCAGGT
ACTTATGTGTCGCCACGGAGCCGTGATTATGATGGCTGGGGACAGGGGACACAAGTGACTGT
GTCCTCTtaatagaagct 
Group 2: 
EG10 with identified CDRs 
QVQLVESGGGLVQAGGSLTLSCAASGGTFSSYAMGWFRQAPGKEREFVAAISGRSSIRNYDDS
VKGRFAISRDSAKNTVYLQMNSLKPEDTAVYYCAADTVFRSFVVGNVKEWGQGTQVTVSS 
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Back-translated and optimised EG10 
CAGGTGCAATTAGTTGAGTCGGGTGGGGGACTGGTGCAAGCTGGTGGATCACTGACCTTGTC
CTGTGCGGCCAGCGGTGGCACATTCAGTAGCTATGCCATGGGCTGGTTTAGACAGGCTCCAG
GGAAAGAACGCGAATTTGTTGCTGCCATAAGTGGGCGCTCTTCCATTCGGAATTACGATGACT
CTGTCAAGGGACGTTTTGCAATCAGCAGAGACTCGGCGAAGAATACGGTCTATCTTCAGATGA
ACTCACTGAAACCTGAGGATACTGCGGTCTACTATTGCGCAGCAGATACTGTATTCCGTTCTTT
CGTAGTGGGTAACGTTAAAGAATGGGGCCAAGGAACACAAGTAACGGTATCAAGT 
Final EG10 synthesized by Entelechon 
tctagaaCAGGTGCAATTAGTTGAGTCGGGTGGGGGACTGGTGCAAGCTGGTGGATCACTGAC
CTTGTCCTGTGCGGCCAGCGGTGGCACATTCAGTAGCTATGCCATGGGCTGGTTTAGACAGGC
TCCAGGGAAAGAACGCGAATTTGTTGCTGCCATAAGTGGGCGCTCTTCCATTCGGAATTACGA
TGACTCTGTCAAGGGACGTTTTGCAATCAGCAGAGACTCGGCGAAGAATACGGTCTATCTTCA
GATGAACTCACTGAAACCTGAGGATACTGCGGTCTACTATTGCGCAGCAGATACTGTATTCCG
TTCTTTCGTAGTGGGTAACGTTAAAGAATGGGGCCAAGGAACACAAGTAACGGTATCAAGTta
atagaagctt 
Group 2: 
EG6 with identified CDRs 
QVKLEESGGGLVQAGGSLTLSCAASGGTFSSYAMGWFRQAPGKEREFVAAISGRSSIRNYDDS
VKGRFAISRDNAKNTVYLQMNSLKPEDTAVYYCAADTVFRSFVVGNVKEWGQGTQVTVSS 
Back-translated and optimised EG6 
CAAGTTAAACTGGAAGAATCAGGAGGAGGCCTGGTACAGGCCGGTGGTTCCCTTACTTTAAG
TTGTGCTGCCAGTGGTGGAACCTTTAGCTCGTATGCTATGGGTTGGTTCCGGCAGGCCCCAGG
GAAAGAGAGAGAGTTCGTGGCGGCAATAAGCGGACGTTCGTCTATCCGTAATTATGATGACA
GTGTAAAGGGGCGTTTTGCAATTTCACGCGATAATGCGAAAAACACGGTATATCTGCAAATGA
ACTCATTGAAACCTGAAGACACTGCTGTGTACTACTGCGCGGCAGATACAGTTTTTAGATCCTT
CGTCGTTGGCAATGTCAAGGAATGGGGCCAAGGGACACAGGTGACGGTCAGC TCT 
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Final EG6 synthesized by Entelechon 
tctagaaCAAGTTAAACTGGAAGAATCAGGAGGAGGCCTGGTACAGGCCGGTGGTTCCCTTACT
TTAAGTTGTGCTGCCAGTGGTGGAACCTTTAGCTCGTATGCTATGGGTTGGTTCCGGCAGGCC
CCAGGGAAAGAGAGAGAGTTCGTGGCGGCAATAAGCGGACGTTCGTCTATCCGTAATTATGA
TGACAGTGTAAAGGGGCGTTTTGCAATTTCACGCGATAATGCGAAAAACACGGTATATCTGCA
AATGAACTCATTGAAACCTGAAGACACTGCTGTGTACTACTGCGCGGCAGATACAGTTTTTAG
ATCCTTCGTCGTTGGCAATGTCAAGGAATGGGGCCAAGGGACACAGGTGACGGTCAGCTCTta
atagaagctt 
Group 3: 
EG7 with identified CDRs 
QVQLVESGGGLVQPGGSLRLSCAASESFFNFDAWGWYRQAPGKQREMVAVVGSTGSTSYAD
FVKGRFTISRDNANNTVYLQMNTLRPEDTAVYYCYARFQSLYNSWGQGTQVTVSS 
Back-translated and optimised EG7 
CAAGTGCAGCTGGTTGAGTCCGGTGGGGGCCTTGTGCAGCCAGGTGGGTCGTTGCGGCTG 
TCTTGCGCAGCCAGCGAATCTTTTTTCAATTTTGATGCGTGGGGCTGGTATCGTCAGGCGCCT 
GGAAAACAACGTGAAATGGTTGCAGTCGTGGGAAGTACGGGATCGACGAGTTACGCTGACTT
TGTAAAGGGGAGATTCACAATAAGTAGAGACAACGCAAATAACACCGTTTATCTGCAAATGA
ACACTTTACGCCCAGAGGATACAGCTGTATACTATTGTTATGCCCGCTTCCAGAGCTTATACAA
TTCATGGGGCCAAGGTACACAAGTAACTGTCTCCTCA 
Final EG7 synthesized by Entelechon 
tctagaaCAAGTGCAGCTGGTTGAGTCCGGTGGGGGCCTTGTGCAGCCAGGTGGGTCGTTGCG
GCTGTCTTGCGCAGCCAGCGAATCTTTTTTCAATTTTGATGCGTGGGGCTGGTATCGTCAGGC
GCCTGGAAAACAACGTGAAATGGTTGCAGTCGTGGGAAGTACGGGATCGACGAGTTACGCTG
ACTTTGTAAAGGGGAGATTCACAATAAGTAGAGACAACGCAAATAACACCGTTTATCTGCAAA
TGAACACTTTACGCCCAGAGGATACAGCTGTATACTATTGTTATGCCCGCTTCCAGAGCTTATA
CAATTCATGGGGCCAAGGTACACAAGTAACTGTCTCCTCAtaatagaagctt 
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Group 3: 
EG43 with identified CDRs 
QVQLVESGGGLVQPGGSLRLPCAASGSIFSLDAWGWYRQAPGKQREMVALVGSDGSTSYADS
VKGRFTISRDNANNTFYLQMNSLKPEDTAVYYCYARFQSLYNSWGQGTQVTVSS 
Back-translated and optimised EG43 
CAGGTACAATTGGTGGAATCTGGAGGGGGCTTAGTTCAACCCGGTGGATCTCTCCGTCTGCCA 
TGTGCCGCAAGTGGCTCGATTTTCAGCCTGGACGCTTGGGGATGGTATCGCCAGGCGCCTGG
CAAACAACGGGAGATGGTCGCACTTGTAGGTTCCGATGGGTCCACAAGTTATGCTGACAGTG
TTAAGGGGAGATTCACCATAAGCCGCGATAATGCGAATAACACTTTTTACCTGCAAATGAACT
CGTTGAAACCGGAAGATACGGCAGTGTATTACTGCTATGCCCGTTTTCAGTCATTATACAATA
GCTGGGGACAGGGTACACAAGTAACTGTCTCATCA 
Final EG43 synthesized by Entelechon 
tctagaaCAGGTACAATTGGTGGAATCTGGAGGGGGCTTAGTTCAACCCGGTGGATCTCTCCGT
CTGCCATGTGCCGCAAGTGGCTCGATTTTCAGCCTGGACGCTTGGGGATGGTATCGCCAGGC
GCCTGGCAAACAACGGGAGATGGTCGCACTTGTAGGTTCCGATGGGTCCACAAGTTATGCTG
ACAGTGTTAAGGGGAGATTCACCATAAGCCGCGATAATGCGAATAACACTTTTTACCTGCAAA
TGAACTCGTTGAAACCGGAAGATACGGCAGTGTATTACTGCTATGCCCGTTTTCAGTCATTATA
CAATAGCTGGGGACAGGGTACACAAGTAACTGTCTCATCAtaatagaagctt 
Group 4:  
EG31 with identified CDRs 
QVKLEESGGGLVQVGGSLRLSCAHSGLPFGINAIGWYRQGPGNQRDLVARITSDGRTILEDSVK
GRFTISRDNAKKTVYVQMNNLKPEDTAVYYCAAEKGGSPLYWGQGTQVTVSS 
Back-translated and optimised EG31 
CAGGTGAAGTTAGAGGAAAGTGGTGGGGGACTTGTTCAAGTGGGGGGAAGTCTCCGTTTGT
CTTGCGCTCATAGCGGCTTGCCCTTTGGCATTAACGCAATAGGATGGTACAGACAGGGTCCGG
GTAACCAGCGTGACTTAGTAGCGAGAATTACATCGGATGGACGCACTATCCTGGAAGATTCGT
AAAAGGGCGGTTCACTATATCTCGCGATAATGCGAAGAAAACCGTTTATGTCCAAATGAATAA
TCTGAAACCTGAGGACACGGCCGTCTATTACTGTGCTGCAGAAAAGGGCGGTTCACCACTGTA
TTGGGGCCAAGGGACACAAGTTACGGTAAGCTCC 
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Pst I site identified in DNA sequence (see below) 
 
and therefore changed bp291 from T to G (lower case below) to give the sequence 
below. 
CAGGTGAAGTTAGAGGAAAGTGGTGGGGGACTTGTTCAAGTGGGGGGAAGTCTCCGTTTGT
CTTGCGCTCATAGCGGCTTGCCCTTTGGCATTAACGCAATAGGATGGTACAGACAGGGTCCGG
GTAACCAGCGTGACTTAGTAGCGAGAATTACATCGGATGGACGCACTATCCTGGAAGATTCA
GTAAAAGGGCGGTTCACTATATCTCGCGATAATGCGAAGAAAACCGTTTATGTCCAAATGAAT
AATCTGAAACCTGAGGACACGGCCGTCTATTACTGTGCTGCgGAAAAGGGCGGTTCACCACTG
TATTGGGGCCAAGGGACACAAGTTACGGTAAGCTCC 
Final EG31 synthesized by Entelechon 
tctagaaCAGGTGAAGTTAGAGGAAAGTGGTGGGGGACTTGTTCAAGTGGGGGGAAGTCTCCG
TTTGTCTTGCGCTCATAGCGGCTTGCCCTTTGGCATTAACGCAATAGGATGGTACAGACAGGG
TCCGGGTAACCAGCGTGACTTAGTAGCGAGAATTACATCGGATGGACGCACTATCCTGGAAG
ATTCAGTAAAAGGGCGGTTCACTATATCTCGCGATAATGCGAAGAAAACCGTTTATGTCCAAA
TGAATAATCTGAAACCTGAGGACACGGCCGTCTATTACTGTGCTGCgGAAAAGGGCGGTTCAC
CACTGTATTGGGGCCAAGGGACACAAGTTACGGTAAGCTCCtaatagaagctt 
The six synthesized sdAbs genes were subsequently cloned into plasmids encoding LHN 
backbones derived from diferent serotypes of botulinum neurotoxin. Entelechon 
reports are submited in the appendix. 
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Chapter 4. Cloning of recombinant antibody based constructs 
 
The synthesized two single chain variable antibody fragments and six single domain 
antibodies were cloned into the LHN backbone. As mentioned in Chapter 1 there are 
seven (named A through G) distinct botulinum neurotoxins produced by Clostridium 
botulinum (BoNT) of which four (A, B, C and D) were used with this study. 
4.1 Re-engineering botulinum neurotoxin  
 
The ability of botulinum neurotoxin to disrupt transmiter release from the target cels, 
often for prolonged periods, has become beneficial for the therapeutic use to treat a 
variety of diseases (Turton, Chaddock and Acharya, 2002) for example acromegaly, 
pain, endocrine. In order to develop novel cel secretion inhibitor drugs it was 
important to re-engineer botulinum neurotoxin to become a non-toxic molecule, 
whilst at the same time maintaining the ability to block secretion. 
In order for this to be achieved, a single chain polypeptide of ̃150kDa, which is 
cleaved to form a di-chain molecule linked by a disulphide bond, has to be produced 
(Turton, Chaddock and Acharya, 2002). The toxic BoNT structure consists of heavy 
chain (HC, ̃100kDa) covalently joint to light chain (LC, ̃50kDa) (Simpson, 1986) (Fig 
21). The HC contains two domains each of ̃50kDa. C-terminal domain (HC) responsible 
for binding to target cels (Shone et. al., 1985, Halpern and Loftus, 1993) and an  N-
terminal domain (HN) involved in intracelular membrane translocation (Shone et. al., 
1987, Koriazova and Montal, 2003). The LC domain is a zinc-depended endopeptidase 
that cleaves SNARE proteins that are essential for neurotransmitter release (Humeau 
et. al., 2000). 
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Figure 21 The di-chain structure of a Clostridial neurotoxin –botulinum neurotoxin A 
(BoNT/A). (Adapted from Turton et. al., 2002) 
 
 
Experiments based on BoNT/A proteolytic cleavage by trypsin gives an opportunity to 
produce active, non-toxic and non-cel binding molecules. These molecules are derived 
from BoNT/A and are ̃100kDa polypeptides caled LHN/A, which represent the LC and 
the HN domains of type A neurotoxin coupled together by a disulphide bond (Shone, 
Hambleton and Meling, 1987). The same LHN/A domains have been expressed and 
purified from a heterologous expression host (Chaddock et. al., 2002). 
Consequently, re-engineering clostridium neurotoxin molecules by the replacement of 
their native binding domain (HC) with an alternative ligand has created functional 
LHN/A fragments to target cels of interest (Chaddock et. al., 2000, Chaddock et. al., 
2000). The first experiments were performed using chemical conjugates, which have 
been prepared by coupling LHN/A fragments to a lectin obtained from Erythrina 
cristagali (ECL) (Duggan et. al., 2002). Lectins are non-immunoglobulin proteins that 
recognize and bind selectively to specific carbohydrates and can therefore be used to 
diferentiate between cel types (Lis and Sharon, 1986, Sharon 1993, Streit et. al., 1985, 
Streit et. al., 1986). Therefore, the lectins are appropriate ligands for selectively 
targeting LHN/A endopeptidase to nociceptive aferents. Additional experiments with 
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LHN/A-ECL conjugates showed that they are able to complete al stages of the 
intoxication process and are able to cause the inhibition of neurotransmitter release 
from cultured eDRG neuronal cel types in preference to spinal cord neurons (Duggan 
et. al., 2002). 
Nevertheless, although these molecules were able to inhibit acetylcholine exocytosis 
their construction by the chemical coupling of the LHN fragment and the targeting 
ligand was not a suitable method for producing pharmaceutical agents. Therefore, a 
new approach has been developed to avoid the inherent problem of the production of 
heterogeneous products observed with the chemical coupling approach. The 
production of a fuly recombinant fusion protein from the recombinant gene encoding 
both the LHN domain of a clostridial neurotoxin and a specific targeting domain has 
been achieved to solve this problem. One of the first constructed molecules was 
composed of the LHN domain of botulinum neurotoxin type C and epidermal growth 
factor (EGF), which was designed to inhibit secretion of mucus from epithelial cels 
(Foster et. al., 2005) (Fig 22). 
 
 
 
 
Legend: EGF (Epidermal growth factor); His (Histidine tag); MBP (Maltose-binding 
protein); IDGR (Residues of the Factor Xa cleavage site)
  
   
 His 
CHKAIDGR  SLYNKTLDC 
 
Light chain EGF HN domain 
Protease site to cleave 
polypeptide at LC-HN linker 
Protease cleavage site  
for MBP removal 
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   Disulphide bond 
 
S………………………S 
Figure 22 LHN domain of botulinum neurotoxin type C and epidermal growth 
factor (EGF) (adapted from Foster, 2005). 
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The work on the re-engineering of botulinum neurotoxin molecules has opened up 
new opportunities for the creation of active LHN fragments fused to a targeting ligand 
(Fig 23). These novel recombinant fusion proteins target clostridial endopeptidase 
activity to a variety of cel types and at the same time achieve prolonged inhibition of 
exocytosis within the target cels. This same approach was used to generate LHN- 
fragments with antibody domains, as ligands. 
Legend applies to figures from 22 to 30: LC (Light chain of LHN); HN (Heavy chain of 
LHN); linker (cleavage site); arow indicates the cleavage site of EK or FXa; spacer 
(peptide linker between HN and ligand); rAb (recombinant antibody); scFv (single 
chain antibody) 
 
 
 
Figure 23 Design of LHN fragment with ligand. 
 
The recent work on antibody targeting of recombinant proteins produces an 
opportunity to produce modified Abs-BoNT. In some cases, the targeting ligand is not 
suited to expression as a recombinant protein; because it would lack essential post-
translational modifications or that there may not be a ligand available with suficient 
specificity. The use of antibody domain fragments or domain antibodies expressed in 
E.coli can therefore be used to target LHN to specific cels (Fig 24). The spacer was 
removed from the original backbone (Fig 23) to simplify structure of novel molecules. 
 
 
Figure 24 Design of LHN fragment with antibody. 
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4.2 Results 
As mentioned in Chapter 3 the DNA ScFvCD117I was synthesised for the production of 
LHN molecules with single chain variable antibody fragments; and six DNA: EGFR6sdAb, 
EGFR7sdA, EGFR10sdAb, EGFR28sdAb, EGFR31sdAbs and EGFR43sdAb for the 
construction of LHN with single domain antibodies. The DNA (5-10 µg) for al of the 
genes were sent in a lyophilised form and was stored at -20°C in the freezer until it was 
dissolved in 50  µl of distiled water by gentle shaking for 10 min. The final DNA 
concentration was approximately 100-200 ng/µl. Subsequently the DNA of the ScFv 
and sdAbs genes was microbanked according to the protocol (submitted in Chapter 2 
Material and Methods). Each gene was assigned an SXNxxxxxx.  
The folowing number was given for single chain variable antibody fragment for 
records in the BIX central home page at Syntaxin Ltd: 
 
SXN101561 – pCR4TOPO – ScFvCD117I referred to throughout as CD117I  
 
The ScFv gene present in SXN101561 was then cloned into the LHN domain of 
botulinum neurotoxin type A, B and C with a His tag to facilitate afinity purification. 
Recombinant scFv-LHN molecule produced possessed a 10 His tag on the N-terminus 
(Fig 25). 
 
 
Figure 25 Design of LHN with single chain antibody fragment. 
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The folowing numbers were given for the single domain antibodies for records in the 
BIX central home page at Syntaxin Ltd: 
 
SXN101841 - pCR4TOPO- EGFR6sdAbs 
SXN101842 – pCR4TOPO- EGFR7sdAbs 
SXN101843 - pCR4TOPO- EGFR10sdAbs 
SXN101844 - pCR4TOPO- EGFR28sdAbs 
SXN101845 - pCR4TOPO- EGFR31sdAbs 
SXN101846 - pCR4TOPO- EGFR43sdAbs 
 
The above single domain antibody genes have been cloned into the LHN domain of 
botulinum neurotoxin type A, B and D with His tags to facilitate afinity purification. Al 
sdAb-LHN molecules produced possess 10 His tag on the N-terminus (Fig 26). Their 
nomenclature is given as LC (for light chain N –terminal) A or B or D for type of BoNT. 
 
 
Figure 26 Design of LHN with single domain antibody. 
 
Two types of linkers were used in order to activate the fusion proteins: EK 
(Enterokinase) and FXa (Factor Xa). Enterokinase is a specific protease that cleaves 
after K Lysine (Lys) at its cleavage site Asp-Asp-Asp-Asp-Lys (Aspartic Acid - Aspartic 
Acid - Aspartic Acid – Aspartic Acid - Lysine), although it wil sometimes cleave at other 
basic residues, depending on the conformation of the protein substrate. Enterokinase 
wil not cleave at a site folowed by P Proline (Pro). Factor Xa cleaves after the R 
Arginine (Arg) residue in its preferred cleavage site Ile - (Glu or Asp) - Gly  – Arg 
(Isoleucine – (Glutamic Acid or Aspartic Acid) – Glycine – Arginine) although it wil 
sometimes cleave at other basic residues, depending on the conformation of the 
protein substrate. The most common secondary site, among those that have been 
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sequenced, are Gly - Arg (Glycine – Arginine). Factor Xa wil not cleave a site folowed 
by Proline (Pro) or Arginine (Arg) residues. 
 
The construct SXN101327 (Fig 27) has been selected as a backbone for the cloning of 
recombinant botulinum neurotoxin type B fragment fused to single chain variable 
antibody fragments.  
 
 
Figure 27 Design of LHN/B fragment with activation side EK (Enterokinase) in 
SXN101327. 
 
The construct SXN100532 (Fig 28) has been selected as a backbone for the cloning of 
recombinant botulinum neurotoxin type A fragment fused to single chain variable 
antibody fragments and single domain antibodies. 
 
 
Figure 28 Design of LHN/A fragment with activation side EK (Enterokinase) in 
SXN100532. 
 
The construct SXN101832 (Fig 29) (pK7-10HT-LD-EK-HD-GS20-GRP-R) has been 
selected as a backbone for the cloning of recombinant botulinum neurotoxin type D 
fragment fused to single domain antibody. 
 
Figure 29 Design of LHN/D fragment with activation side by EK (Enterokinase) in 
SXN101832. 
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Al backbones described above include an activation site, which is cleaved between the 
LC and HN domains by Enterokinase as indicated above. 
 
The construct SXN101641 (Fig 30) has been selected as a backbone for the cloning of 
the recombinant botulinum neurotoxin type B fused to single chain variable antibody 
fragments and single domain antibodies. 
 
Figure 30 Design of LHN/B fragment with activation side FXa (factor Xa) in 
SXN101641. 
 
The construct SXN100736 (Fig 31) has been selected as a backbone for the cloning of 
recombinant botulinum neurotoxin type C fragment fused to single chain antibody.  
 
 
Figure 31 Design of LHN/C fragment with activation side FXa (factor Xa) in 
SXN100736. 
 
Backbones derived from molecules SXN101641 and SXN100736 include an activation 
site, which is cleaved between the LC and HN domains by Factor Xa as indicated above. 
 
Plasmid DNA was digested with XbaI (TCTAGA) and HindII (AAGCTT) restriction 
endonucleases in order to insert ScFv or sdAbs in the place of the natural HC binding 
domain within the vector backbone pK7 that has been modified from pET26b vector. 
The figures below demonstrate the cloning steps. 
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Figure 32 Cloning of DNAs encoding single variable antibody fragments (scFvs) and 
the single domain antibodies (sdAbs) with restriction endonucleases: XbaI on the (5ʹ 
end) and HindII on the (3ʹ end) into modified pET25b vector. 
XbaI HindII 
XbaI HindII 
Inserted into modified pET26b 
vector 
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Figure 33 Modified pET26b vector with inserted scFv or sdAb. 
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Al DNA manipulations involving cloning were performed according to standard 
procedures. Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor 
Laboratory Press), Sambrook, Fritsch and Maniatis (eds), 1990. 
The extraction and purification of DNA from agarose gels and the purification of 
plasmid DNA were prepared according to standard protocols (Chapter 2 Method and 
Materials). The correct sizes of the cloned constructs were confirmed by using a 1 kb 
DNA ladder (NEB) in a 0.8 % agarose gel during electrophoresis (Fig 14, pg 55). Figures 
36, 38, 39, 41, 42 and 43 ilustrate cut and uncut plasmids DNA used for the cloning of 
scFvCD117I gene into backbones A, B and C, as wel as sdAbs genes cloned into 
backbones A, B and D. Figures 37, 40, 44, 45 and 46 ilustrate products obtained from 
the cloning of scFvCD117I and sdAbs genes inserted into backbones. In the end, the 
cloning was confirmed by submitting the DNA for sequencing to Source BioScience 
Lifescience former Geneservice htp://www.lifesciences.sourcebioscience.com/. A 
large quantity of sequencing data was obtained and analysed using SeqMan (DNASTAR 
Lasergene 8 program); only one is presented as an example for molecule SXN101861 
(LHN/B-EGFR6sdAb) (Fig 34). 
The DNA of al the constructs was transformed into TOP10 cels (Invitrogen) and BL21 
(DE3) cels (Novagen) according to the protocols provided by the suppliers. The novel 
constructs were microbanked according to the standard protocol (Chapter 2 Methods 
and Materials) and stored at the -80°C in the freezer, an SXNxxxxxx number was 
alocated for the DNA microbank stocks, and an Exxxxxx number was given for the 
expression microbank stocks. DNA sequence maps were generated for 26 molecules 
listed in the table 10, pg 123-124. As noted above, many linear maps were created 
using SeqBuilder DNASTAR Lasergene 8 program; only one is presented as an example 
for molecule SXN101869 (LNN/A-EGFR7sdAb) (Fig 35). 
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Figure 34 DNA sequencing of LHN/B-EGFR6sdAb=SXN101861.
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Figure 35 Linear map (SeqBuilder) of molecule LNN/A-EGFR7sdAb=SXN101869. 
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Figure 36 0.8% agarose gel of purified cut plasmid DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 
10.0 
0.5 
Lane M is a 1kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows the position of the excised backbone SXN101327 (Fig 27) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/B (indicated by arrow);  
Lane 2 shows the position of the excised backbone SXN100532 (Fig 28) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/A (indicated by arrow);  
Lane 3 shows the pCR TOPO vector digested with XbaI and HindII and the position of  the 
excised scFvCD117I gene obtained from the digest (indicated by arrow);  
The plasmid SXN101327 is 7.11 kb, with a 6.89 kb backbone pK7 containing the LHN/B.  
The plasmid SXN100532 is 7.48 kb, with a 6.87 kb backbone pK7 containing the LHN/A.  
The pCR4 TOPO vector is a total of 4.73 kb, with a 0.75 kb of excised scFvCD117I gene. 
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Figure 37 Products obtained folowing HindII and HindII/XbaI digests on plasmids 
LHN/AscFvCD117I=SXN101623 and LHN/BscFvCD117I=SXN101624 sent to 
Geneservice for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10.0 
3.0 
0.5 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lanes 1 and 3 show plasmid DNA in duplicate for LHN/AscFvCD117I=SXN101623 (Table 10) 
digested with HindII to unsure the correct products have been produced from ligation that was 
confirmed by Geneservice; 
Lanes 2 and 4 show plasmid DNA in duplicate for LHN/AscFvCD117I=SXN101623 (Table 10) 
digested with HindII/XbaI to ensure that correct size gene (scFvCD117I) was inserted to the 
backbone LHN/A;  
Lanes 5 and 7 show plasmid DNA in duplicate for LHN/BscFvCD117I=SXN101624 (Table 10) 
digested with HindII to unsure the correct products have been produced from ligation that was 
confirmed by Geneservice; 
Lanes 6 and 8 show plasmid DNA in duplicate for LHN/BscFvCD117I=SXN101624 (Table 10) 
digested with HindII/XbaI to ensure that correct size gene (scFvCD117I) was inserted to the 
backbone LHN/B; 
The plasmid LHN/AscFvCD117I=SXN101623 is 7.63 kb.  
The plasmid LHN/BscFvCD117I=SXN101624 is 7.64 kb. 
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Figure 38 0.8% agarose gel of purified uncut and cut plasmid DNA of scFvCD117I. 
 
 
 
 
 
 
 
 
  
 
Figure 39 0.8% agarose gel of purified uncut and cut plasmid DNA of SXN101641. 
 
 
 
 
 
 
 
 
3.0 
3.0 
0.5 
0.5 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  lane 1 shows the pCR4 
TOPO vector digested with XbaI and HindII and the position of the excised scFvCD117I gene 
obtained from the digest (indicted by arrow);  
The pCR4 TOPO vector is a total of 4.73 kb, with a 0.75 kb of excised scFvCD117I gene. 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  lane 1 shows the 
SXN101641 gene digested with XbaI and HindII and the position of the excised  vector 
backbone obtained from the digest (indicted by arrow);  
 
The plasmid SXN101641 is 6.99 kb, with a 6.82 kb backbone pK7 containing the LHN/B. 
10.0 
10.0 
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Figure 40 Product obtained folowing HindII and HindII/XbaI digest on plasmid 
LHN/BscFvCD117I=SXN101776 sent to Geneservice for sequencing. 
 
 
 
Figure 41 0.8% agarose gel of purified uncut plasmid DNA of sdAbs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and 
Methods);  
Lane 1 shows plasmid DNA LHN/BscFvCD117I=SXN101776 (Table 10) 
digested with HindII to unsure the correct products have been 
produced from ligation that was confirmed by Geneservice;  
Lane 2 shows plasmid DNA LHN/BscFvCD117I=SXN101776 (Table 10) 
digested with HindII/XbaI to ensure that correct size gene 
(scFvCD117I) was inserted to the backbone LHN/B; 
 
The plasmid LHN/BscFvCD117I=SXN101776 is 7.65 kb. 
3.0 
10.0 
0.5 
Lane M is a 1kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows the pCR4 TOPO vector containing the EGFR43 sdAb gene (SXN101846);  
Lane 2 shows the pCR4 TOPO vector containing the EGFR31 sdAb gene (SXN101845);  
Lane 3 shows the pCR4 TOPO vector containing the EGFR28 sdAb gene (SXN101844);  
Lane 4 shows the pCR4 TOPO vector containing the EGFR10 sdAb gene (SXN101843);  
Lane 5 shows the pCR4 TOPO vector containing the EGFR7  sdAb gene (SXN101842);  
Lane 6 shows the pCR4 TOPO vector containing the EGFR6  sdAb gene (SXN101841); 
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Figure 42 0.8% agarose gel of purified cut plasmid DNA of sdAbs. 
 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows the pCR4 TOPO vector containing the EGFR43 sdAb gene (SXN101846);  
Lane 2 shows the pCR4 TOPO vector containing the EGFR31 sdAb gene (SXN101845);  
Lane 3 shows the pCR4 TOPO vector containing the EGFR28 sdAb gene (SXN101844);  
Lane 4 shows the pCR4 TOPO vector containing the EGFR10 sdAb gene (SXN101843);  
Lane 5 shows the pCR4 TOPO vector containing the EGFR7  sdAb gene (SXN101842);  
Lane 6 shows the pCR4 TOPO vector containing the EGFR6  sdAb gene (SXN101841); 
 
The SXN101846 plasmid is a total of 4.3 kb, with a 3.94 kb vector and 0.36 kb of excised EGFR43 sdAb 
gene (indicated by arrow).  
The SXN101845 plasmid is a total of 4.3 kb, with a 3.94 kb vector and 0.36 kb of excised EGFR31 sdAb 
gene (indicated by arrow).  
The SXN101844 plasmid is a total of 4.3 kb, with a 3.91 kb vector and 0.39 kb of excised EGFR28 sdAb 
gene (indicated by arrow).  
The SXN101843 plasmid is a total of 4.3 kb, with a 3.92 kb vector and 0.38 kb of excised EGFR10 sdAb 
gene (indicated by arrow).  
The SXN101842 plasmid is a total of 4.3 kb, with a 3.94 kb vector and 0.36 kb of excised EGFR7 sdAb 
gene (indicated by arrow).  
The SXN101841 plasmid is a total of 4.3 kb, with a 3.92 kb vector and 0.38 kb of excised EGFR6 sdAb 
gene (indicated by arrow).  
 
 
 
 
 
 
 
3.0 
0.5 
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Figure 43 0.8% agarose gel of purified cut plasmid DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows the position of the excised backbone SXN101832 (Fig 29) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/D (indicated by arrow); 
Lane 2 shows the position of the excised backbone SXN101641 (Fig 30) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/B (indicated by arrow); 
Lane 3 shows the position of the excised backbone SXN100736 (Fig 31) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/C (indicated by arrow); 
Lane 4 shows the position of the excised backbone SXN100532 (Fig 28) digested with XbaI and 
HindII to obtain the vector backbone pK7 containing the LHN/A (indicated by arrow); 
The plasmid SXN101832 is 7.05 kb, with a 6.89 kb backbone pK7 containing the LHN/D. 
The plasmid SXN101641 is 6.99 kb, with a 6.82 kb backbone pK7 containing the LHN/B. 
The plasmid SXN100736 is 7.04 kb, with a 6.88 kb backbone pK7 containing the LHN/C. 
The plasmid SXN100532 is 7.48 kb, with a 6.87 kb backbone pK7 containing the LHN/A. 
3.0 
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Figure 44 Products obtained folowing HindII and HindII/PstI digests on LHN/sdAbs 
plasmids sent to Geneservice for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows plasmid DNA LHN/A-EGFR6sdAb=SXN101868 (Table 10) digested with HindII to unsure the 
correct products have been produced from ligation;  
Lane 2 shows plasmid DNA LHN/A-EGFR6sdAb=SXN101868 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR6sdAb) was inserted to the backbone LHN/A; 
Lane 3 shows plasmid DNA LNN/A-EGFR7sdAb=SXN101869 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 4 shows plasmid DNA LNN/A-EGFR7sdAb=SXN101869 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR7sdAb) was inserted to the backbone LHN/A; 
Lane 5 shows plasmid DNA LHN/A-EGFR10sdAb=SXN101870 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 6 shows plasmid DNA LHN/A-EGFR10sdAb=SXN101870 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR10sdAb) was inserted to the backbone LHN/A; 
Lane 7 shows plasmid DNA LHN/A-EGFR28sdAb=SXN101871 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 8 shows plasmid DNA LHN/A-EGFR28sdAb=SXN101871 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR28sdAb) was inserted to the backbone LHN/A; 
Lane 9 shows plasmid DNA LHN/A-EGFR31sdAb=SXN101872 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 10 shows plasmid DNA LHN/A-EGFR31sdAb=SXN101872 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR31sdAb) was inserted to the backbone LHN/A; 
Lane 11 shows plasmid DNA LHN/A-EGFR43sdAb=SXN101873 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 12 shows plasmid DNA LHN/A-EGFR43sdAb=SXN101873 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR43sdAb) was inserted to the backbone LHN/A; 
Lane 13 shows plasmid DNA LHN/B-EGFR6sdAb=SXN101861 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 14 shows plasmid DNA LHN/B-EGFR6sdAb=SXN101861 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR6sdAb) was inserted to the backbone LHN/B; 
Lane 15 shows plasmid DNA LHN/B-EGFR7sdAb=SXN101862 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 16 shows plasmid DNA LHN/B-EGFR7sdAb=SXN101862 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR7sdAb) was inserted to the backbone LHN/B; 
Lane 17 shows plasmid DNA LHN/B-EGFR10sdAb=SXN101863 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 18 shows plasmid DNA LHN/B-EGFR10sdAb=SXN101863 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR10sdAb) was inserted to the backbone LHN/B; 
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Figure 45 Products obtained folowing HindII and HindII/PstI digests on LHN/sdAbs 
plasmids sent to Geneservice for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.0 
 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows plasmid DNA LHN/B-EGFR28sdAb=SXN101864 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 2 shows plasmid DNA LHN/B-EGFR28sdAb=SXN101864 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR28sdAb) was inserted to the backbone LHN/B; 
Lane 3 shows plasmid DNA LHN/B-EGFR31sdAb=SXN101865 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 4 shows plasmid DNA LHN/B-EGFR31sdAb=SXN101865 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR31sdAb) was inserted to the backbone LHN/B; 
Lane 5 shows plasmid DNA LHN/B-EGFR43sdAb=SXN101866 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 6 shows plasmid DNA LHN/B-EGFR43sdAb=SXN101866 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR43sdAb) was inserted to the backbone LHN/B; 
Lane 7 shows plasmid DNA LHN/D-EGFR6sdAb=SXN101874 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 8 shows plasmid DNA LHN/D-EGFR6sdAb=SXN101874 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR6sdAb) was inserted to the backbone LHN/D; 
Lane 9 is blank; 
Lane 10 is blank; 
Lane 11 shows plasmid DNA LHN/D-EGFR7sdAb=SXN101875 (Table 10) digested with HindII to unsure 
the correct products have been produced from ligation;  
Lane 12 shows plasmid DNA LHN/D-EGFR7sdAb=SXN101875 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR7sdAb) was inserted to the backbone LHN/D; 
Lane 13 shows plasmid DNA LHN/D-EGFR10sdAb=SXN101876 (Table 10) digested with HindII to 
unsure the correct products have been produced from ligation;  
Lane 14 shows plasmid DNA LHN/D-EGFR10sdAb=SXN101876 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR10sdAb) was inserted to the backbone LHN/D; 
Lane 15 shows plasmid DNA LHN/D-EGFR28sdAb=SXN101877 (Table 10) digested with HindII to 
unsure the correct products have been produced from ligation;  
Lane 16 shows plasmid DNA LHN/D-EGFR28sdAb=SXN101877 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR28sdAb) was inserted to the backbone LHN/D; 
Lane 17 shows plasmid DNA LHN/D-EGFR31sdAb=SXN101878 (Table 10) digested with HindII to 
unsure the correct products have been produced from ligation;  
Lane 18 shows plasmid DNA LHN/D-EGFR31sdAb=SXN101878 (Table 10) digested with HindII/PstI to 
ensure that correct size gene (EGFR31sdAb) was inserted to the backbone LHN/D; 
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Figure 46 Products obtained folowing HindII and HindII/PstI digests on LHN/sdAb 
plasmid and LHN/C-scFvCD117I=SXN101882 sent to Geneservice for sequencing. 
 
 
 
 
 
 
 
 
 
 
 
Lane M is a 1 kb DNA ladder (Fig 14, Chapter 2 Material and Methods);  
Lane 1 shows plasmid DNA LHN/D-EGFR43sdAb=SXN101879 (Table 10) digested with HindII to 
unsure the correct products have been produced from ligation;  
Lane 2 shows plasmid DNA LHN/D-EGFR43sdAb=SXN101879 (Table 10) digested with HindII/PstI 
to ensure that correct size gene (EGFR43sdAb) was inserted to the backbone LHN/D; 
Lane 3 is blank; 
Lane 4 is blank; 
lane 5 shows plasmid DNA LHN/C-scFvCD117I=SXN101882 (Table 10) digested with HindII to 
unsure the correct products have been produced from ligation that was confirmed by 
Geneservice;  
Lane 6 shows plasmid DNA LHN/C-scFvCD117I=SXN101882 (Table 10) digested with HindII/XbaI 
to ensure that correct size gene (scFvCD117I) was inserted to the backbone LHN/C; 
 
The plasmid LHN/A-EGFR6sdAb=SXN101868 is 7.26 kb. 
The plasmid LHN/A-EGFR7sdAb=SXN101869 is 7.24 kb. 
The plasmid LHN/A-EGFR10sdAb=SXN101870 is 7.26 kb. 
The plasmid LHN/A-EGFR28sdAb=SXN101871 is 7.26 kb. 
The plasmid LHN/A-EGFR31sdAb=SXN101872 is 7.24 kb. 
The plasmid LHN/A-EGFR43sdAb=SXN101873 is 7.24 kb. 
The plasmid LHN/B-EGFR6sdAb=SXN101861 is 7.28 kb. 
The plasmid LHN/B-EGFR7sdAb=SXN101862 is 7.26kb. 
The plasmid LHN/B-EGFR10sdAb=SXN101863 is 7.29kb. 
The plasmid LHN/B-EGFR28sdAb=SXN101864 is 7.29 kb. 
The plasmid LHN/B-EGFR31sdAb=SXN101865 is 7.26 kb. 
The plasmid LHN/B-EGFR43sdAb=SXN101866 is 7.26 kb. 
The plasmid LHN/D-EGFR6sdAb=SXN101874 is 7.28 kb. 
The plasmid LHN/D-EGFR7sdAb=SXN101875 is 7.26 kb. 
The plasmid LHN/D-EGFR10sdAb=SXN101876 is 7.28 kb 
The plasmid LHN/D-EGFR28sdAb=SXN101877 is 7.29 kb 
The plasmid LHN/D-EGFR31sdAb=SXN101878 is 7.26 kb 
The plasmid LHN/D-EGFR43sdAb=SXN101879 is 7.26 kb 
The plasmid LHN/C-scFvCD117I=SXN101882 is 7.64 kb 
3.0 
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Table 10 LHN antibody based chimeras cloned for purpose of this study. 
 
 
SXN 
number 
 
E number 
 
Vector 
 
Tag 
 
LHN 
 
Activati
on side 
Type of 
recombinant 
antibody 
MW 
(molecula
r weight) 
kDa 
Domain-wise 
order used in a 
text 
SXN10
1623 
 
E001219 
 
pK7 
 
10HT 
 
LHN /A 
 
EK 
 
ScFvCD117I 
128534.5 LHN/A-
scFvCD117I= 
SXN101623 
SXN10
1624 
 
E001220 
 
pK7 
 
10HT 
 
LHN /B 
 
EK 
 
ScFvCD117I 
129741.2 LHN/B-
scFvCD117I= 
SXN101624 
SXN10
1776 
 
E001342 
 
pK7 
 
10HT 
 
LHN /B 
 
FXa 
 
ScFvCD117I 
129883.7 LHN/B-
scFvCD117I= 
SXN101776 
SXN10
1882 
 
E001427 
 
pK7 
 
10HT 
 
LHN /C 
 
FXa 
 
ScFvCD117I 
129173.8 LHN/C-
scFvCD117I= 
SXN101882 
SXN10
1861 
 
E001406 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR6sdAb 
116880.5 LHN/B-
EGFR6sdAb= 
SXN101861 
SXN10
1862 
 
E001407 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR7sdAb 
116653.2 LHN/B-
EGFR7sdAb= 
SXN101862 
SXN10
1863 
 
E001408 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR10sdAb 
116986.6 LHN/B-
EGFR10sdAb=   
SXN101863 
SXN10
1864 
 
E001409 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR28sdAb 
117604.1 LHN/B-
EGFR28sdAb=
SXN101864 
SXN10
1865 
 
E001410 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR31sdAb 
115531.3 LHN/B-
EGFR31sdAb=
SXN101865 
SXN10
1866 
 
E001411 
 
pK7 
 
10HT 
 
LHN/B 
 
FXa 
 
EGFR43sdAb 
129565.3 LHN/B-
EGFR43sdAb=
SXN101866 
SXN10
1868 
 
E001413 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR6sdAb 
116345.0 LHN/A-
EGFR6sdAb= 
SXN101868 
SXN10
1869 
 
E001414 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR7sdAb 
115140.8 LNN/A-
EGFR7sdAb= 
SXN101869 
SXN10 
1870 
 
E001415 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR10sdAb 
115474.2 LHN/A-
EGFR10sdAb= 
SXN101870 
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SXN10
1871 
 
E001416 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR28sdAb 
116091.7 LHN/A-
EGFR28sdAb=
SXN101871 
SXN10
1872 
 
E001417 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR31sdAb 
114832.6 LHN/A-
EGFR31sdAb=
SXN101872 
SXN10
1873 
 
E001418 
 
pK7 
 
10HT 
 
LHN/A 
 
EK 
 
EGFR43sdAb 
114957.6 LHN/A-
EGFR43sdAb=
SXN101873 
SXN10
1874 
 
E001419 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
EGFR6sdAb 
116458.1 LHN/D-
EGFR6sdAb= 
SXN101874 
SXN10
1875 
 
E001420 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
EGFR7sdAb 
116067.5 LHN/D-
EGFR7sdAb= 
SXN101875 
SXN10
1876 
 
E001421 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
EGFR10sdAb 
116401.0 LHN/D-
EGFR10sdAb=
SXN101876 
SXN10
1877 
 
E001422 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
EGFR28sdAb 
117018.5 LHN/D-
EGFR28sdAb=
SXN101877 
SXN10
1878 
 
E001423 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
EGFR31sdAb 
115759.4 LHN/D-
EGFR31sdAb=
SXN101878 
SXN10
1879 
 
E001424 
 
pK7 
 
10HT 
 
LHN/D 
 
EK 
 
GFR43sdAb 
115884.4 LHN/D-
EGFR43sdAb=
SXN101879 
 
 
 
Table 11 LHN control chimeras available at Syntaxin Ltd. 
 
 
SXN number 
 
E 
number 
 
 
Vector 
 
 
Tag 
 
 
LHN 
 
Activation 
side 
MW 
(molecular 
weight) 
kDa 
Domain-wise order 
used in a text 
SXN100590 E000445 pK7 10HT LHN/A EK 101070.5 LHN/A=SXN100590 
SXN101687 E001283 pK7 10HT LHN/B FXa 102419.7 LHN/B=SXN101687 
SXN101654 E001250 pK7 10HT LHN/C EK 102535.7 LHN/C=SXN101654 
SXN101655 E001251 pK7 10HT LHN/D EK 101997.2 LHN/D=SXN101655 
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Chapter 5. Expression of recombinant antibody-based constructs 
 
Successful production of novel antibody-botulinum toxin molecules has been obtained 
in an E. coli expression system using an expression vector modified in-house caled pK7 
that is based upon pET26b.   
5.1 Overview of expression system 
Expression systems are designed to produce large amounts of the desired protein 
within the host cel. In order to accomplish this, the gene encoding the required 
protein is cloned into an expression vector, which is then transformed into a host cel. 
Typicaly, the expression vector contains genetic elements to control protein 
expression which include a promoter sequence appropriate to the host cel, a DNA 
sequence that terminates transcription and a DNA sequence that codes for ribosome 
binding (Heler et. al., 2001). 
Recombinant antibody fragments (rAb) have been expressed in wide variety of hosts 
including prokaryotes, such as E. coli (Martin et. al., 2006), eukaryotes, including S. 
cerevisiae (Hackel et. al., 2006), Pichia pastoris (Ren et. al., 2008), insect cels (Bruenke 
et. al., 2004), plant cels (Mayfield et. al., 2003), plants (Makvandi-Nejad et. al., 2005) 
and mammalian cels (Natsume et. al., 2006). The large-scale production of antibody 
fragments for therapeutic purposes has been made possible through the development 
of expression systems that are efective and cost eficient (Andersen and Reily, 2004). 
The optimal expression system depends on the type of recombinant antibody 
fragments, the precise sequence of the individual antibody being expressed, as wel as 
the required purity and quantity of the final product (Verma, Boleti and George, 1998). 
The glycosylation process is critical for monoclonal antibody production (Jeferis, 
2005). N-linked glycosylation at N Asparagine (Asn) -297 of the CH2 domain of IgG has 
functional and structural consequences because it afects the interaction of the FC 
region with celular FC. Therefore, the mammalian cel expression system is the most 
suitable for the production of monoclonal antibodies (Filpula, 2007). The antibody 
fragments, such as sdAbs or ScFvs do not require glycosylation process, as they are lack 
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the CH2 domain. Therefore bacterial or yeast fermentation can be used for the large-
scale production of recombinant protein. In the case of single chain antibodies, a few 
expression systems have been assessed. The successful production in yeast and fungi 
have been achieved in S. cerevisiae (Shusta et. al., 1998, Hackel et. al., 2006) Pichia 
pastoris (Ren et. al., 2008, Gurkan et. al., 2004, Shi et. al., 2003, Helwing et. al., 2001, 
Cunha et. al., 2004, Eldin 1997, Boado, Ji and Pardrige, 2000) Aspergilus awamori 
(Sotiriadis et. al., 2001) and Kluyveromyces lactis (Swennen et. al., 2002). This 
expression systems ofers cost-efectiveness and scale up benefits combined with 
advantages of eukaryotic expression, including protein processing, folding and post 
translation modifications. Additionaly purified protein does not contain endotoxins 
which are a contaminant present in proteins purified folowing expression in E.coli 
(Weisser and Hal, 2009). Although the recombinant antibody production in fungi and 
especialy in yeast is practicable, there is stil a need to shorten the process time to 
increase the volumetric productivity (Gasser and Matanovich, 2007). Recent research 
based on the compression of S. cerevisiae, Pichia pastoris and E. coli expression 
systems indicated that E. coli was the fastest and most consistent way to obtain and 
characterize purified scFvs (Miler et. al., 2005). Another method of expressing single 
chain antibodies is using transgenic plants (Makvandi-Nejad et. al., 2005). The 
advantage of producing rAbs in plants is that they lack any mammalian pathogens and 
contain no endotoxin contamination; however, the long initial time for production, 
regulatory uncertainties and questions about the suitability of plant glycans in human 
therapeutics (Andersen and Reily, 2004) has postponed their implementation for 
commercial production (Pujol et. al., 2005). 
Single domain antibodies are often produced in E. coli (Arbabi-Ghahroudi et. al., 1997, 
Rahbarizadeh et. al., 2005). There is only one example of VHH sdAb production in 
filamentous fungi, which resulted in limited proteolytic degradation of the secreted 
product (Joosten et. al., 2005), because of high levels of proteases secreted by this 
host (Gerngross, 2004). The single domain antibodies have been also produced in the 
yeast expression host S. cerevisiae (Frenken et. al., 2000, Thomassen et. al., 2002, Van 
der Vaart, 2002) and Pichia pastoris (Rahbarizadeh et. al., 2006). However occasionaly 
yeast produced, are N-glycosylated sdAbs (Frenken et. al., 2000, Harmsen et. al., 2005) 
which can reduce antigen binding (Van der Vaart et. al., 2006). In addition, the 
 
 
 
131 Engineering botulinum-antibody proteins 
presence of yeast specific oligosacchariades can result in high immunogenicity and 
decreased serum half-life of the recombinant protein (Sethuraman and Stadheim 
2006). 
E. coli is the most suitable bacterial expression system for production of smal non-
glycosylated recombinant antibody fragments (Wang et. al., 2008). For the purpose of 
this study the single domain or single chain antibodies were fused to recombinant 
botulinum neurotoxin fragments. It has been reported that one of the best approach 
to stabilize proteins is to express them as a fusion proteins (Uhlen et. al., 1992, Nygren 
et. al., 1994, LaValie and McCoy, 1995). There are several fusion tags to be considered 
as solubilising agents; that is when they fused with insoluble partner the product is a 
fusion protein with enhanced solubility (Shaki-Loewenstein et. al., 2005). The most 
popular solubilising fusion tags include glutathione S-transferase (GST) (Tudyka and 
Skerra, 1997), thioredoxin (LaValie et. al., 1993) and maltose-binding protein (MBP)  
(Kapust and Waugh, 1999). The successful expression of the LHN fragment of serotype 
A was first reported in 2002. The presence of GST as a fusion partner on the N-terminal 
of light chain alowed the expression of soluble LHN/A protein in the cytosol of 
Escherichia coli. The expression of these molecules opened up an opportunity to 
produce a non-toxic 100kDa endopeptidase species of clostridia neurotoxin, which are 
able to cleave the relevant SNARE protein (Foster and Chaddock, 2007). The E. coli 
expression system has been used for the production of antibody targeting LHN 
molecules of diferent types of endopeptidases.  
5.2 Escherichia coli expression system  
The bacterial expression system is commonly used for the production of 
immunoglobulin fragments. The main advantage of this system is the ability to 
produce high quantities of protein. The transformation of E. coli cels with the foreign 
DNA is straightforward and can be accomplished with smal amount of DNA. This 
inexpensive expression system is usualy a first choice for protein production in many 
biotech companies. It has been employed for antibody production, where 
glycosylation process is not required. The antibody fragments expressed in E. coli  are 
stable, highly soluble and react specificaly and with high affinity to the antigens 
(Rahbarizadeh et. al., 2005). The wel-established knowledge of the basic celular 
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processes of E. coli opens the way for easy genetic manipulation and characterization 
of protein expression and a determination of what factors could improve the yield and 
quality of purified proteins (Leong and Chen, 2007). The expression eficiency of 
recombinant molecules depend on the eficiency of transcription, translation and 
correct folding or refolding, which usualy is due to the characteristics of the individual 
recombinant protein and their interaction with the expression system. Various 
strategies have been developed for targeting the expression of active rAbs to distinct 
compartments of E. coli cels. Secretion during the bacterial expression can occur into 
extracelular and periplasmic spaces, the inner and outer membrane or within the 
cytoplasm. (Weisser and Hal, 2009) (Fig 34). 
 
 
 
Figure 47 Structure of Escherichia coli cel envelope. (adapted from Weisser and Hal, 
2009) 
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The expression of the recombinant antibody fragments in the reducing environment of 
the cytoplasm usualy results in the formation of insoluble inclusion bodies that 
contain unfolded protein (Martineau et. al., 1998). The purification of recombinant 
products from inclusion bodies has recently been improved by the combination of 
genetic engineering techniques and metal-afinity chromatography. Periplasmic 
secretion increases the probability of correct protein folding due to the more oxidizing 
celular environment that favours correct disulphide bond formation. (Skerra and 
Pluckthun, 1988). The formation of intra-domain disulphide bonds that are essential 
for correct folding and functionality of the antibody fragments design for this research 
are more likely to be stabilized in a presence of LHN molecule. Up to date the 
production of LHN molecules fused to various ligands has been successfully employed 
in E. coli and therefore this expression system may be appropriate for the production 
of novel antibody-botulinum toxin molecules. In addition, the production of 
recombinant immunotoxin in Escherichia coli has been reported to be stabilized by a 
disulphide bond (Brinkmann et. al., 1993). 
 
In order to achieve successful expression, the gene encoding the recombinant 
molecule must be placed in the context of appropriate control sequences that alow 
transcription and translation of the protein. Inducible promoters are normaly used to 
control expression of the protein. This is important to prevent loss or mutation of the 
gene should expression of the recombinant protein prove to be toxic to the bacteria. 
There are a few wel-known promoters, but for this research, the T7 RNA promoter has 
been used to obtain tightly controled, high level expression (Tabor and Richardson, 
1985, Studier and Mofatt, 1986). A second important factor for eficient production in 
E. coli is the presence of a prokaryotic ribosome-binding site (Gold et. al., 1981). The 
last control element is the transcription terminator, which prevents transcription 
beyond the desired gene and adds stability to the mRNA (Verma, Boleti and George, 
1998). Taking to account al considerations the pET system was specificaly developed 
for the cloning and expression of recombinant proteins in E. coli. 
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5.3 pET system 
W. F. Studier and B. A. Mofatt developed the pET expression system in 1986 for tightly 
regulated and high expression of recombinant protein in E.coli, which used the highly 
specific bacteriophage T7 RNA polymerase (Studier and Mofat, 1986) (Fig 35). The in-
house expression vector, pK7, used in this system is a vector derived from the pET26b 
vector Syntaxin Ltd modified pET26b to remove the pel B leader sequence, to 
introduce a multiple cloning site to include specific restriction endonuclease sites and 
to convert the vector mobilisation status from deficient to defective.  
For protein production, the recombinant plasmid (pK7) is transferred into an E. coli 
strain containing a chromosomal copy of the gene for T7 RNA polymerase. The host 
used is BL21 (DE3) bacteria. The (DE3) designation indicates that the host is a lysogen 
of λ bacteriophage DE3, which carries a chromosomal copy of T7 RNA polymerase gene 
under the control of the lacUV5 promoter and DNA fragment containing the lacI gene 
(Studier et. al., 1986). Once a DE3 lysogen is produced, the only promoter which wil 
direct transcription of the T7 RNA polymerase gene is the lacUV5 promoter, which is 
induced by addition of isopropyl-B-galactosidase (IPTG) to the culture medium 
(Weisser and Hal, 2009) (Fig 35). 
 
 
Figure 48 Protein production in pET expression system. 
(Figure adapted from Novagen pET System Manual) 
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5.4 Results 
The successful expressions of novel molecules in a bacterial expression system have 
been advantage to this study. Expressed scFv is usualy insoluble; however, one 
method that can improve its solubility is fusion with another protein (Zengh et al., 
2003). In addition, the purification of His-tagged scFv with an increased concentration 
of imidazole also has shown improved solubility of these molecules (Hamilton et al., 
2003). These considerations could potentialy explain the lack of inefective production 
of scFv fused to LHN backbone and purified on an afinity column. The successful 
soluble expression of the single domain antibodies was more likely expected, as they a 
high stability and solubility (Harmsen and Haard, 2007). 
E.coli BL21 (DE3) cels transformed with the expression plasmids were grown in the 
shaking culture (220 rpm, 37°C) in LB (Luria Bertani) broth supplemented with 30 
µg/ml kanamycin and 20% glucosamine to an OD of 0.5-0.6 at 600 nm. Protein 
expression was induced by the addition of 1 mM isopropyl-B-D-thiogalactopyranoside 
(IPTG, Sigma) for 20 h, at 16°C, 220 rpm. The harvested cel pelets were re-suspended 
in 50 mM Hepes pH 7.2, 200 mM NaCl and stored at – 80°C until required. Another 
method used for the purification of these molecules difered in the harvest of the cel 
pelets. The harvested cels were re-suspended in the 50 mM Hepes pH 7.2, 500 mM 
NaCl bufer and centrifuged at 12500 rpm for 30 min. The supernatant was removed 
and the cel pelets were kept frozen at -80̊C. This additional re-suspension of the cel 
pelets in the high salt concentration bufer should help to remove E. coli contaminants 
and unwanted debris in order to obtain high purity of the expressed protein. The 
expressions of soluble LHN single domain antibodies (Figure 49, 50 and 51) and LHN 
single chain antibody fragment (Figure 52 and 53) have been accomplished. 
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Figure 49 SafeStain NuPage 4-12% Bis-Tris gel (A) and Western blot against light 
chain (B) showing expression of LHN/A with a single domain antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50 SafeStain NuPage 4-12% Bis-Tris gel (A) and Western blot against light 
chain (B) showing expression of LHN/B with a single domain antibody. 
 
 M  1    2   3    4   5   6   7   8   9  10  11      M   1  2   3   4  5   6   7  8   9  10  11   
A B 
120kDa 
50kDa 
50kDa 
120kDa 
120kDa 
50kDa 
120kDa 
50kDa 
A B 
Lane M on the SDS PAGE gel (A) is a Benchmark ladder and on Western blots (B) is a Magic Mark; sizes in 
kDa (Fig 16 in chapter 2 Material and Methods);  
Lanes 1 (LNN/A-EGFR7sdAb=SXN101869), 3 (LNN/A-EGFR10sdAb=SXN101870), 
5 (LNN/A EGFR28sdAb=SXN101871), 7 (LNN/A-EGFR31sdAb=SXN101872) and  
9(LNN/A-EGFR43sdAb=SXN101873) show the E. coli extract containing the expression plasmid prior to 
induction; 
Lanes 2 (LNN/A-EGFR7sdAb=SXN101869), 4 (LNN/A-EGFR10sdAb=SXN101870), 6 (LNN/A-
EGFR28sdAb=SXN101871), 8 (LNN/A-EGFR31sdAb=SXN101872) and 10 (LNN/A-EGFR43sdAb=SXN101873) 
show the E. coli extract containing the expression plasmid after induction;  
Lane 11 shows the control LHN/A=SXN100590 indicated by orange arrow (Table11); 
 
  M    1    2    3    4    5    6   7   8   9       M   1   2   3   4   5   6   7  8   9 
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Figure 51 SafeStain NuPage 4-12% Bis-Tris gel (A) and Western blot against light 
chain (B) showing expression of LHN/D with a single domain antibody. 
 
           
   
 
Lane M on the SDS PAGE gel (A) is a Benchmark ladder and on Western blots (B) is a Magic Mark; sizes in 
kDa (Fig 16 in chapter 2 Material and Methods);  
Lanes1 (LHN/B-EGFR6sdAb=SXN101861), 3 (LHN/B-EGFR7sdAb=SXN101862), 5 (LHN/B-
EGFR10sdAb=SXN101863) and 7(LHN/B-EGFR28sdAb=SXN101864) show the E. coli extract containing the 
expression plasmid prior to induction; 
Lanes 2(LHN/B-EGFR6sdAb=SXN101861), 4(LHN/B-EGFR7sdAb=SXN101862), 6(LHN/B-
EGFR10sdAb=SXN101863) and 8(LHN/B-EGFR28sdAb=SXN101864) show the E. coli extract containing the 
expression plasmid after induction; 
Lane 9 shows the control LHN/B=SXN101687 indicated by orange arrow (Table11); 
Lane M on the SDS PAGE gel (A) and on Western blots (B) is a Magic Mark; sizes in kDa (Fig 16 in chapter 2 
Material and Methods);  
Lanes 2 (LHN/D-EGFR28sdAb=SXN101877), 4 (LHN/D-EGFR31sdAb=SXN101878) and 6 (LHN/D-
EGFR43sdAb=SXN101879) show the E. coli extract containing the expression plasmid prior to induction; 
Lanes 1(LHN/D-EGFR28sdAb=SXN101877), 3 (LHN/D-EGFR31sdAb=SXN101878) and 5 (LHN/D-
EGFR43sdAb=SXN101879) show the E. coli extract containing the expression plasmid after induction; 
Lane 11 shows the control LHN/D=SXN101655 indicated by orange arrow (Table11); 
B A 
 M     1     2     3     4     5     6    7       M    1    2    3    4    5    6    7 
50kDa 
50kDa 
120kDa 
120kDa 
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Figure 52 SafeStain NuPage 4-12% Bis-Tris gel showing expression of LHN/C with a 
single chain antibody fragment. 
 
 
 
 
 
 
 
 
 
 
 
Figure 53 SafeStain NuPage 4-12% Bis-Tris gel (A) and Western blot against light 
chain (B) showing expression of LHN/B with a single chain antibody fragment. 
A B 
50kDa 
50kDa 
50kDa 
120kDa 
120kDa 120kDa 
Lane M on the SDS PAGE gel is a Benchmark ladder; sizes in kDa (Fig 16 in chapter 2 Material and 
Methods);  
Lanes 1 (LHN/C-scFvCD117I=SXN101882) and lane 3 (LHN/C-scFvCD117I=SXN101882) show the E. coli 
extract containing the expression plasmid prior to induction; 
Lanes 2 (LHN/C-scFvCD117I=SXN101882), 3 (LHN/C-scFvCD117I=SXN101882) show the E. coli extract 
containing the expression plasmid after induction; 
Lane 11 shows the control LHN/C=SXN101654 indicated by orange arrow (Table11); 
   M      1        2       3        4       5         
     
Lane M on the SDS PAGE gel is a Benchmark ladder; sizes in kDa (Fig 16 in chapter 2 Material and 
Methods);  
Lanes 1 (LHN/B-scFvCD117I=SXN101776) and lane 3 (LHN/B-scFvCD117I=SXN101776) show the E. 
coli extract containing the expression plasmid prior to induction; 
Lanes 2 (LHN/B-scFvCD117I=SXN101776), 3 (LHN/B-scFvCD117I=SXN101776) show the E. coli extract 
containing the expression plasmid after induction; 
Lane 11 shows the control LHN/B=SXN101687 indicated by orange arrow (Table11); 
 
 M      1        2      3       4       5           M     1     2     3      4      5    
 
 
139 Engineering botulinum-antibody proteins 
 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
Purification of recombinant antibody 
based constructs 
 
 
 
140 Engineering botulinum-antibody proteins 
Chapter 6. Purification of recombinant antibody based constructs 
 
The purification was one of the most fundamental elements of this research. The 
ability to purify soluble, ful-length products gives opportunities to perform cel and 
pharmacology tests that wil provide data regarding to functionality of these 
molecules. The stability of purified single domain antibodies has been confirmed 
during the concentration to over 10 mg/ml. The molecules show neither signs of 
aggregation nor change of colour.  
6.1 Overview of protein purification 
Proteins play a crucial role in many biochemical processes, such as binding, catalysis, 
transport. These various possibilities derive from chemical diversity, the flexibility of 
the polypeptide chain and folding ability of polypeptide chains into many three-
dimensional structures. Only proteins that retain functional are useful components to 
study biochemical interactions, what can subsequently lead to discovery of new 
therapeutic. In order to analyze protein it preferably needs to be purified, optimaly to 
high standards. The quality of purified protein depends on the purification process, 
which often need to be developed specificaly for the target protein. In order to 
develop accurate method it is important to establish the purpose of the protein of 
interest. The study based on activity of protein wil require less pure compound in 
comparison to the protein used for study of the structure of molecule. However, the 
presence of active contaminants, which interfere with the activity of enzyme, cannot 
be acceptable by any circumstances and need to be removed. In case of proteins 
applied for therapeutic use, al associated contaminates need to be separated from 
target proteins. In this instance, it is necessary to introduce additional steps to remove 
contaminants, such as endotoxin, aggregates, and DNA. The quality of final product is 
always considered in the first place, but there are also diferent aspects, which need to 
be taken to account, while developing purification process. The quantity, cost and time 
have usualy a crucial impact on the establishment of the final purification process. 
The protein source is the significant part of the development of purification procedure, 
as these impacts on the yield and contaminant profile. Currently, growing cels in 
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culture, such as Escherichia coli, Saccharomyces cerevisiae or mammalian cels are the 
most common approach for protein production. The more detailed description of 
these cels can be found in the expression of novel antibody-botulinum chimera’s 
chapter. The application of suitable expression system for molecules wil subsequently 
have influence on the purification method. Though recombinant systems can enhance 
the yield of target protein, host cel can bring some disadvantages to expressed 
proteins, such as presence of contaminants, lack of a protein glycosylation, insolubility 
or unfolding of protein. These factors can bring some limitations to purified protein 
and in order to avoid them it is essential to possess knowledge of chemical and 
physical properties of the protein to utilize robust purification techniques. The 
purification methods of botulinum toxins and their fragments have been improved 
together with reengineering this molecule during the years. 
6.2 Introduction to the purification of BoNT  
Al natural botulinum neurotoxins are synthesised as complexes with non-toxic 
proteins, which under conditions of high ionic strength and high pH dissociate 
(Sugiyama, 1980). Combining these procedures with anion exchange chromatography 
and gel filtration alowed the first isolation of pure type A neurotoxin from its complex 
(Dasgupta et al., 1966; Dasgupta and Borof 1967, 1968). Afterwards, the purification 
process of neurotoxins was improved by introducing ammonium sulphate 
precipitations to enrich the toxin from culture extracts (Dasgupta et al., 1970; Tse et 
al., 1982). This step has been added to the purification of Clostridia neurotoxins and it 
is a routine enrichment step for many proteins. 
Further research brought a nickel column to capture His-tagged BoNT’s into the 
development of purification process (Moberg and Sugiyama 1978). This modification 
together with introduction of DEAE-Sephacel anion-exchange step generated the 
procedure used routinely for the large-scale purification of type A or B neurotoxin (Tse 
et al., 1982; Wiliams et al., 1983; Evans et al., 1986). The procedure established for 
purification of C1, D (Shone, 1987) and E was completed at the same time as the rapid 
method for purification of type F neurotoxin was in the process of development 
(Wadsworth et al., 1990). 
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First attempts to isolate neurotoxin polypeptides (HC and LC) was chalenging, as the 
neurotoxin shows a remarkable decrease in solubility upon reduction of its intra- and 
inter- chain disulfide bonds. In this case, the purification of BoNT type B subunits 
involved maintaining solubility by reducing the disulfide bridges in the presence of 1-2 
M urea prior to isolation by gel filtration (Kozaki and Sakaguchi 1975; Kozaki et al., 
1977). On another hand, the extremely low solubility of the LC of BoNT type A was 
used to purify pure HC in the presence of 0.5 M NaCl and 1% (w/v) nicotinamide 
adenine dinucleotide (NAD) (Krysinski and Sugiyama, 1980). Later on, the purification 
of both chains from BoNT type A were obtained by adsorbing the toxin on the column 
of QAE-Sephadex folowed by thiol reduction with dithiothreitol (DTT) in the presence 
of 2 M urea and 1 M NaCl (Kozaki et al., 1981). The modification of this method during 
subsequent years developed procedure for isolation of the chains from BoNT types A 
and B (Maisey et al., 1988). The digestion of the neurotoxin type A with trypsin has led 
to isolation of the H2L fragment. These experiments were a good starting point for the 
purification of the amino terminal moiety of the heavy chain H2 (Shone et al., 1985, 
1987). The techniques for the toxin purification have become more robust during 
years, but it become easier while producing recombinant non-toxic version of this 
molecule.  Various techniques have been used to purify recombinant fragments of 
BoNT’s. 
The LHNA-ECL (Erythrina cristagali) non-toxic molecule mentioned in the chapter  4 
C͵loningʹ was successfuly purified by others in two step process, involving size 
exclusion chromatography (SEC) to remove unconjugated ECL folowed by afinity 
chromatography to remove unconjugated LHN/A. The final product detected on the 
SDS-PAGE gel had a molecular mass at approximately 220 kDa (Chaddock et al., 2004). 
The demonstration of catalytic activity of LHN/A was confirmed to be maintained by 
using an in vitro synaptosomal-associated protein cleavage assay (Halis, B., James, B. 
A. F., Shone, C. C., 1996). The purified LHN/A –ECL product was able to inhibit the 
release of the neurotransmiter glutamate and the neuropeptide substance P from 
multiple vesicle population (Duggan et al., 2002). The more highly developed non-toxic 
version of LHN molecule EGF-LHN/C was purified using a nickel chelating Sepharose 
afinity column where fusion protein was eluted with 100 mM Imidazole. The purified 
recombinant EGF-LHN/C has shown activity of a functional endopeptidase and access 
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to the NCI-H292 cels (Foster et al., 2005). The introduction of nickel column to aid 
purification of His tagged EGF-LHN/C molecule opened a new way of producing soluble 
fusion protein containing an active LHN fragment. During recent years, the purification 
method has been slightly modified and improved, but afinity column continues as a 
first step capture for purification of non-toxic tagged LHN fragments. The purification 
of novel antibody-botulinum toxin molecules was prepared according to standard two-
step afinity chromatography, as wel as using methods developed during this study to 
achieve high purity of protein. 
6.3 Purification of recombinant antibody based constructs 
Purification of recombinant antibody based constructs was performed using diferent 
columns and techniques. The standard protein purification techniques can be applied 
to various proteins. However, it is not always the case that proteins belonging to the 
same class and exhibiting close structural and functional relationship can be suitably 
purified by the same methodology. A combination of methods has been developed to 
purified antibodies, such as ion-exchange chromatography or afinity chromatography. 
As the purification process of recombinant botulinum neurotoxin is a very wel 
established it helped to develop the upstream process for the recombinant antibody-
toxin chimeras. It is important to distinguish purification of the single chain antibodies 
from the single domain antibodies, as these structures are difer one from another. As 
mentioned before the single chain antibodies (scFvs) has a linker between light and 
heavy chain, which potentialy can have an efect on the isolation of the final product. 
The single domain antibodies (Abs) are simpler in structure; this can make purification 
process more successful.  
The development of techniques and the selection of an appropriate purification 
process for the production of recombinant antibody-botulinum toxin molecules were 
mainly based on the requirements in relation to functionality and purity of the final 
product. The molecules designed for this study carry polyhistidine afinity tags, which 
consist of ten consecutive Histidine residues on the N-terminus. In this case, the most 
common method used for purification of this kind of molecules is immobilized metal 
afinity chromatography (IMAC), which alows diferentiation of recombinant proteins 
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expressed in bacterial system from the background of total celular proteins. 
Immobilized metals such as Co2+, Cu2+, Ni2+,Zn2+, Ca2+ and Fe3+ can be used to purify 
polyhistidine fusion proteins. 
6.4 Results 
In the capture step, chelating Sepharose (Amersham Bioscience) charged with 
immobilized Ni2+ ions was used for the purifications of novel chimeras. The cel paste 
was homogenized using a Constant Systems homogenizer and clarified by 
centrifugation. The clarified lysate was loaded onto the afinity column. The bound 
proteins were eluted from the column using an imidazole step-wise gradient (from 40 
mM to 250 mM). Fractions were dialyzed against a 50 mM Hepes pH 7.2, 150 mM NaCl 
bufer or a 50 mM Hepes pH 7.2, 50 mM NaCl. The samples were analyzed by SDS-
PAGE on 4-12% acrylamide gels. The choice of dialyzing bufer depends on the type of 
enzyme used for activation. Al molecules require an activation process with a 
proteolytic enzyme, such as Enterokinase (EK BioLabs) or FXa (Factor Xa BioLabs) after 
the first afinity step. The enzyme selection is determined by enzyme specific 
recognition sites within the primary structure of the molecule. The choice of second 
column was dictated by the purity of the cleaved molecule. Afinity chromatography or 
hydrophobic interaction chromatography (HIC) was used in the final polishing step of 
this purification process. In every case, proteins were purified using a two-column 
method: two sequential nickel columns or an initial nickel column folow by HIC. The 
purified protein was filtered and stored in aliquots at -20°C or -80°C. On occasions, the 
purification process between single chain variable antibody fragments-LHN and single 
domain antibody-LHN chimeras was significantly diverse due to diferent observations 
recorded during the purification process, these diferences are described in detail in 
each section below.  
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6.4.1 Purification of single chain variable antibody fragments-LHN chimera 
Purification of LHN/B-scFvCD117I=SXN101624 (Table 10) was atempted a number of 
times in order to improve activation and minimize truncations of ful-length product. 
The products obtained folowing purification with nickel column through a step elution 
are shown in figure 54. 
When subjected to SDS-PAGE under non-reducing conditions the pure proteins 
migrated as single bands of molecular weight 129741.2 Da (MW). However, non-
specific cleavage was observed, seen as two bands with 117516.7 Da (MW) and 
103578.3 Da (MW) on SDS-PAGE (Fig 54). 
 
 
Figure 54 NuPage 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101624 produced from 
a nickel column. 
 
 
 
 
 
 
 
M    1     2     3    4     5     6    7     8  
50kDa 
120kDa 
129741.2 Da 
117516.7 Da 
103578.3 Da 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate;  
Lane 2 is a flow through after His column; 
Lane 3 is a 40mM Imidazole wash; Lane 4 is a 100mM Imidazole wash; Lanes 5, 6, 7, 8 are a 
250mM Imidazole washes; 
The arrows indicate a truncated products of LHN/B-scFvCD117I=SXN101624; 
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According to the interpretation of bands on the SDS-PAGE (Fig 54), the truncation 
within a ful-length structure took place on the afinity column, as it is not visible in the 
lane 1 total lysate or lane 2 flows through. Truncated bands as indicated in the lane 8 
started to appear during elution of the fusion protein by Imidazole. Also it was 
confirmed by Western Blot against the light chain of B (Fig 56). The sizes of truncated 
products were estimated by ProtoPram programme. The band at around 117516.7 Da 
(MW) probably represents the lack of scFv light chain and the band around 103578.3 
Da (MW) most likely represents LHBK191A-ScFv that lacks ScFv ligand. It was noted 
that the truncation of LHN/B-scFvCD117I=SXN101624 was less prominent around the 
lower band of 103578.3 Da (MW). 
Subsequently, the molecule was cleaved by EK at 25°C. The cleavage is detectable 
under reducing conditions (+DTT) on the SDS-PAGE gel (Fig 55, lane 6). The intensity of 
bands in lanes 2 and 4 are higher in comparison to lanes 1, 3 and 5 (indicated by purple 
arrow) due to the presence of DTT that has changed the accessibility of the Safe Stain 
to protein resulting in an increase in signal strength of target protein LHN/B-
scFvCD117I=SXN101624. Furthermore bands representing two distinguish domains, 
one HN-CD117I at 74744.9 Da and the other 10HT-LC at 55151.3 Da have a noticeable 
higher intensity to the band of ful-length product of LHN/B-scFvCD117I=SXN101624 at 
129741.2 Da in lane 5. These observations could suggest that there is a presence of 
truncated product cleaved by EK or there are forms of aggregates that correspond to 
the same ful-length compound. The control samples without addition of Enterokinase 
were unstable in both temperatures, as under reducing conditions (Fig 55, lanes 2 and 
4) presence of band at 74744.9 Da corresponds to the molecular weight of the HN-
CD117I product visible in lane 6. 
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Figure 55 NuPage 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101624 produced from 
a cleavage process. 
 
 
 
 
 
 
 
M     1      2      3      4      5      6      
50kDa 
120kDa 
74744.9 Da 
(HN-CD117I) 
55151.3 Da 
(10HT-LC) 
129741.2 Da 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-scFvCD117I=SXN101624 incubated at -20̊C; 
Lane 2 is a control sample LHN/B-scFvCD117I=SXN101624 incubated at -20̊C under reducing condition 
with addition of DTT;  
Lane 3 is a control sample LHN/B-scFvCD117I=SXN101624 incubated at +25̊C; 
Lane 4 is a control sample LHN/B-scFvCD117I=SXN101624 incubated at +25̊C under reducing condition 
with addition of DTT;  
Lane 5 is a cleaved LHN/B-scFvCD117I=SXN101624 incubated at +25̊C; 
Lane 6 is a cleaved LHN/B-scFvCD117I=SXN101624 incubated at +25̊C under reducing condition with 
addition of DTT; 
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Figure 56 Quality control of the target protein LHN/B-scFvCD117I=SXN101624 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against light chain (B). 
 
 
 
 
 
 
 
 
 
 M   1   2    3    4    5    6    7   8   9 
M  1    2    3    4    5    6    7    8   9 
50kDa 
120kDa 
120kDa 
60kDa 
A 
B 
Lane M on the gel (A) is a Benchmark ladder and on Western blot (B) is a Magic Mark; sizes in kDa 
(Fig 16 in chapter 2 Material and Methods);  
Lane 1 shows clarified lysate of LHN/B-scFvCD117I=SXN101624; 
Lane 2 is a -20̊C control; 
Lane 3 is a +25̊C control; 
Lane 4 is a final target fusion protein LHN/B-scFvCD117I=SXN101624 at 0.1 mg/ml loaded at 5µl; 
Lane 5 is a final target fusion protein LHN/B-scFvCD117I=SXN101624 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 6 is a final target fusion protein LHN/B-scFvCD117I=SXN101624 at 0.1 mg/ml loaded at 10µl; 
Lane 7 is a final target fusion protein LHN/B-scFvCD117I=SXN101624 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 8 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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The fragment of ScFvCD117I molecule was cloned into the LHB backbone activated by 
FXa (LHN/B-scFvCD117I=SXN101776) and purified using diferent purification 
techniques to check if the cleavage process can be improved and truncations could be 
reduced. The cleavage step was performed at the folowing temperatures: 25°C and 
4°C. There are not significant dissimilarities in the outcome of cleavage between these 
temperatures. The elimination of non-specific cleavage was not successful in this 
instance; therefore, purification was repeated by alternative methods.  
The LHN/B-scFvCD117I=SXN101776 was expressed in E. coli bacterial system and 
captured on the afinity column charged with Ni2+ (Fig 56). 
Figure 57 NuPAGE 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 produced 
from a nickel column. 
 
 
M    1     2     3    4     5     6    7     8 
50kDa 
120kDa 
129741.2 Da 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash; Lane 4 is a 100mM Imidazole wash; Lanes 5, 6, 7, 8 are a 
250mM Imidazole washes; 
The arrows indicate a truncated products of LHN/B-scFvCD117I=SXN101776; 
117516.7 Da 
103578.3 Da 
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The fusion protein LHN/B-scFvCD117I=SXN101776 was cleaved by FXa at +25̊C (Fig 
57). 
 
 
 
 
 
Figure 58 NuPAGE 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 cleaved by 
FXa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M     1      2      3      4      5      6      
120kDa 
50kDa 
74744.9 Da 
(HN-CD117I) 
55151.3 Da 
(10HT-LC) 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-scFvCD117I=SXN101776 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/B-scFvCD117I=SXN101776 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/B-scFvCD117I=SXN101776 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/B-scFvCD117I=SXN101776 at +25̊C without addition of FXa (+DTT); 
Lane 5 is cleaved LHN/B-scFvCD117I=SXN101776 by FXa at +25̊C; 
Lane 6 is cleaved LHN/B-scFvCD117I=SXN101776 by FXa at +25̊C (+DTT); 
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The outcome of this purification is shown on SDS-PAGE story gel (A), where the 
presence of the ful-length LHN/B-scFvCD117I=SXN101776 target protein was detected 
by Western blots against His tag (B) and light chain of B (C) (Fig 58). 
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Figure 59 Quality control of the target protein LHN/B-scFvCD117I=SXN101776 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against His tag (B) and light chain of B (C). 
 
 
 
 
 
 
 
In a repeated experiment using LHN/B-scFvCD117I=SXN101776 molecule, the 
alternative FXa enzyme purchased from R&D System was tested during the cleavage 
process (B) (Fig 59). The test was set up at + 25°C, overnight for Recombinant Human 
Coagulation Factor X (R&D System) (B) and Factor X (BioLabs) (A). Additional sample 
was prepared with 4 mM CaCl2 to check if it could enhance the activity of the FXa 
enzyme. The FXa (R&D System) did not cleave protein even in the presence of 4 mM 
CaCl2 (B); therefore, FXa (BioLabs) was used to cleave fusion protein (A) (Fig 59). 
  M    1    2   3    4    5    6    7    8   
120kDa 
50kDa 
C 
Lane M on the gel (A) is a Benchmark ladder and on Western blots (B and C) is a Magic Mark; sizes in 
kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 shows clarified lysate of LHN/B-scFvCD117I=SXN101776; 
Lane 2 is a -20̊C control; 
Lane 3 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 5µl; 
Lane 4 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 6 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 10µl; 
Lane 7 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 8 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 60 NuPAGE 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 cleaved by 
FXa New England BioLabs and R&D System. 
 
 
 
 
 
  M   1   2   3  4  5   6 
 M   1   2  3   4   5   6   7  8 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-scFvCD117I=SXN101776 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/B-scFvCD117I=SXN101776 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/B-scFvCD117I=SXN101776 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/B-scFvCD117I=SXN101776 at +25̊C without addition of FXa (+DTT); 
Lane 5 on the picture A is cleaved LHN/B-scFvCD117I=SXN101776 by FXa New England BioLabs at +25̊C; 
Lane 6 on the picture A is cleaved LHN/B-scFvCD117I=SXN101776 by FXa New England BioLabs at +25̊C (+DTT); 
Lane 5 on the picture B is cleaved LHN/B-scFvCD117I=SXN101776 by FXa R&D System at +25̊C; 
Lane 6 on the picture A is cleaved LHN/B-scFvCD117I=SXN101776 by FXa R&D System at +25̊C (+DTT); 
A 
B 
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Subsequently, in the final step, a His afinity nickel column was substituted with Q 
column for purification of LHN/B-scFvCD117I=SXN101776. The molecule was purified 
using a linear gradient. The Q Sepharose column partialy separated the band at 
103578.3 Da (MW) (indicated by red arrow) from the ful-length product 129741.2 Da 
(indicated by green arrow), however the band at 117516.7 Da (MW) (indicated by blue 
arrow) stil remains and dominates over the ful-length product (Fig 60). 
 
 
 
 
Figure 61 NuPage 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 produced from 
a Q Sepharose column. 
 
 
 
 
 
 
 
 
 
 
 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 is a cleaved LHN/B-scFvCD117I=SXN101776 by FXa; 
Lanes 2, 3,4,5,6,7,8,9, 10, 11 and 12 show a eluted fractions during linear gradient on a Q column; 
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SDS-PAGE (A) (Fig 61) corresponds to the Western blots against His tag (B) and light 
chain of B (C) which detected evidence of truncation in purified protein (Fig 61). 
 
 
 
 
Figure 62 Quality control of the target protein LHN/B-scFvCD117I=SXN101776 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against His tag (B) and light chain of B (C). 
 
 
 
 
 
 
 
M   1   2   3   4   5   6   7    8   
  M  1   2   3  4   5  6   7   8    M  1   2   3   4   5   6   7   8    
50kDa 
50kDa 
50kDa 
120kDa 
120kDa 120kDa 
Lane M on the gel (A) and on Western blots (B) is a Benchmark ladder on the Western blot (C) is a Magic 
Mark; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/B-scFvCD117I=SXN101776; 
Lane 2 is a -20̊C non-cleaved control LHN/B-scFvCD117I=SXN101776; 
Lane 3 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 10µl; 
Lane 4 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 6 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 5µl; 
Lane 7 is a final target fusion protein LHN/B-scFvCD117I=SXN101776 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 8 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
 
B 
A 
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The unsuccessful purification of LHN/B-scFvCD117I=SXN101776 molecule was decided  
to be rescued by using the Q Sepharose column as a capture step for purification. In 
addition, the HIC column was considered as a good alternative to prevent truncations 
of target protein. The Q Sepharose (Fig 62) and HIC hydrophobic Interaction 
Chromatography (Fig 63) columns substituted the afinity column in the first 
purification step of LHN/B-scFvCD117I=SXN101776. 
 
 
 
 
Figure 63 NuPage 4-12% Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 produced from 
a Q Sepharose column as first purification step. 
 
 
 
 
 
 
 
 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate of LHN/B-scFvCD117I=SXN101776; 
Lane 2 is a flow through colected after a Q Sepharose column run; 
Lanes 3,4,5,6,7,8,9,10,11 and 12 show a eluted fractions during linear gradient on a Q column; 
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Figure 64 NuPage 4-12 % Bis-Tris gel of LHN/B-scFvCD117I=SXN101776 produced 
from a (HIC) Hydrophobic Interaction Chromatography column as first purification 
step. 
 
 
 
The application of Q Sepharose or HIC column resulted in non-specific cleavage of the 
eluted proteins, so these methods of purification were not routinely used. 
The CD117IScFv was cloned into LHNC backbone with an FXa cleavage site. The lysate 
extract containing soluble recombinant LHN/C-scFvCD117I=SXN101882 molecule was 
subject to IMAC purification and desalted on the same day in order to reduce non-
specific cleavage. The fusion protein eluted at 250 mM Imidazole (Fig 64) was cleaved 
with 1.5 Unit of FXa per 1 mg of protein at 25 °C, overnight (Fig 65), but the truncations 
remained as previously observed for the LHN/B-scFvCD117I=SXN101624 or 
LHN/BscFvCD117I=SXN101776 molecule. 
 
  M  1   2   3   4   5   6   7   8       M   9   10   11  12   13   14   15 
50kDa 
120kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate of LHN/B-scFvCD117I=SXN101776; 
Lane 2 is a flow through colected after a HIC column run; 
Lanes 3,4,5,6,7,8,9,10,11,12,13,14 and 15 show a eluted fractions during linear gradient on a Q 
column; 
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Figure 65 NuPAGE 4-12 % Bis-Tris gel of LHN/C-scFvCD117I=SXN101882 produced 
from a nickel column. 
 
 
 
 
 
 
 
Figure 66 NuPAGE 4-12 % Bis-Tris gel of LHN/C-scFvCD117I=SXN101882 cleaved by 
FXa. 
 
 
 
 M   1   2   3    4   5    6   7   8   9   10  11  
   M     1     2     3      4      5      6       
120kDa 
120kDa 
50kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash;  
Lane 4, 5, 6, 7, 8, 9, 10 and 11 are desalted 250mM Imidazole washes; 
The arrows indicate a truncated products of LHN/C-scFvCD117I=SXN101882; 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/C-scFvCD117I=SXN101882 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/C-scFvCD117I=SXN101882 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/C-scFvCD117I=SXN101882 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/C-scFvCD117I=SXN101882 at +25̊C without addition of FXa (+DTT); 
Lane 5 is cleaved LHN/C-scFvCD117I=SXN101882 by FXa at +25̊C; 
Lane 6 is cleaved LHN/C-scFvCD117I=SXN101882 by FXa at +25̊C (+DTT); 
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117516.7 Da 
103578.3 Da 
 
159 Engineering botulinum-antibody proteins 
The fusion protein of LHN/C-scFvCD117I=SXN101882 molecule is shown on the SDS-
PAGE gel (A). Western blots against His tag (B) and light chain of C (C) detected 
evidence of truncation in purified protein (Fig 66).  
 
 
 
 
 
 
Figure 67 Quality control of the target protein LHN/C-scFvCD117I=SXN101882 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against His tag (B) and light chain of C (C). 
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Lane M on the gel (A) and on Western blots (B) is a Benchmark ladder on the Western blot (C) is a Magic 
Mark; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/C-scFvCD117I=SXN101882; 
Lane 2 is a -20̊C non-cleaved control LHN/C-scFvCD117I=SXN101882; 
Lane 3 is a cleaved LHN/C-scFvCD117I=SXN101882 by FXa; 
Lane 3 is a final target fusion protein LHN/C-scFvCD117I=SXN101882at 0.1 mg/ml loaded at 5µl; 
Lane 4 is a final target fusion protein LHN/C-scFvCD117I=SXN101882at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 6 is a final target fusion protein LHN/C-scFvCD117I=SXN101882at 0.1 mg/ml loaded at 10µl; 
Lane 7 is a final target fusion protein LHN/C-scFvCD117I=SXN101882at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 8 is an unliganded control LHN/C=SXN101654 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/C=SXN101654 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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The molecule LHN/C-scFvCD117I=SXN101882 was sent for a N-terminal sequencing to 
Alta Bioscience at Birmingham University, in order to establish the accurate position of 
truncations within ScFv molecules. An N-terminal sequencing was performed on the 
ful-length and reduced proteolyticaly digested protein. The results indicated that the 
Mr band 129173.8 is a ful-length product starting with the primary sequence of  MH 
(Methionine-Histidine) indicated by the blue arrow (Fig 68) this corresponds to the 
sequence of LHN/C-scFvCD117I=SXN101882. The FXa cleaved protein in reducing 
conditions represents the correct band indicated by purple arrow in the figure 69, 
which starts at SLYNKTL motif after IDGR activation site. One of the truncated 
products possibly begins just after the heavy chain of LHn/C backbone at NLE (Mr 
102654.6) motif (indicated by red arrow in figure 70) and the second one at GTL (Mr 
115371.8) motif (indicated by green arrow), which separates the heavy chain of ScFv 
from light chain of ScFv just before the GS15 linker. The introduction of an EEGEFSAR 
linker, which is shorter than the GGGGSGGGGSGGGGS linker used in the existing ScFvs, 
could be a first approach to resolve the nonspecific cleavage within these molecules. 
 
Figure 68 Protein sequence report from Alta Bioscience. 
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Figure 69 Protein sequence report from Alta Bioscience. 
 
 
 
Figure 70 Protein sequence report from Alta Bioscience. 
 
 
 
Figure 71 Protein sequence report from Alta Bioscience. 
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6.4.2 Purification of single domain antibodies-LHN chimera 
Purification of recombinant single domain antibodies as a part of LHN chimeras 
seemed to be more promising than single chain variable antibody fragments-LHN 
chimeras, as their structure is less complicated in comparison to recombinant single 
chain antibodies. AktaExpress System was used to purify molecules 
LHN/B-EGFR31sdAb=SXN101865, LHN/B-EGFR43sdAb=SXN101866 and LHN/A-
EGFR6sdAb=SXN101868 (Table 10) on the IMAC column. The fusion proteins eluted at 
250 mM Imidazole were activated with FXa and subsequently passed through the 
IMAC column once more. The bufer was exchanged by a desalting column, which 
shortens the purification process to two days.  
The molecules LHN/B-EGFR6sdAb=SXN101861, LHN/A-EGFR31sdAb=SXN101872, 
LHN/D-EGFR28sdAb=SXN101877 and LHN/D-EGFR31sdAb=SXN101878 (Table 10) were 
purified by the afinity chromatography in the capture step and on the HIC 
(Hydrophobic Interaction Chromatography) during second step. The afinity 
chromatography method is based on the bufer with higher salt concentration, which 
is 50 mM Hepes pH 7.2, 500 mM NaCl. The higher salt concentration should enhance 
production of soluble protein and disassociate contaminants from the fusion protein. 
An HIC phenyl Sepharose column was introduced as a second purification step to 
increase purity of the target protein, so they can be used for crystalography study at 
Bath University. 
Al ful-length fusion proteins of LHN single domain antibodies chimeras obtained in 
this study are listed in the table 12. 
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Both LHN/ B based molecules the LHN/B-EGFR31sdAb=SXN101865 (Fig 72) and the 
LHN/B-EGFR6sdAb=SXN101861 (Fig 73) were purified with high purity and yield.  
 
 
 
Figure 72 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR31sdAb=SXN101865 produced 
from a nickel column. 
 
 
 
 
 
 
Figure 73 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR6sdAb=SXN101861 produced from 
a nickel column. 
 
 
 
M   1   2   3    4   5   6   7   8   9  10   11  
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  M    1     2    3     4     5     6     7    8     
120kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3, 4, 5, 6, 7, 8, 9, 10 and 11 show a desalted 250mM Imidazole elution; 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash; Lanes 4, 5, 6, 7 and 8 are a 250mM Imidazole washes; 
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The outcome of activation was better for LHN/B-EGFR31sdAb=SXN101865 (Fig 74) 
than EGFR6sdAb=SXN101861 (Fig 75) molecule; however, both represent high quality 
data according to the QC procedure at Syntaxin Ltd (Fig 76 and 77). 
 
Figure 74 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR31sdAb=SXN101865 cleaved by 
FXa. 
 
 
 
 
 
 
 
 
 
Figure 75 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR6sdAb=SXN101861 cleaved by 
FXa. 
 
  M     1      2     3      4      5     6        
   M    1     2     3     4     5     6       
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-EGFR31sdAb=SXN101865 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/B-EGFR31sdAb=SXN101865 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/B-EGFR31sdAb=SXN101865 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/B-EGFR31sdAb=SXN101865 at +25̊C without addition of FXa (+DTT); 
Lane 5 is cleaved LHN/B-EGFR31sdAb=SXN101865 by FXa at +25̊C; 
Lane 6 is cleaved LHN/B-EGFR31sdAb=SXN101865 by FXa at +25̊C (+DTT); 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-EGFR6sdAb=SXN101861 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/B-EGFR6sdAb=SXN101861 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/B-EGFR6sdAb=SXN101861 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/B-EGFR6sdAb=SXN101861 at +25̊C without addition of FXa (+DTT); 
Lane 5 is cleaved LHN/B-EGFR6sdAb=SXN101861 by FXa at +25̊C; 
Lane 6 is cleaved LHN/B-EGFR6sdAb=SXN101861 by FXa at +25̊C (+DTT); 
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Figure 76 Quality control of the target protein LHN/B-EGFR31sdAb=SXN101865 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against His tag (B) and light chain of B (C). 
 
 
 
 
Lane M on the SDS PAGE gel (A) and on Western blot (C) is a Benchmark ladder on the Western blot (B) is 
a Magic Mark; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/B-EGFR31sdAb=SXN101865; 
Lane 2 is a -20̊C control of LHN/B-EGFR31sdAb=SXN101865; 
Lane 3 is a cleaved LHN/B-EGFR31sdAb=SXN101865 by FXa; 
Lane 4 is a final target fusion protein LHN/B-EGFR31sdAb=SXN101865 at 0.1 mg/ml loaded at 10µl; 
Lane 5 is a final target fusion protein LHN/B-EGFR31sdAb=SXN101865 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 6 is a final target fusion protein LHN/B-EGFR31sdAb=SXN101865 at 0.1 mg/ml loaded at 5µl; 
Lane 7 is a final target fusion protein LHN/B-EGFR31sdAb=SXN101865 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 8 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 77 Quality control of the target protein LHN/B-EGFR6sdAb=SXN101861 
represent on the NuPage 4-12% Bis-Tris gel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
On another instance the molecule LHN/B-EGFR43sdAb=SXN101866 was purified with 
the low yield (Fig 78), did not activate and in addition the unspecific cleavage was 
observed on the SDS-PAGE gel picture (indicated by turquoise arrow) (Fig 79). This 
fusion protein was lost during the second part of purification. 
 
 M   1    2    3    4    5    6    7    8    9   
120kDa 
50kDa 
Lane M is a Benchmark; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/B-EGFR6sdAb=SXN101861; 
Lane 2 is a -20̊C control of LHN/B-EGFR6sdAb=SXN101861; 
Lane 3 is a cleaved LHN/B-EGFR6sdAb=SXN101861 by FXa; 
Lane 4 is a final target fusion protein LHN/B-EGFR6sdAb=SXN101861 at 0.1 mg/ml loaded at 10µl; 
Lane 5 is a final target fusion protein LHN/B-EGFR6sdAb=SXN101861 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 6 is a final target fusion protein LHN/B-EGFR6sdAb=SXN101861at 0.1 mg/ml loaded at 5µl; 
Lane 7 is a final target fusion protein LHN/B-EGFR6sdAb=SXN101861at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 8 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/B=SXN101687 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 78 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR43sdAb=SXN101866 produced 
from a nickel column. 
 
 
 
 
 
 
 
 
 
Figure 79 NuPage 4-12% Bis-Tris gel of LHN/B-EGFR43sdAb=SXN101866 cleaved by 
FXa. 
 
 
 
 
 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3, 4, 5, 6, 7, 8 and 9 show a desalted 250mM Imidazole elution; 
M    1    2    3    4     5    6    7    8    9   
120kDa 
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50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/B-EGFR43sdAb=SXN101866 at -20̊C without addition of FXa; 
Lane 2 is a control sample LHN/B-EGFR43sdAb=SXN101866 at -20̊C without addition of FXa (+DTT);  
Lane 3 is a control sample LHN/B-EGFR43sdAb=SXN101866 at +25̊C without addition of FXa; 
Lane 4 is a control sample LHN/B-EGFR43sdAb=SXN101866 at +25̊C without addition of FXa (+DTT); 
Lane 5 is cleaved LHN/B-EGFR43sdAb=SXN101866 by FXa at +25̊C; 
Lane 6 is cleaved LHN/B-EGFR43sdAb=SXN101866 by FXa at +25̊C (+DTT); 
   M     1       2      3      4       5      6        
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As mentioned in the chapter two ͵Choice of sdAbʹ according to the tests described in 
the patent, the EGFR-43sdAb have the highest yield per litre of culture and ability of 
binding to EGFR-ECD. The EGFR-31sdAb compared to EGFR-43sdAb has five time’s 
lower yield and reduced binding capability. The conclusion made in the patent did not 
correspond to observations made after purification of single domain antibodies as a 
part of recombinant botulinum chimeras. This could indicate that single domain 
antibodies in the presence of recombinant molecules show diferent characteristics, 
which could be a result of changes within the structure. 
Similar observations were made while purifying LHN/A-EGFR6sdAb=SXN101868 (Fig 
80) and LHN/A-EGFR31sdAb=SXN101872 (Fig 82) molecules.  Both molecules were 
purified to high purity; however, LHN/A-EGFR6sdAb=SXN101868 was fuly activated 
(Fig 81), while LHN/A-EGFR31sdAb=SXN101872 stil carried some inactivated ful-
length material (Fig 83). 
 
 
Figure 80 NuPage 4-12% Bis-Tris gel of LHN/A-EGFR6sdAb=SXN101868 produced from 
a nickel column. 
 
M   1   2    3   4    5    6   7   8   9  10 
120kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3, 4, 5, 6, 7, 8, 9 and 10show a desalted 250mM Imidazole elution; 
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Figure 81 NuPage 4-12% Bis-Tris gel of LHN/A-EGFR6sdAb=SXN101868 cleaved by EK. 
 
 
 
 
 
Figure 82 NuPage 4-12% Bis-Tris gel of LHN/A-EGFR31sdAb=SXN101872 produced 
from a nickel column. 
 
 
 
 
  M     1      2      3      4      5      6        
120kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/A-EGFR6sdAb=SXN101868 at -20̊C without addition of EK; 
Lane 2 is a control sample LHN/A-EGFR6sdAb=SXN101868 at -20̊C without addition of EK (+DTT);  
Lane 3 is a control sample LHN/A-EGFR6sdAb=SXN101868 at +25̊C without addition of EK; 
Lane 4 is a control sample LHN/A-EGFR6sdAb=SXN101868 at +25̊C without addition of EK (+DTT); 
Lane 5 is cleaved LHN/A-EGFR6sdAb=SXN101868 by EK at +25̊C; 
Lane 6 is cleaved LHN/A-EGFR6sdAb=SXN101868 by EK at +25̊C (+DTT); 
 
 
M   1     2     3    4      5     6    7     8   
120kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash; Lane 4 is a 80mM Imidazole wash; Lanes  5, 6, 7 and 8 are a 
250mM Imidazole washes; 
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Figure 83 NuPage 4-12% Bis-Tris gel of LHN/A-EGFR31sdAb=SXN101872 cleaved by 
EK. 
 
 
 
 
Regarding the data available in house, the LHN/A based constructs do not activate as 
wel as an LHN/A-EGFR6sdAb=SXN101868, therefore the hypothesis that the EGFR-
6sdAbs improve cleavage and enhance purity could be accepted. It is also important to 
emphasize that the LHN/A-EGFR6sdAb=SXN101868 was purified only on the two-step 
IMAC columns, whereas an LHN/A-EGFR31sdAb=SXN101872 was passed on the HIC 
phenyl Sepharose in the second purification step, which further improves the purity of 
this molecule (Fig 84). Nevertheless, the LHN/A-EGFR6sdAb=SXN101868 compound 
was of higher quality in comparison to compound LHN/A-EGFR31sdAb=SXN101872, 
despite of less advanced purification process being implemented. 
 M     1      2      3      4      5      6        
120kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/A-EGFR31sdAb=SXN101872 at -20̊C without addition of EK; 
Lane 2 is a control sample LHN/A-EGFR31sdAb=SXN101872 at -20̊C without addition of EK (+DTT);  
Lane 3 is a control sample LHN/A-EGFR31sdAb=SXN101872 at +25̊C without addition of EK; 
Lane 4 is a control sample LHN/A-EGFR31sdAb=SXN101872 at +25̊C without addition of EK (+DTT); 
Lane 5 is cleaved LHN/A-EGFR31sdAb=SXN101872 by EK at +25̊C; 
Lane 6 is cleaved LHN/A-EGFR31sdAb=SXN101872 by EK at +25̊C (+DTT); 
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Figure 84 NuPage 4-12% Bis-Tris gels of LHN/A-EGFR31sdAb=SXN101872 produced 
from a HIC column. 
 
 
 
 
On this instance, the data shown in the patent regarding to the molecule EGFR-
31sdAbs has been confirmed, where an EGFR-31sdAb molecule out of four tested, has 
the lowest final yield as wel as an LHN/A-EGFR31sdAb=SXN101872 molecule cloned 
for this study. 
The molecule EGFR-6sdAb was not included in the experiments described in the 
patent, but it belongs to group 2 together with EGFR-10sdAb, which has reasonable 
ability of binding in the longest period in comparison to other tested molecules, also it 
has shown a reasonable yield after purification.  
In overal, the high quality of data can be obtained by a combination of appropriate 
choice of the single domain antibody and the LHN structure of the diferent serotype 
(Fig 85 and 86). 
120kDa 120kDa 
50kDa 
50kDa 
M   1    2    3     4     5     6    7   8   9     M  1     2    3     4     5     6    7   8     
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a cleaved LHN/A-EGFR31sdAb=SXN101872; 
Lanes 2, 3, 4, 5, 6, 7, 8 and 9 are elution fractions after hydrophobic interaction chromatography 
column; 
The samples on the SDS PAGE gel (A) were run in oxidizing condition; 
The samples on the SDS PAGE gel (B) were run in reducing condition (+DTT); 
 
A B 
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Figure 85 Quality control of the target protein LHN/A-EGFR6sdAb=SXN101868 
represent on the NuPage 4-12% Bis-Tris gel (A) and confirmed by Western blot 
against His tag (B) and light chain of A (C). 
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Lane M on the SDS PAGE gel (A) and on Western blot (B) is a Benchmark ladder on the Western blot 
(C) is a Magic Mark; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/A-EGFR6sdAb=SXN101868; 
Lane 2 is a -20̊C control of LHN/A-EGFR6sdAb=SXN101868; 
Lane 3 is a cleaved LHN/A-EGFR6sdAb=SXN101868by EK; 
Lane 4 is a final target fusion protein LHN/A-EGFR6sdAb=SXN101868at 0.1 mg/ml loaded at 10µl; 
Lane 5 is a final target fusion protein LHN/A-EGFR6sdAb=SXN101868at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 6 is a final target fusion protein LHN/A-EGFR6sdAb=SXN101868at 0.1 mg/ml loaded at 5µl; 
Lane 7 is a final target fusion protein LHN/A-EGFR6sdAb=SXN101868at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 8 is an unliganded control LHN/A=SXN100590 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/A=SXN100590 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 86 Quality control of the target protein LHN/A-EGFR31sdAb=SXN101872 
represent on the NuPage 4-12 % Bis-Tris gel. 
 
 
 
 
 
In addition to these, the LHN/D based molecules LHN/D-EGFR28sdAb=SXN101877 (Fig 
87) and LHN/D-EGFR31sdAb=SXN101878 (Fig 88) were purified, therefore the data 
were compared to establish more robust conclusion about the single domain 
antibodies in the combination of LHN structure. 
 
 M   1    2   3    4     5    6    7   8   9   
120kDa 
50kDa 
Lane M is a Benchmark ladder; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/A-EGFR31sdAb=SXN101872; 
Lane 2 is a -20̊C control of LHN/A-EGFR31sdAb=SXN101872; 
Lane 3 is a cleaved LHN/A-EGFR31sdAb=SXN101872by EK; 
Lane 4 is a final target fusion protein LHN/A-EGFR31sdAb=SXN101872 at 0.1 mg/ml loaded at 10µl; 
Lane 5 is a final target fusion protein LHN/A-EGFR31sdAb=SXN101872 at 0.1 mg/ml loaded at 10µl 
(+DTT); 
Lane 6 is a final target fusion protein LHN/A-EGFR31sdAb=SXN101872 at 0.1 mg/ml loaded at 5µl; 
Lane 7 is a final target fusion protein LHN/A-EGFR31sdAb=SXN101872 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 8 is an unliganded control LHN/A=SXN100590 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/A=SXN100590 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 87 NuPage 4-12% Bis-Tris gel of LHN/D-EGFR28sdAb=SXN101877 produced 
from a nickel column. 
 
 
 
 
 
 
 
 
 
 
 
Figure 88 NuPage 4-12% Bis-Tris gel of LN/D-EGFR31sdAb=SXN101878 produced from 
a nickel column. 
 
 
120kDa 
120kDa 
50kDa 
50kDa 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash; Lane 4 is a 80mM Imidazole wash; Lanes 5, 6, 7 and 8 are a 
250mM Imidazole washes; 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 is a clarified lysate; 
Lane 2 is a flow through from His column; 
Lane 3 is a 40mM Imidazole wash; Lane 4 is a 80mM Imidazole wash; Lanes 5, 6, 7 and 8 are a 
250mM Imidazole washes; 
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The molecules LHN/D-EGFR28sdAb=SXN101877 and LHN/D-EGFR31sdAb=SXN101878 
purified to high standards were cleaved efectively by Enterokinase, as shown on SDS-
PAGE in figure 89 and 90. 
 
Figure 89 NuPage 4-12% Bis-Tris gel of LHN/D-EGFR28sdAb=SXN101877 cleaved by 
EK. 
 
 
 
 
 
 
 
 
 
Figure 90 NuPage 4-12% Bis-Tris gel of LHN/D-EGFR31sdAb=SXN101878 cleaved by 
EK. 
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Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 is a control sample LHN/D-EGFR28sdAb=SXN101877 at -20̊C without addition of EK; 
Lane 2 is a control sample LHN/D-EGFR28sdAb=SXN101877 at -20̊C without addition of EK (+DTT);  
Lane 3 is a control sample LHN/D-EGFR28sdAb=SXN101877 at +25̊C without addition of EK; 
Lane 4 is a control sample LHN/D-EGFR28sdAb=SXN101877 at +25̊C without addition of EK (+DTT); 
Lane 5 is cleaved LHN/D-EGFR28sdAb=SXN101877 by EK at +25̊C; 
Lane 6 is cleaved LHN/D-EGFR28sdAb=SXN101877 by EK at +25̊C (+DTT); 
 
Lane M is a Benchmark ladder, sizes in kDa (Fig 16 in chapter 2 Material and Methods);  
Lane 1 is a control sample LHN/D-EGFR31sdAb=SXN101878 at -20̊C without addition of EK; 
Lane 2 is a control sample LHN/D-EGFR31sdAb=SXN101878 at -20̊C without addition of EK (+DTT);  
Lane 3 is a control sample LHN/D-EGFR31sdAb=SXN101878 at +25̊C without addition of EK; 
Lane 4 is a control sample LHN/D-EGFR31sdAb=SXN101878 at +25̊C without addition of EK (+DTT); 
Lane 5 is cleaved LHN/D-EGFR31sdAb=SXN101878 by EK at +25̊C; 
Lane 6 is cleaved LHN/D-EGFR31sdAb=SXN101878 by EK at +25̊C (+DTT); 
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However, an LHN/D-EGFR31sdAb=SXN101878 (Fig 92) molecule has higher purity than 
an LHN/D-EGFR28sdAb=SXN101877 (Fig 91) fusion protein; the yield of LHN/D-
EGFR28sdAb=SXN101877 is almost four times higher in comparison to the molecule 
LHN/D-EGFR31sdAb=SXN101878. 
 
Figure 91 Quality control of the target protein LHN/D-EGFR28sdAb=SXN101877 
represent on the NuPage 4-12% Bis-Tris gel. 
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Lane M is a Benchmark ladder; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/D-EGFR28sdAb=SXN101877; 
Lane 2 is a -20̊C control of LHN/D-EGFR28sdAb=SXN101877; 
Lane 3 is a cleaved LHN/D-EGFR28sdAb=SXN101877 by EK; 
Lane 4 is a final target fusion protein LHN/D-EGFR28sdAb=SXN101877 at 0.1 mg/ml loaded at 5µl; 
Lane 5 is a final target fusion protein LHN/D-EGFR28sdAb=SXN101877 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 6 is a final target fusion protein LHN/D-EGFR28sdAb=SXN101877 at 0.1 mg/ml loaded at 10µl; 
Lane 7 is a final target fusion protein LHN/D-EGFR28sdAb=SXN101877 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 8 is an unliganded control LHN/D=SXN101655 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/D=SXN101655 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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Figure 92 Quality control of the target protein LHN/D-EGFR31sdAb=SXN101878 
represent on the NuPage 4-12 % Bis-Tris gel. 
 
 
 
 
 
 
 
 
 
 
The data obtained from purification of the LHN/A-EGFR31sdAb=SXN101872 and the 
LHN/D-EGFR31sdAb=SXN101878 in a LHN/A and a LHN/D backbone are comparable to 
the data obtained in the patent WO 2008/141449 A1 on the EGFR31sdAb.  The final 
yield of purified molecules is lower in comparison to the yield of other LHN single 
domain antibodies and the same time similar to the yield of EGFR31sdAb. The 
exception was observed for the compound based on a LHN/B backbone, where 
compound LHN/B-EGFR31sdAb=SXN101865 gave outstanding results in comparison to 
the other molecules, the same time it becomes so far the best choice to achieve high 
quality of data. 
It is also important to compare the data obtained from the purification of LHN/D-
EGFR28sdAb=SXN101877 molecule to the data of EGFR28sdAb obtained from the 
patent. This molecule EGFR28sdAb has not been tested by assays established in the 
patent. However, the EGFR2-sdAb that belongs to the same group as the EGFR28sdAb 
showed the strongest binding ability in the longest time and it did not give high yields 
120kDa 
50kDa 
 M   1    2    3    4     5    6   7   8    9   
Lane M is a Benchmark ladder; sizes in kDa (Fig 16 in chapter 2 Material and Methods); 
Lane 1 shows clarified lysate of LHN/D-EGFR31sdAb=SXN101878; 
Lane 2 is a -20̊C control of LHN/D-EGFR31sdAb=SXN101878; 
Lane 3 is a cleaved LHN/D-EGFR31sdAb=SXN101878 by EK; 
Lane 4 is a final target fusion protein LHN/D-EGFR31sdAb=SXN101878 at 0.1 mg/ml loaded at 5µl; 
Lane 5 is a final target fusion protein LHN/D-EGFR31sdAb=SXN101878 at 0.1 mg/ml loaded at 5µl (+DTT); 
Lane 6 is a final target fusion protein LHN/D-EGFR31sdAb=SXN101878 at 0.1 mg/ml loaded at 10µl; 
Lane 7 is a final target fusion protein LHN/D-EGFR31sdAb=SXN101878 at 0.1 mg/ml loaded at 10µl (+DTT); 
Lane 8 is an unliganded control LHN/D=SXN101655 (Table 11) at 0.1mg/ml loaded at 10µl; 
Lane 9 is an unliganded control LHN/D=SXN101655 (Table 11) at 0.1mg/ml loaded at 10µl (+DTT); 
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of the final expressed product. The yield of purified LHN/D-EGFR28sdAb=SXN101877 is 
comparable to the yield of EGFR2-sdAb; therefore it seems to be comparable to data 
obtained from the patent. This conclusion can be only accepted if I assume that the 
grouping system of the single domain antibodies in the patent is analogous. 
 
Table 12. The fusion proteins of the ful-length antibody-LHN chimeras obtained in 
this study. 
 
Name 
 
SXN number 
 
E number 
 
MW Molecular 
Weight Da 
 
Purification 
method 
 
Purity 
% 
 
A280nm
mg/ml 
 
Yield
mg 
 
BCA 
assay 
mg/ml 
10HT-LD-EK-
HD-
EGFR31sdAb 
SXN101878 E001423 115759.4 His-EK-HIC 90 9.8 6.8 5.0 
10HT-LB-A-
linker-Xa-
HB-
EGFR6sdAb 
SXN101861 E001406 116880.5 His-EK-HIC 96 5.7 18.9 4.1 
10HT-LB-A-
linker-Xa-
HB-
EGFR31sdAb 
SXN101865 E001410 116345.0 His-Desalt-
Fxa-His 
96 6.1 18.3 4.2 
10HT-LA-EK-
HA-
EGFR6sdAb 
SXN101868 E001413 115531.3 His-Desalt-
Fxa-His 
97 3.6 3.3 3.0 
10HT-LA-EK-
HA-
EGFR31sdAb 
SXN101872 E001417 114832.6 His-EK-HIC 100 7 9.5 5.0 
10HT-LD-EK-
HD-
EGFR28sdAb 
SXN101877 E001422 117018.5 His-EK-HIC 74 11.8 24.8 N/A 
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Chapter 7. Activation Studies 
 
Engineering functional recombinant proteins based on antibody domains and 
fragments of C. botulinum neurotoxin was the concept of the project that is described 
in chapters 3 to 6. The successful production of the molecules gave opportunity to 
perform additional experiments, which were not required for purpose of this project, 
but they covered the area of personal interest. The area of interest includes the 
investigation of the functionality of produced molecules by studying activation and 
internalization of constructs of this type and other Syntaxin TSIs (Targeted Secretion 
Inhibitors). The preparation of activation and internalization study also enabled to 
develop new techniques.  
7.1 Principle of the activation study 
The purpose of experiment was to measure a receptor activation and phosphorylation 
on cels. The experiments were based on the tyrosine kinase receptor family, as the 
produced Syntaxin Ltd molecules carried ligand against this receptor. This is EGF the 
(Epidermal growth factor) ligand of the tyrosine kinase family of receptors. 
7.2 Ligand binding 
A ligand is a substance that is able to bind and form a complex with biomolecules to 
serve a biological purpose. A ligand in this study is a single domain or a single chain 
ant-EGFR antibody fragment that is a part of recombinant botulinum neurotoxin 
molecule.  The biomolecule that forms a complex with ligand is a receptor in the 
plasma membranes. 
Receptors possess sites accessible to the extracelular environment, where binding of 
soluble ligands can take place. The amino acids, which make up the binding site, 
determine specificity and afinity for the ligand. John Newport Langley discovered the 
concept of specific binding site for a ligand (Langley, 1878). 
Receptors bind ligands via weak noncovalent interactions, such as ionic interactions, 
van der Waals forces, hydrogen bonding or hydrophobic interactions. As the 
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irreversible covalent binding between ligand and receptor does not take place, so the 
docking is reversible. Therefore, the receptor can be recycled for subsequent use. The 
strength of binding ligand to receptor is its afinity. The concentration of ligand has an 
impact on the detection of the ligand by receptor and subsequently an afinity. Low 
concentration of ligand present on the ligand-binding site results in high afinity ligand 
binding, while high concentration of ligand implies to low afinity of ligand.  
The Docking is a method that predicts the preferred orientation of one molecule to a 
second when bound to each other to form a stable complex. Molecular docking is 
described as a ͵best-fitʹ  orientation  of  a ligand that  binds to  a  particular  protein  of 
interest. Molecular definition of docking represents two analogy: ͵lock-and-keyʹ  and 
h͵and-in-gloveʹ.  The second  analogy seems to  be  more  appropriate since the ligand 
and the receptor are flexible to achieve the ͵best fitʹ (Hancock, 1997). 
The orientation of the two interacting molecules (receptor and ligand) may afect a 
type of signal produced. A ligand is caled antagonist or agonist based on the signal 
produced. An antagonist is a ligand that binds to receptor, but does not result in the 
activation of it. However if the ligand binds to a receptor which then is activated it is 
caled an agonist. This binding stimulates the intracelular response via a complex 
signal-transduction pathway. The cel needs to respond to a variety of signals, 
therefore a range of receptors are involved in this role. 
Signaling receptors are divided into five classes: ion channel linked, G protein linked, 
containing intrinsic enzymatic activity, tyrosine kinase linked, intracelular. I have been 
interested in the tyrosine kinase pathway, as EGFR belongs to this family. 
7.3 Receptor Tyrosine Kinases 
Receptor tyrosine kinases (RTK)s are the high afinity cel surface receptors. These 
receptors possess an extracelular ligand-binding domain, a single transmembrane 
domain, and a cytoplasmic domain that contains the kinase activity. The binding of the 
ligand into extracelular binding site of the receptor activates the kinase activity on the 
cytoplasmic side of the membrane. EGF (epidermal growth factor) is the most common 
extracelular protein ligand that initiates the MAPK/ERK pathway, which tests were 
attempted in these experiments. 
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In the diagram, "P" represents phosphate. Note EGF at the very top. 
 
   
 
Figure 93 The key components of the MAPK/ERK pathway (adapted from 
JWSchmidt). 
 
Beginning of the MAPK/ERK pathway cascade requires a signal from the receptor on 
the surface of the cel to be transduced to the DNA in the nucleus. The signal starts 
when EGF binds to the epidermal growth factor receptor (EGFR) on the cel surface and 
ends when the DNA in the nucleus expresses a protein and produces some change in 
the cel. Binding of epidermal growth factor to EGFR activates the tyrosine kinase on 
the cytoplasmic surface. On this stage, two processes occur, phosphorylation and 
dimerization of the receptor. Phosphorylation is the signal for binding other 
cytoplasmic proteins. Where the dimerization occurs, it alows the formation of high-
The kinase cascade starts from the 
moment when EGF binds to EGFR 
and activates tyrosine kinase 
activity on the cytoplasmic domain 
of the receptor.  
 
 
The EGFR becomes 
phosphorylated. The pathway 
of this activation leads to 
MAPK activation and 
phosphorylation. 
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afinity, binding sites important for eficient phosphorylation of the protein that can be 
in low abundance within the cel. 
On occupation by its ligand EGF, the EGF-R forms a dimer and this induces a change in 
the confirmation of the cytoplasmic domain that reveals its latent tyrosine protein 
kinase activity. This alows auto-phosphorylation of certain tyrosine residues on the 
dimerized receptor molecule. The dimerized phosphorylated molecule constitutes the 
catalyticaly active receptor. The Grb2 protein attaches to the tyrosine-phosphorylated 
receptor (EGFR) through its SH2 domain, while SH3 domain is involved in the activation 
of RAS protein. Activated RAS associates with protein kinase RAF (proto-oncogene 
serine/threonine-protein kinase), and subsequently activates MEK (Mitogen-activated 
protein kinase). The MEK kinase phosphorylates ERK (MAPK) on tyrosine and threonine 
residue. Dimerization of ERK (MAPK) exposes a signal that alows this MAP kinase to 
interact with proteins that promote its translocation into nucleus. The result is altered 
transcription. 
7.4 Epidermal growth factor (EGF) 
Stanley Cohen of Vanderbilt University along with Rita Levi-Montalcini received the 
Noble Prize in 1986 for the discovery of EGF described as a contaminating factor that 
causes precocious growth in epidermis (Cohen, 1958, 1964). 
The EGF that binds and activates EGF receptors (EGFR) belongs to class of first 
messengers, as it initiates intracelular activity. It stimulates growth, initiates 
apoptosis, diferentiation, and gene expression. Growth factors (including EGF) are 
involved in tumour maintenance and growth and many tumour cels therefore express 
high levels of EGF-R. Therefore, recombinant antibodies to such receptors are 
promising leads in cancer biology. If an activation is detected it can suggest that the 
protein wil be able to internalize into cels and any attached cargo wil have an efect 
in the cel. The experiments were designed to check and measure the phosphorylation 
of EGFR binding and EGFR-Ab BoNT fusions. 
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7.5 Results 
The aim of this study was to measure activation and phosphorylation of EGF. EGF was 
biotin labeled and become biotinylated to reduce its aggregation in solution. A biotin 
was brought from Pierce, UK. Molecule was tested on A549 cels, which carry receptor 
for EGF. A549 cels are adenocarcinomic human alveolar basal epithelial cels.  
The A549 cels were grown on Petri dishes at 37°C in the incubator.  EGF was diluted in 
media to 100 nM and 1 nM. The dilutions were prepared in series to obtain accurate 
values. 10 ml of media for each dilution of EGF was added to three plates. Al plates 
were incubated at 37°C for: 5, 10, and 45 minutes. An additional control plate with 10 
ml of media only was incubated for 45 minutes. The control was a plate with cels 
lacking an EGF ligand. The phosphorylation process was stopped on ice after each 
incubation stage for each dilution. Subsequently a Cel Lysis Bufer was applied to 
colect cels for analysis. The concentration of protein was determined by BCA assay to 
ensure the same amount of protein was loaded onto the gel for each sample. A control 
sample with no added ligand was included on each gel. 
 
The outcome of an activation experiment using EGF was interpreted by Western blots 
against β-actin, EGFR, phospho-EGFR, MAPK, and phospho-MAPK. The β-actin Western 
Blot (Fig 94) detected equal amount of the protein loaded onto the gel. The MAPK 
(Mitogen activated protein kinase) (Fig 95) and p-MAPK (phosphorylated Mitogen 
activated protein kinase) (Fig 96) blots  detected bands with expected size of 42-44 
kDa. However, there was detection of undesirable  MAPK and p-MAPK in the control 
sample that indicates the presence of EGF in the cels or suggests that the assay had 
not worked. Both the concentration of EGF added to the cels and the length of 
incubation has impact on the signal. The highest concentration of EGF 100 nM kept for 
45 min gave the lowest signal. It can be due to cel death, therefore the cel did not 
respond to the presence of ligand. The Western blot against EGFR (Fig 97) should 
reveal a band around 175 kDa, which was noticeable in reduced visibility. The same 
experiment was set up using LHN/ C-EGF fusion protein (product of Syntaxin Ltd). The 
data were not shown, as they similar to that of EGF.  
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The presence of EGF in the control sample did not alow me to validate activation and 
phosphorylation process, even if detection of MAPK/p-MAPK and EGF/p-EGF in the 
course of Western blots was possible. The experiments wil need to be repeated with 
media free of EGF to establish robust assay for testing of EGFR-Ab BoNTs. 
 
 
 
 
Figure 94 Western blot against β actin. 
 
 
 
 
 
 
 
Figure 95 Western blot against MAPK. 
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Figure 96 Western blot against phosphorylated MAPK. 
 
 
 
 
 
 
 
Figure 97 Western blot against EGFR. 
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120kDa 
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175kDa estimated size of chimera 
This legend applies to figure 94, 95, 96 and 97. 
10
6
 A549 cels were added to each Petri dishes and 1nm or 100nm of EGF was added for 5, 20 
and 45 minutes before samples were taken and extracts prepared for SDS PAGE and Western 
blotting. A BCA assay was used so that, equivalent amounts of protein were loaded per lane 
(40µg). The developed β actin blot revealed similar loadings. 
Lane 1 is a control sample without addition of EGF; Lanes 2, 4 and 6 show test sample with 
1nM of EGF taken in the diferent duration of time; Lanes 3, 5 and 7 show test samples with 
100nM of EGF taken in the diferent duration of time; 
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Chapter 8. Internalisation Studies 
8.1 Endocytosis 
Internalization (endocytosis) of macromolecules into a cel can occur by a variety of 
mechanisms. Pathways and can be subdivided into four categories: clathrin-mediated 
endocytosis, caveolae, macropinocytosis, and phagocytosis (Fig 98). 
 
 
 
Figure 98 Endocytosis pathways (adapted from Cel Biology, Wikipedia 2009). 
 
However, for this study I am most interested in the process of clathrin-dependent 
endocytic pathway for eukaryotic cels, because BoNTs are known to enter this way. 
Receptor-mediated endocytosis (RME) can be clathrin-dependent or clathrin 
independent at high ligand doses. RME is a process by which cels internalize proteins in 
clathrin-mediated endocytosis. The internalization takes place only upon the formation 
of endocytic clathrin-coated vesicles, which occur through the interactions of cytosolic 
adaptors and clathrin proteins with cytosolic domains of ligand-bound receptors on 
the plasma membrane. The biogenesis of clathrin-coated vesicle is best characterized 
in nerve terminals, where it serves as the major pathway for recycling of synaptic 
vesicle components after release of neurotransmitter in response to action potentials. 
The correct sorting of endocytic ligands and receptors is essential for many celular 
activities. A primary function of the endocytic system is to sort internalized ligands and 
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receptors to diferent destinations, where they can be targeted to diferent organeles 
for processing or directed to specific celular locations for function (Lakadamyali, 
2006). 
Epidermal growth factor (EGF) primarily enters cels via clathrin-mediated endocytosis 
when added at low concentration (Carpenter and Cohen, 1979). At high 
concentrations, some EGF molecules are diverted to other pathways such as 
cholesterol dependent caveolae and clathrin independent pathway (Jiang and Sorkin, 
2003; Sigismund et al., 2005). Most probably, EGF first enters a common pool of early 
endosomes where sorting takes place (Dickson et al., 1982; Ghosh et al., 1994). 
Receptor tyrosine kinases such as the EGF receptor possess intrinsic protein tyrosine 
kinase activity. Ligand binding causes a change in the conformation of the monomeric 
receptor that leads to non-covalent dimerization of two receptors (Lakadamyali, 2006). 
Dimerization facilitates tyrosine auto-phosphorylation, as described in Chapter 7. 
Ligand-induced internalization of the EGF receptor has been shown to depend on 
intrinsic tyrosine kinase activity, but receptor auto-phosphorylation is not required for 
endocytic activity because mutant receptors lacking any auto-phosphorylation sites 
can undergo ligand-induced internalization (Lakadamyali, 2006). Other sites in EGFR 
interact with AP-2 adaptors. These in turn recruit clathrin to form a coat to promote 
budding. Folowing clathrin unseating, the vesicles fuse with endosomes. Even at low 
pH, the receptors do not dissociate from ligand. The complexes can be recycled if they 
do not become trapped in the intralumenal vesicles of multivesicular bodies (MVB), 
the MVB is degraded (Sorkin and Goh, 2008). 
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Figure 99 Pathway of Clathrin depended Endocytosis (adapted from Grant and Sato, 
2005). 
 
 
 
 
 
8.2 Exocytosis 
The successful internalization of LHN based chimeras lead to the inhibition of synaptic 
vesicles to blocks exocytosis that is the opposite process to endocytosis. 
As mentioned Chapter 1 specific Neuronal complexes termed soluble N-
ethylmaleimide-sensitive factor (NSF) attachment protein (SNAP) receptor or (SNARE) 
proteins  are essential to mediate the release of neurotransmitter contents, such as 
acetylcholine from synaptic vesicles (Montecucco, 2005). The cytosolic synaptic vesicle 
(SV)  binds and fuses  with  presynaptic  nerve terminal  membrane to release its 
Mechanism of clathrin-dependent endocytosis. Clathrin and cargo molecules are assembled into 
clathrin-coated pits on the plasma membrane together with an adaptor complex caled AP-2 that links 
clathrin with transmembrane receptors, concluding in the formation of mature clathrin-coated vesicles 
(CCVs). CCVs are then actively uncoated and transported to early/sorting endosomes. 
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neurotransmiter contents into the synaptic cleft (Hua and Scheler, 2001, Han et. al., 
2004). 
The pre synaptic SNARE proteins are the specific substrates of the seven-botulinum 
neurotoxins: BoNT/A-G. The assembly of specific multimeric SNARE complexes is 
crucial for al stages of exocytosis. Delivery of zinc-endopeptidase N-terminal domain LC 
(light chain) of BoNT to the cytosol prevents neurosecretion by cleavage of one of 
SNARE proteins that are essential for formation of a functional SNARE complex 
between synaptic vesicle and plasma membrane (Montecucco, 2005). 
The three SNARE proteins associate into SNARE complex through interaction of coil 
domains between four helices. The coiling process continues until the formation of 
~12nm long four helices bundle with a paralel orientation is accomplished and ready 
to membrane fusion (Fig 100) (Lin and Scheler, 1997). The SNARE complex has a trans 
configuration with charged surface, what enable specific protein-protein interaction. 
(Jahn et. al., 2003). This complex brings the vesicle and plasma membrane into close 
contact to initiate membrane fusion, which in the case of neuronal cel of synaptic 
vesicles indicates the final step of neuroexocytosis (Weber et. al., 1998). 
 
Figure 100 Secretion SNARE mediated fusion. 
 
The interaction of HC domain with specific receptors (polysialyl, gangliosides and 
protein receptor) on the neuronal surface permits BoNTs to bind to target motor 
neurons. The conformational change in the toxin and formation of ion channels by HN 
domain takes a place in an endosomal compartment after internalization (Foster and 
 
 
 
192 Engineering botulinum-antibody proteins 
Chaddock, 2007). The ion channels permit the light chain (LC) to reach its substrates 
(Oblatt-Montal et. al., 1995).  
There are numerous opportunities for the development of therapeutics based on 
botulinum neurotoxin fragments; therefore, inhibition of secretion for extended 
periods by retargeted LC domain is one of main approaches (Chaddock and Marks, 
2005). The inhibition of secretion can only take place when the light chain successfuly 
internalized into the cytosol. 
 
8.3 Results 
8.3.1 Internalization assay 
The purpose of this experiment was to measure internalization of biotinylated EGF and 
LHN/ C-EGF (SXN100501) fusion proteins. The internalization assay using biotinylated 
proteins was based on the information obtained from two sources of experiments: 
• Irie et al. Nat Cel Biol 2005 – showed an increase in the internalization of 
biotinylated transferrin in the presence of ephrinB2 in a EphB2R transfected 
cel line  
• Bronfman et al. J Neuroscience 2003 – showed internalization of biotinylated 
NGF into PC12 and nnr5 cels 
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Figure 101 Method for internalization assay. 
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The cels used for this experiment are (1-5 × 106) A549 cels that were treated for 2-180 
min hour with either biotinylated EGF or biotinylated LHN/ C-EGF fusion protein (300-
600 nM). The experiment was performed at 37̊C in a water bath or at 0̊C on the ice. 
Four samples in triplicate were prepared for each tested construct. Additionaly two 
controls lacking the addition of construct were kept at both temperatures. Al samples 
in triplicates  were run  on SDS  PAGE.  The control samples  at  37̊C  and  0̊C  as  wel as 
untreated test samples were run on each gel. The biotin marker was used for 
determination of bands size. The graphical representation of quantified data was 
generated using a Prism programme (Fig 102 and 103). The internalization of 
biotinylated EGF and LHN/C-EGF was not detected; the represented data can suggest 
that EGF or LHN/C-EGF become bound to the cels. It wil be necessary to optimize the 
signal for internalized molecules. The graphs below represent an example of 
internalization experiments prepared with the biotinylated EGF and LHN/C-EGF. 
 
 
 
 
 
 
 
 
 
Internalization of biotinylated
EGF in A549 cels
C 
N
W
°0
C 
Y
W
°0
C 
N
W
°
37
C 
Y
W
°
37
0.0
0.1
0.2
0.3
R
el
at
i
v
e 
b
a
n
d 
i
nt
e
n
si
t
y
 
Figure 102 Internalization of biotinylated EGF in A549 cels. 
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Figure 103 Internalization of biotinylated LHC-EGF in A549 cels.  
 
Legend below corresponds to graphs represented above; (Fig 102 and Fig 103) 
 
The 300-600nM was added to 1-5 × 106 A549 cels;  
The samples were divided to two groups and incubated at 37̊C or 0̊C for 2-180 min; 
Cel were washed in cold PBS containing 1 mM MgCl2 and 0.1 mM CaCl2 three times to 
remove al unbound biotinylated fusion protein LHC-EGF or biotinylated EGF. On this 
stage, cels from each temperature group were divided on half. One-half was acid 
stripped by 50 mM Glycin pH 5.0, 450 mM NaCl (YW – wash with acid) and the other was 
not (NW – no wash with acid). The acid strip should remove al biotinylated fusion 
protein LHC-EGF or biotinylated EGF bound to the surface of the cels, so a biotinylated 
fusion protein LHC-EGF or biotinylated EGF that were internalized inside the cels wil 
remain present. Subsequently, the lysis bufer with cocktail protease inhibitors lysed 
cels and supernatant was pooled with Streptavidin magnetic particles. The samples 
were resolved by SDS PAGE and bloted against Streptavidin-HRP in 1/2000 dilution.  
The relative band intensity corresponds to total bound biotinylated fusion protein LHC-
EGF or biotinylated EGF at 0̊C or 37̊C without stripping. 
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Chapter 9. Conclusions 
 
This study was set out to investigate whether antibodies and antibody fragments could 
be successfuly engineered onto botulinum toxin fragments to create novel targeted 
proteins.  The studies have focussed on six key areas, which Chapters 3 to  8 have 
described in detail. The conclusions from this work are listed below.  
DNA encoding twenty-six novel recombinant multi-domain proteins have been 
successfuly designed, cloned and transformed into a suitable E. coli expression host 
(Table 10, pg 125-126).  
The E. coli bacterial expression system selected for this study (T7 promoter; BL21 (DE3) 
host) has been successfuly used for the generation of novel, soluble recombinant 
fusion proteins comprising fragments of botulinum neurotoxin and antibodies (Chapter 
5). 
Where scFv were cloned onto the LHN backbone (Chapter 4), this study focussed on 
the use of a Gly-Ser repeat spacer (GS15) between the variable light and variable heavy 
domains (Section 3.1.4). This has resulted in the successful expression of ful-length 
fusion protein (Fig 52 and 53), of which ones truncations were observed during the 
imidazole elution phase of the IMAC afinity chromatography (Refer to figure 54, 57, 
59, 61, 62, 65, 66 and 67 in the section 6.4.1 ͵Purification of single chain variable 
antibody fragments-LHN chimeraʹ). Unfortunately, attempts to improve the recovery of 
ful-length protein using alternative chromatographic procedures such as an ion-
exchange chromatography (Q-Sepharose) (Figure 61 and 63) or hydrophobic 
interaction chromatography (HIC-phenyl Sepharose) (Figure 64) were unsuccessful.  
To explore the potential impact of serotype and activation enzyme on the ability to 
create single chain antibody-LHN molecules, four novel constructs were designed 
incorporating scFvCD117I with one of LHA, LHB or LHC and with one of FXa or EK 
activation site (Table 10). Most often, the activation of the single chain antibody-LHN 
was unsuccessful despite the use of diferent conditions. However, the best results 
were achieved from the activation of LHC-scFvCD117I with 1.5U of Factor Xa per 1 mg 
of fusion protein at 25̊C, which achieved almost completed activation (Figure 66 and 
67). 
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Truncations of LHC-scFvCD117I were investigated by an N-terminal sequencing (Figure 
68, 67, 69, 70 and 71). The truncation appeared to be in two places within the primary 
structure of the protein. One was after the heavy chain of the LHN/C backbone but 
before the start of the single chain antibody and another one was after the heavy 
chain of scFv but before the start of the intra-domain GS15 linker. It is important to 
note that a ful-length product was detected using an N-terminal sequencing.  
Expression of the single domain antibody fragments with LHN A (Figure 49), B (Figure 
50) and D (Figure 51) was successful. The purification of six single domain antibody-
LHN chimeras was completed successfuly (Table 12). Ful-length material of high purity 
and yield was achieved by using afinity chromatography, incorporating a step gradient 
elution scheme. This study investigated the use of an additional HIC column to improve 
purity of the final material. However, the data indicated that the purity of LHN/A-
EGFR31sdAb=SXN101872 purified on HIC column was not significantly enhanced 
(Figure 84) in comparison to LHN/A-EGFR6sdAb=SXN101868 purified on His column. 
The quality control SDS PAGE gels of these molecules shows high purity (Fig 85 and 86).  
In one case (Figure 78 and 79), the quality of the protein did not meet criteria 
established within Syntaxin Ltd for in vitro celular assay. This was due to non-specific 
cleavage within the LHN component.  
The choice of the successful candidate depends on many aspects, but one of the most 
important is that activation should be above 85%. The folowing molecules, LHN/A-
EGFR6sdAb=SXN101868, LHN/B-EGFR31sdAb=SXN101865, LHN/D-
EGFR31sdAb=SXN101878, LHN/B-EGFR6sdAb=SXN101861, LHN/D-
EGFR28sdAb=SXN101877, and LHN/A-EGFR31sdAb=SXN101872 were categorized in 
descending percentage of molecule cleavage, respectively: 100%, 100%, 88%, 88%, 
76% and 66%. Although the cleavage of the last two molecules is not suficient 
according to the required criteria the chimera LHN/A-EGFR31sdAb=SXN101872 
exhibits 100% of purity, therefore if the efectiveness of activation would be increased 
this construct could be a potential candidate.  
The antibody sequences for the construction of the recombinant chimera comprising 
single antibody domains were obtained from patent WO/2007/127317. In a number of 
cases, the protein characteristics of the chimera have not matched the predicted 
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properties of the domain antibody alone, which were described in the patent. It 
appears that a compromise must be reached between the botulinum neurotoxin 
serotype and choice of the antibody fragment in order to find a high quality of target 
protein. 
An assay for detection EGFR activation through tyrosine kinase was attempted. 
Activation of EGFR in E549 cels was demonstrated using EGF (Sigma) (Figure 94, 95, 96 
and 97), but the presence of pMAPK in control cels suggests that further optimisation 
is required for example by use of growth factor free media. It was also possible to 
detect MAPK phosphorylation on the Western Blots but it was impossible to confirm 
that EGF bound to EGFR on the cels. This assay could be used in the future to 
investigate whether the antibody-LHN molecules can activated the receptor once the 
controls are satisfactory. 
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Chapter 10.Discussion 
Antibody fragments and their recombinant derivatives have important practical 
applications in research, diagnostic and therapy. Utilization of antibodies as drug 
delivery vehicles has become a successful application. There are, however significant 
manufacturing implications with conventional antibodies. For most applications, high-
yield production, solubility, stability and smal size are critical factors. Attempts to 
reduce size of antibodies, while retaining its antigen-binding properties have been 
reported. It resulted in a production of antibody fragments constructs, such as single 
chain antibody (scFv). New opportunities arose with the discovery of heavy chain 
antibodies (hcAbs) in camels in 1993. The use of single domain antibodies has been 
rapidly growing for biotechnological applications. The deep penetration into tissues 
and rapid elimination via the kidney make antibody fragments and single domain 
antibody favourable tools for the delivery of cytotoxic agents (Holt et. al., 2003). 
This study serves as the first demonstration that the antibody fragments and single 
domain antibodies can be engineered into the LHN domains of recombinant BoNTs, 
subsequently expressed in an E. coli system and purified. In order to choose the best 
antibody candidate it wil be important to perform additional experiments on cels and 
pharmacology assays in order to establish a functional characterization of novel 
compounds. 
During this study there have been a number of observations and occurrences that are 
worthy of further discussion. For example, during the cloning phase, the recombinant 
scFv and sdAbs DNA sequences obtained from Entelechon were incorporated into the 
LHN backbone DNA using restriction enzymes XbaI and HindII, though successful 
method is susceptible to frame shift. It was required to introduce ʹA͵ base after XbaI 
side (TCTAGA) to avoid the frame shifting during cloning. 
Truncation of the scFv-containing constructs was a major observation of this study. It 
could be hypothesised that the simplicity of single domain antibody structure 
compared to scFv enhanced production of a ful-length product, as the stability of the 
scFv depends on the VH-VL domains and their interaction with the flexible linker.  A 
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number of the scFv sequences were obtained from patent WO/2007/127317, in which 
the linker was reported to be EEGEFSAR. In this study, it was decided to replace this 
linker with a flexible GS15 (GGGGSGGGGSGGGGS) linker as this had been found to give 
the best results during screening tests done on the LHN chimeras with diferent linkers 
lengths (Data obtained from Syntaxin Ltd databases). It is possible that the truncations 
observed within scFvs could be due to the diferent linker design than that proposed in 
the patent WO/2007/127317 (linker EGGEFSAR), but this hypothesis needs to be 
checked by performing the additional experiments. One experiment would be to 
substitute the GS15 linker with the linker EEGEFSAR proposed in the patent. In 
addition, removal of the spacer from LHN-ligand TSIs (Fig 23 and 24) between the 
heavy chain and the ligand could potentialy cause truncation of the ful-length protein. 
The reorganization of the single chain antibody structure is a necessity in order to 
progress any additional purification experiments since attempts to resolve truncation 
issues during the purification process were inefective, even after substitution of the 
first His chromatography column for an ion exchange or a hydrophobic interaction 
chromatography. From these results, it was noted that the detailed engineering of the 
scFv antibody construct requires further exploration in order to be optimise in the 
context of an LHN fusion.  
These studies have also given valuable insight into the insights of recombinant LHN 
fusions. For example, the single domain antibody - LHN molecules have shown higher 
purity than many of the routinely produced LHN-ligand (TSI) molecules. In order to 
purify routinely made TSIs of high purity the additional changes have been made to the 
standard method (attached in the chapter 2 methods and materials), one of them is 
use of the 50 mM Hepes pH 7.2, 500 mM NaCl bufer during cel lysis and column 
steps. The bufer with higher salt concentration eliminates non-specific contaminants 
from E. coli expression system. The use of high salt for the purification of LHN-single 
domain antibody molecules was not required, as the final purity in presence or without 
50 mM Hepes pH 7.2; 500 mM NaCl bufer gave the same results. It looks like during 
the expression of the novel designed molecules the occurrence of protein contaminant 
from E. coli system is lower in compare to purification of LHN molecules in the 
presence of ligands other than the single domain antibody fragments. The production 
can be similar, but removal of contaminants during the beginning of purification seems 
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to be much more straightforward. There can be a number of reasons for this 
occurrence; however, the element, which is missing from the typical C terminal 
structure, is the spacer between the heavy chain of recombinant BoNT (Fig 24) and the 
presence of single domain antibody, which simplifies the structure of novel molecule. 
It has been reported that some E. coli proteins form aggregates with recombinantly 
expressed target protein and such a complex can be carried throughout purification or 
can be disassociated by diferent methods. The orientation of novel molecules could 
have an impact on the level of complexes aggregating, which are carried over during 
the purification. This hypothesis could be checked through purification experiments 
based on the novel LHN single antibody chimeras and new design LHN molecules with 
ligand lacking spacer from the side of heavy chain. 
Only the production of the single domain antibody-LHN molecule LHN/B-
EGFR43sdAb=SXN101866, so far was unsuccessful. This molecule was purified with a 
very low yield after the first afinity column and did not cleave with protease (Fig 78 
and 79). According to the patent WO 2008/141449 A1, EGFR43sdAbs gave the best 
results after production in E. coli and purification on the IMAC column, the final yield 
being 42mg per 1-litre of culture. There can be a number of reasons for this 
dissimilarity of data. There are two aspects worth considering. Firstly, the single 
domain antibody EGFR43 fragment in the presence of LHH molecule can obstruct some 
of the properties, which influence the protein production. On the other hand, the 
substitution of the expression vector from pSJF2 to pK7 can be a reason for the lower 
yield of the soluble protein, which did not apply to other tested molecules, however it 
is less likely  a case, especialy that it did not have an efect on other single domain 
antibody molecules. It wil be worth to consider preparing the N-terminal sequencing 
to confirm correct sequence start point of protein and purifying EGFR43sdAb in the 
presence of serotype A and D. 
The single domain antibody LHN molecules ranked in order of purity from the highest 
to the lowest in the folowing order, LHN/A-EGFR31sdAb=SXN101872, LHN/A-
EGFR6sdAb=SXN101868, LHN/B-EGFR31sdAb=SXN101865, LHN/B-
EGFR6sdAb=SXN101861, LHN/D-EGFR31sdAb=SXN101878,  and  LHN/D-
EGFR28sdAb=SXN101877. Their outstanding purity qualified five of them to be used 
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for a crystal generation that leads to X-ray structural studies. The idea was 
incorporated from the article: A Crystal Structure of the anti-His tag antibody 3D5 
single-chain fragment complexed to its antigen (Kaufmann et. al., 2002), where anti-
His scFv crystals are proposed to act as a framework for the crystalization of His-
tagged target proteins dificult to crystalize. The authors used a scFv antibody 
fragment for the purpose of this study, but since the single domain antibody 
represents high quality, it was worth the attempt to determine the single domain 
antibody-LHN structure. The successful outcome of crystalization is a combination of 
luck, total protein concentration and high purity, therefore protein purification and 
concentration need to be accurate as possible. The reading A280nm measures tyrosine 
and tryptophan, in the presence of unwanted proteins often this reading is inaccurate. 
The reliable data can be obtain by BCA or Bradford assay. According to data provided 
in chapter six, there was not much discrepancy in the purity of molecules between two 
assays (Table 12). This indicates that the novel molecules have high purity and the 
presence of E. coli proteins is not significant. Experimental studies are ongoing, but the 
evidence that crystals have been formed is confirmation for the quality of the proteins 
prepared in this study.  
 
One of the aspects, which wil be considered during the selection of antibody 
fragments, is functionality in cel assays, such as activation and internalization. The 
activation assay was wel established, however needs to be improved in order to be  
used for the purpose of future studies, while the internalization studies performed as 
wel as activation assays on EGF require introduction of diferent type experiments to 
make reliable conclusions. Initialy novel molecules should be tested in an activation 
assay to show binding to the desired receptor to represent the detection of an 
activated signaling pathway within cels. If obtained, the protein can be tested in an 
internalization assay. 
A number of valuable outcomes have emerged from a study that can be applied across 
Syntaxin’s TSI (Targeted Secretion Inhibitors) platform. These include: (i) methods for 
improved activation of TSIs; (i) improved yield folowing incorporation of an N-
terminal His tag; (ii) the diference in stability behaviour between serotypes means 
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that multiple serotypes should be used in the initial screening phase; (iv) improved 
purity of purified molecules. 
In summary, the ability to engineer the antibody-LHN chimeras opens new prospects of 
research areas for Syntaxin Ltd. The novel molecules can target a wider spectrum of 
cels and therefore broaden the applications to diferent areas of diseases. Specific and 
selective targeting is a major goal in today’s research, where one of the leading aims is 
to improve therapeutics against cancer. The identification of the antibody-LHN 
chimeras efectively targeting EGFR could potentialy treat solid tumors and other 
diseases. However, a number of obstacles stil need to be resolved before clinical 
application of novel antibody-LHN chimeras become possible.  
List of obstacles: 
• Redesign of single chain antibody in order to avoid truncations; 
• Optimisation of activation assay on EGFR; 
•  Development of robust internalization assay;  
• In view of this approach together with attributes of recombinant botulinum-
neurotoxin chimeras the eficient delivery of therapeutic to target cels could 
be developed; 
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The analyzes of triplet position vs. usage table and each codon vs. usage table (Chapter 
3). 
 
 
Figure 104 Each triplet position usage table sdAb EGF28. 
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Figure 105 Each codon usage table sdAb EGF28. 
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Figure 106 Each triplet position usage table sdAb EGF28 final adjustments. 
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Figure 107 Each codon usage table sdAb EGF28 final adjustments. 
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Figure 108 Each triplet position usage table sdAb EGF10. 
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Figure 109 Each codon usage table sdAb EGF10. 
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Figure 110 Each triplet position usage table sdAb EGF10 final adjustments. 
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Figure 111 Each codon usage table sdAb EGF10 final adjustments. 
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Figure 112 Each triplet position usage table sdAb EGF6. 
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Figure 113 Each codon usage table sdAb EGF6. 
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Figure 114 Each triplet position usage table sdAb EGF6 final adjustments. 
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Figure 115 Each codon usage table sdAb EGF6 final adjustments. 
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Figure 116 Each triplet position usage table sdAb EGF7. 
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Figure 117 Each triplet position usage table sdAb EGF7 final adjustments. 
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Figure 118 Each codon usage table sdAb EGF7 final adjustments. 
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Figure 119 Each triplet position usage table sdAb EGF43. 
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Figure 120 Each codon usage table sdAb EGF43. 
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Figure 121 Each triplet position usage table sdAb EGF43 final adjustments. 
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Figure 122 Each codon usage table sdAb EGF43 final adjustments. 
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Figure 123 Each triplet position usage table sdAb EGF31. 
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Figure 124 Each codon usage table sdAb EGF31. 
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Figure 125 Each triplet position usage table sdAb EGF31 final adjustments. 
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Figure 126 Each codon usage table sdAb EGF31 final adjustments. 
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Figure 127 Each triplet position usage table scFv CD117I. 
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Figure 128 Each codon usage table scFv CD117I. 
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Figure 129 Each triplet position usage table scFv CD117I final adjustments. 
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Figure 130 Each codon usage table scFv CD117I final adjustments. 
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  Gene synthesis received from Entelechon. 
 
 
Figure 131 Entelechon report for single domain antibodies 
 
 
 
237 Engineering botulinum-antibody proteins 
 
 
 
Figure 132 Entelechon report for single domain antibodies. 
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Figure 133 Entelechon report for single chain antibody fragment. 
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Figure 134 pCR4TOPO vector for cloned molecules by Entelechon. 
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Figure 135 Entelechon CD117I gene report with quality control. 
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Figure 136 Entelechon EG6 gene report and quality control. 
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Figure 137 Entelechon EG7 gene report and quality control. 
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Figure 138 Entelechon EG10 gene report and quality control. 
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Figure 139 Entelechon EG28 gene report and quality control. 
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Figure 140 Entelechon E31 gene report and quality control. 
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Figure 141 Entelechon EG43 gene report and quality control. 
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